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Summary 
 
Plasmodium parasites are developing unacceptable levels of resistance to one drug 
after another and many insecticides are no longer useful against mosquitoes transmitting the 
disease. Years of vaccine research have produced few hopeful candidates and although 
scientists are redoubling the search, an effective vaccine is at best years away. Therefore there 
is need for identification of new drug targets and alternative antimalarial regimes. In response 
to this dire situation the study aimed at evaluating the pentose phosphate pathway of the 
malaria parasite P. falciparum in particular the bifunctional enzyme glucose-6-phosphate 
dehydrogenase-6-phosphogluconolactonase, understanding the kynurenine pathway of 
tryptophan metabolism in particular the enzymes indoleamine 2,3-dioxygenase (1 and 2) and 
unravelling more knowledge about the thioredoxin system networks in search for a new 
potential drug target and new drug alternatives. 
The first two steps of the pentose phosphate pathway in Plasmodium falciparum are 
catalysed by the enzyme glucose 6-phosphate dehydrogenase-6-phosphogluconolactonase 
(PfGluPho) which is a unique bifunctional enzyme exclusively found in the genus 
Plasmodium. In spite of the importance of the role this enzyme plays in the parasite’s pentose 
phosphate pathway as well as in overcoming oxidative stress, the characteristics of PfGluPho 
are still a mystery. For the first time PfGluPho has been successfully cloned, heterologously 
overexpressed and purified to homogeneity. The recombinant enzyme was found to be a 
hexamer which exhibits lower Km values that favour substrate turnover by the parasite 
enzyme when compared to the human homologue. The steady state kinetics of PfGluPho’s 
glucose-6-phosphate dehydrogenase (PfGluPho’s G6PD) demonstrates that the enzyme 
follows an ordered sequential mechanism with NADP+ being the leading substrate. Three 
novel inhibitors of PfGluPho’s G6PD which are active at the lower micromolar range were 
identified and found to be non-competitive with respect to glucose-6-phosphate and NADP+. 
The study offers the first clear documentation of the cloning, heterologous overexpression, 
biochemical as well as kinetic characterisation, crystallisation and the first novel inhibitors of 
PfGluPho.  
For 30 years, the established dogma regarding tryptophan catabolism was that the first 
step of the kynurenine pathway, the cleavage of the 2,3–double bond of the indole ring of 
tryptophan was performed by two enzymes, indoleamine 2,3-dioxygenase-1 (IDO-1) and 
tryptophan 2,3-dioxygenase (TDO). Recently, indoleamine 2,3-dioxygenase-2 (IDO-2) a third 
enzyme capable of performing this reaction has been discovered. Reported here is a study of 
the kinetic activity, pH stability, oligomeric structure as well as secondary structural features 
of recombinant mouse IDO-2 in direct comparison with mouse IDO-1. A screen for new more 
potent inhibitors of IDO-1 which lack the indole core and avoid the liability arising from the 
use of indole derivatives which have been reported to be neuroactive gave rise to compound 
55D11 (Ki 0.05 µM) which is more potent than the already existing IDO inhibitors. A 
structure activity study was done using various derivatives of compound 55D11 to determine 
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the elements that could be modified to increase potency. The study clearly demonstrates that 
IDO-1 and IDO-2 differ significantly in terms of their affinity for substrates as well as 
structure. 
 The malarial parasite Plasmodium falciparum possesses a functional glutathione and 
thioredoxin system comprising the redox-active proteins thioredoxin (Trx), glutaredoxin 
(Grx), and plasmoredoxin (Plrx) which all belong to the thioredoxin superfamily and share the 
active site motif Cys-X-X-Cys. A better understanding of the role of these members of the 
thioredoxin superfamily in P. falciparum as well as other systems could be achieved if more 
was known about their target proteins. Using thioredoxin affinity chromatography prepared 
by immobilising mutants of the redoxins lacking the resolving cysteine at the active site on 
CNBr- activated sepharose, target proteins of P. falciparum cell extract were trapped. The 
covalently linked proteins were eluted with dithiothreitol and analyzed by matrix assisted 
laser desorption ionization time of flight (MALDI-TOF). Twenty one potential targets were 
identified for plasmoredoxin. Besides confirming known interacting proteins, potential target 
candidates involved in processes such as; protein biosynthesis, energy metabolism and signal 
transduction were identified. Further confirmations of the interaction of plasmoredoxin and 
the target proteins were done using BIAcore surface plasmon resonance experiments. 
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Zusammenfassung 
 
Der Malaria-Parasit Plasmodium entwickelt bemerkenswert hohe Resistenzen 
gegenüber einem Medikament nach dem anderen. Außerdem verlieren viele Insektizide, die 
gegen die Überträger-Moskitos eingesetzt werden, an Wirkung. Jahrelange Forschung an 
Impfstoffen gegen Malaria hat bisher nur wenige hoffnungsvolle Kandidaten erbracht und 
obwohl Wissenschaftler Ihre Bemühungen verstärken, ist eine effektive Impfung  bestenfalls 
immer noch Jahre entfernt. Deshalb sind dringend neue Zielmoleküle für die Medikamenten- 
entwicklung zu identifizieren, die zu alternativen Behandlungsmethoden führen können. 
Diese Situation vor Augen, waren es Ziele dieser Arbeit, i) das bifunktionelle Enzym 
Glukose-6-Phosphatdehydrogenase-6-Phosphogluconolactonase aus dem Pentosephosphat-
weg des Parasiten als potentielles Wirkungsziel zu bestätigen, ii) den Kynurenin-
Stoffwechselweg, insbesondere die Enzyme Indolamin 2,3-Dioxygenase (1 und 2) der Maus 
als Modell näher zu charakterisieren und iii) mehr über das Redox-Netzwerk des 
Malariaparasiten zu erfahren, um neue mögliche Zielmoleküle aufzuzeigen. 
Die ersten zwei Schritte des Pentosephosphatweges werden in Plasmodium falciparum 
durch das Enzym Glukose-6-Phosphatdehydrogenase-6-Phosphogluconolactonase (PfGluPho) 
katalysiert. Dieses ist ein einzigartiges bifunktionelles Enzym, das bisher nur in Plasmodien 
gefunden wurde. Obwohl diesem Enzym im Pentosephosphatweg des Parasiten und damit 
auch in der Bekämpfung oxidativen Stresses eine enorme Bedeutung zukommt, ist das Enzym 
aus P. falciparum nicht besonders gut charakterisiert, da es bisher nicht kloniert werden 
konnte. Zum ersten Mal konnte PfGluPho jetzt kloniert und überexprimiert werden und das 
Genprodukt konnte bis zur Reinheit gebracht werden. Es wurde gezeigt, dass das 
rekombinante Enzym als Hexamer vorliegt, welches niedrigere Km-Werte im Vergleich zu 
seinen humanen Orthologen aufweist, die einen bevorzugten Substratumsatz durch das 
parasitäre Enzym aufzeigen. Kinetische Untersuchungen zeigen, dass der Glukose-6-
Phosphatdehydrogenase (G6PD)-Teil von PfGluPho einem geordneten Mechanismus folgt, 
bei dem NADP+ das erste Substrat ist. Drei neue Inhibitoren, die den G6PD-Teil des Enzym 
im unteren mikromolaren Konzentrationsbereich hemmen, konnten gefunden werden und 
zeigten sich gegenüber Glukose-6-Phosphat und NADP+ als nicht-kompetitiv. Somit zeigt 
diese Arbeit die Klonierung, heterologe Expression, biochemische und kinetische 
Charakterisierung von PfGluPho auf, sowie darüberhinaus die Kristallisation und erste, neue 
Inhibitoren. 
Seit 30 Jahren ist es ein etabliertes Dogma, dass im Tryptophan-Katabolismus der 
erste Schritt des Kynurenin-Stoffwechselweges die 2,3-Doppelbindung des Indolringes des 
Tryptophans durch zwei Enzyme gespalten werden kann: einerseits durch Indolamin 2,3-
Dioxigenase (IDO), anderseits durch Tryptophan 2,3-Dioxigenase (TDO). Kürzlich konnte 
mit IDO-2 ein drittes Enzym in der Maus und im Menschen entdeckt werden, das in der Lage 
ist, diese Reaktion zu vollziehen. In dieser Arbeit sind Daten zur Kinetik, pH-Stabilität, zu 
oligomeren Strukturen, sowie Besonderheiten der Sekundärstruktur von rekombinanter IDO-2 
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der Maus im direkten Vergleich mit rekombinanter IDO-1 der Maus erhoben worden. Die 
Suche nach neuen, effektiveren Inhibitoren für IDO-1, die den Indolkern nicht mehr besitzen 
und somit weniger neurotoxisch sein könnten, führte zu 55D11 (Ki 0,05 µM), einer Substanz 
aus einer öffentlichen Sammlung von Naturstoffen. Zahlreiche Derivate von 55D11 wurden 
untersucht, um Molekülreste zu zeigen, die verändert werden können und die Aktivität noch 
erhöhen. Die Untersuchungen zeigen, dass sich IDO-1 und IDO-2 eindeutig hinsichtlich ihrer 
Affinität zu Substraten, aber auch in ihrer Struktur unterscheiden. 
Der Malaria-Parasit Plasmodium falciparum besitzt ein funktionelles Glutathion-, 
sowie ein Thioredoxin-System, die unter anderem aus den redox-aktiven Proteinen 
Thioredoxin (Trx), Glutaredoxin (Grx) und Plasmoredoxin (Plrx) bestehen, die alle zur 
sogenannten Thioredoxin-Superfamilie gehören und das Motiv Cys-X-X-Cys im aktiven 
Zentrum besitzen. Wenn mehr Interaktionspartner dieser Redoxproteine bekannt wären, 
könnte die jeweilige Rolle der Redoxine in ihrem Netzwerk besser verstanden werden. 
Deshalb wurden Thioredoxin-Affinitätschromatographien an CNBr--aktivierter Sepharose 
durchgeführt. Hierzu wurden immobilisierte Mutanten der Redoxine, denen das sogenannte 
„resolving cysteine“  aus ihrem aktiven Zentrum fehlt, mit Zellextrakt aus P. falciparum 
versetzt. Kovalent an die Fängerproteine (Redoxine) gebundene Reaktanden wurden mit 
Dithiothreitol eluiert und mittels (Maldi-ToF) analysiert. Einundzwanzig potentielle 
Zielproteine wurden für Plasmoredoxin als mögliche Interaktionspartner identifiziert. Neben 
bekannten Interaktionspartnern waren darunter auch Kandidaten, die eine mögliche 
Redoxregulierung der Proteinbiosynthese, des Energiemetabolismus sowie der 
Signaltransduktion in Plasmodium vermuten lassen können. Weitere Untersuchungen, um 
diese Wechselwirkungen zu bestätigen, wurden mit Plasmoredoxin und einigen seiner 
potentiellen Interaktionspartner mithilfe von BIACORE Oberflächen-Resonanzexperimenten 
durchgeführt. 
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1 Introduction 
1.1 Malaria  
Malaria is a life-threatening parasitic disease transmitted by mosquitoes. The term 
malaria is derived from the Italian word “mal’aria”, which means ‘bad air’, from the early 
association of the disease with marshy areas. In 1880, Charles Louis Alphonse Laveran 
discovered that the real cause of malaria was a single cell parasite called Plasmodium. Later 
Dr. Ronald Ross discovered that the parasite was transmitted from one person to another 
through the bite of a mosquito and the Italian professor Giovanni Battista Grassi subsequently 
showed that human malaria could only be transmitted by female Anopheles mosquitoes which 
require blood to nurture their eggs. 
Today more than 2 billion people (approximately 40% of the world's population) are at 
risk of contracting malaria with 300-660 million clinical cases of malaria and over 1.3 million 
deaths reported to occur per annum [Snow et al., 2005]. Ninety per cent of deaths due to 
malaria occur in Africa south of the Sahara mostly among young children where malaria kills 
an African child every 30 seconds. Many children who survive an episode of severe malaria 
may suffer from learning impairments or brain damage [Snow et al., 2004]. Pregnant women 
and their unborn children are also particularly vulnerable to malaria, which is a major cause of 
perinatal mortality, low birth weight and maternal anaemia. 
There are four Plasmodium species that infect humans (Plasmodium vivax, 
Plasmodium malariae, Plasmodium ovale and Plasmodium falciparum) and can be 
distinguished by morphology. Plasmodium ovale and P. malariae are not lethal and are rare, 
most commonly found in parts of Africa and Papua New Guinea. Plasmodium vivax and P. 
falciparum are the two most prevalent species worldwide and P. falciparum causes the most 
deadly type of malaria infection. Plasmodium falciparum malaria is endemic in Africa, 
accounting in large part for the extremely high mortality in this region. South and East Asia, 
South America, the Caribbean, and the Middle East also experience P. falciparum malaria. 
There are also worrying indications of the spread of P. falciparum malaria into new regions of 
the world and its reappearance in areas where it had been eliminated. Plasmodium vivax is 
typically nonlethal and endemic in India, Latin America, and parts of the Eastern 
Mediterranean [Daily, 2006]. 
Malaria has a broad distribution in both the subtropics and tropics, with many areas of 
the tropics where the temperature and rainfall are most suitable for the development of the 
malaria causing Plasmodium parasites in Anopheles mosquitoes being endemic for the 
disease. The countries of sub-Saharan Africa account for the majority of all malaria cases. 
Malaria once occurred widely in temperate areas, including Western Europe and the United 
States, but it receded with economic development and public health measures. The disease 
was finally eliminated in the United States between 1947 and 1951 through a campaign that 
included household spraying of the residual insecticide dichlorodiphenyl trichloroethane 
(DDT) throughout the southeastern states [Zucker, 1996]. 
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The Global Malaria Eradication Programme was launched by the WHO in 1955 
[WHO, 1999] and depended on two key tools: chloroquine for treatment and prevention and 
DDT for vector control. Implementation of these tools had a substantial impact in some areas, 
particularly areas with relatively low transmission rates, such as India and Sri Lanka [WHO, 
1999]. Despite these successes, the campaign foundered in the face of lost political will and 
the emergence of chloroquine resistant Plasmodium parasites and DDT resistant Anopheles 
mosquitoes. Global eradication was officially abandoned as a goal in 1972 [Brito, 2001]. 
Furthermore, the campaign never attempted to eradicate malaria in most parts of Africa, 
where malaria transmission is intense. 
 
        
Figure 1: Global distribution of malaria [WHO, 2007] 
 
Since the Global Malaria Eradication Programme ended, the burden of malaria 
increased substantially in many parts of the world, and the resurgence of malaria has 
sometimes been dramatic, such as the epidemics in Sri Lanka (1968–1969) and in Madagascar 
(1987–1988) [Roberts et al., 2000]. Childhood deaths in Africa due to malaria have increased 
relentlessly as chloroquine resistant Plasmodium parasites spread across the continent [Snow 
et al., 2001]. The rapid emergence of Plasmodium parasites resistant to sulfadoxine 
pyrimethamine (Fansidar®) soon after this drug replaced chloroquine as first-line therapy in 
many parts of Africa can be described as a disaster in Africa [White et al., 1999]. 
Vector control intervention using insecticide treated nets (ITNs) or long lasting 
insecticide treated nets (LLINs) has been reported to reduce clinical episodes of malaria 
caused by P. falciparum and P. vivax infections by 50 % on average (range 39–62 %), as well 
as reducing the prevalence of high density parasitemia. ITNs reduce child mortality due to 
malaria by an average 18 % (range 14–29 %) in sub-Saharan Africa [WHO, 2007; Killeen et 
al., 2007; Clarke et al., 2001; Lengeler, 2004]. The general implication is that 5.5 lives could 
be saved per year for every 1000 children under 5 years of age. Although  ITNs are a success 
in terms of vector control interventions there are many teething problems that have to be 
overcome before their potential can be fully realised. For instance in most malaria endemic 
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countries, ITN coverage is still below agreed targets. This has lead to the ITNs use to be 
limited to young children and pregnant women who are the most vulnerable groups. 
Currently, most mosquito nets are made of polyester and rarely last long. They are therefore 
easily compromised due to their poor physical condition under field situations. Besides, the 
cost of ITNs is still beyond the reach of communities living in areas where malaria is endemic 
[WHO, 2007]. 
Science still has no magic bullet for malaria, the Plasmodium parasites are developing 
unacceptable levels of resistance to one drug after another and many insecticides are no 
longer useful against mosquitoes transmitting the disease. Years of vaccine research have 
produced few hopeful candidates and although scientists are redoubling the search, an 
effective vaccine is at best years away. In response to this dire situation, the global 
community is now taking steps to deliver more effective interventions throughout Africa and 
other malaria endemic areas, including drug combinations with artemisinin derivatives and 
anti-vector measures. The dramatic success of these measures in a few specific areas, such as 
Kwa Zulu-Natal in South Africa [Barnes et al., 2005], Eritrea [Nyarango et al., 2006] and the 
Tanzanian island of Zanzibar [Bhattarai et al., 2007], has inspired a new call for global 
eradication. Achieving this ambitious goal depends on the development of new tools to treat, 
prevent, and monitor malaria. 
 
1.1.1 Life Cycle of Plasmodium Parasite 
Among the four Plasmodium species (P. falciparum, P. vivax, P. ovale and P. 
malariae) that cause malaria in humans, Plasmodium falciparum is the most virulent. This 
species causes the vast majority of deaths from malaria and is also distinguished by its ability 
to bind to endothelium during the blood stage of the infection and to sequester in organs, 
including the brain. Plasmodium vivax is less deadly but highly disabling; it is common in 
tropical areas outside Africa (most Africans lack the Duffy blood group antigen that is 
expressed on the surface of erythrocytes and is a necessary receptor for P. vivax invasion of 
these cells). The ability of P. vivax and also P. ovale to remain dormant for months as 
hypnozoites in the liver makes infection with these parasites difficult to eradicate. 
Plasmodium malariae does not form hypnozoites, but it can persist for decades as an 
asymptomatic blood stage infection. A fifth species, P. knowlesi, which was originally 
described as a malaria parasite of long tailed macaque monkeys, also naturally infects humans 
in some areas, such as Malaysia [Singh et al., 2004]. 
Infection of the human host with a Plasmodium parasite begins with the bite of an 
infected Anopheles mosquito that inoculates the individual with sporozoites (Figure 2). The 
number of sporozoites normally inoculated is usually more than 25. These motile forms of the 
parasite rapidly access the blood stream and then the liver, where they invade hepatocytes. 
The asymptomatic liver stage of infection lasts about 6 days, with each sporozoite yielding 
tens of thousands of merozoites that then invade and develop within erythrocytes. Once inside 
the erythrocyte, the parasite lies within the erythrocyte cytosol enveloped by its own plasma 
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membrane and a surrounding parasitophorous vacuolar membrane. Within the erythrocytes, 
the merozoites develop from small ring forms to the trophozoites feeding stages after about 24 
hours of invasion. Approximately 36 hours after merozoites invasion repeated nuclear 
division takes place to form schizonts or the segmenter form. This then ruptures and releases 
merozoites (at least 8-20 per schizont every 48 hours or 72 hours for P. malariae). Merozoites 
released from erythrocytes can invade other red blood cells and continue the cycle of 10 fold 
parasite multiplication, with extensive red blood cell distraction. The asexual reproduction of 
the parasites in the red blood cells (called schizogony or merogony) and the release of 
infectious offsprings (merozoites) when the red blood cells lyse are responsible for the 
pathogenesis of the disease and infected individuals manifest diverse symptoms affecting 
different organ systems. In some cases, the merozoites enter red blood cells but do not divide. 
Instead they differentiate into male and female gametocytes (the crescents of Laveran). When 
ingested by the female mosquito, the male gametocyte divides into eight flagellated 
microgametes, which escape from the enclosing red blood cells (exflagellation). These swim 
to the macrogamete, one microgamete fertilises the macrogamete, and the resultant motile 
zygote (the ookinete) moves between or through cells of the stomach wall. This encysted 
zygote, resembling a wart on the outside of the mosquito stomach is an oocyst. Through 
asexual multiplication, threadlike sporozoites are produced in the oocyst, which burst and 
release sporozoites into the body cavity of the mosquito. These sporozoites quickly find their 
way to the salivary glands. When the female mosquito feeds again, the transmission cycle is 
complete. The mosquito becomes infectious to its next blood meal donor approximately two 
weeks after ingesting gametocytes, a time frame that is influenced by the external 
temperature. Development of P. vivax within the mosquito can occur at a lower environmental 
temperature than that required for the development of P. falciparum, explaining the 
preponderance of P. vivax infections outside tropical and subtropical regions. 
During its peripatetic existence, the unicellular malaria causing parasite uses a toolkit 
of more than 5,000 genes [Gardner et al., 2002] to undergo dramatic metamorphoses that are 
suited to the numerous environments and barriers it encounters. These changes include the 
development, at different points in its life cycle, of motile, invasive, encysted, intracellular, 
sexual, and dormant forms. These distinct forms of the parasite help enable it to complete its 
full life cycle (Figure 2), during which it must pass through the mosquito midgut and salivary 
glands; localise and penetrate skin vessels; perforate and traverse macrophages and several 
hepatocytes prior to enveloping itself in an intrahepatocytic vacuole; and attach to and 
reorient itself on the surface of erythrocytes prior to invasion. Each of the developmental 
stages represents a potential target at which the life cycle can be interrupted. Vaccines, drugs, 
and anti-vector measures are being developed to prevent infection, disease, and transmission. 
Despite numerous potential targets, the most widely used old compound (quinine, isolated 
from Cinchona bark in 1820) and the best new compound (artemisinin, purified from 
Artemisia annua in 1972) for treatment are both derived from ancient herbal therapies. 
Further, progress with developing a vaccine is incomplete. These limitations stem, in part, 
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from the fact that since its discovery in 1880 the parasite has been slow to reveal its secrets, 
including its metabolic pathways and its antigens that are targeted by protective immunity 
[Greenwood et al., 2008]. However, recent advances in determining the genome sequences 
for humans, Anopheles mosquitoes, and Plasmodium parasites have raised hopes that 
developing new interventions might be feasible. 
 
        
Figure 2: Life cycle of Plasmodium parasite [Greenwood et al., 2008] 
 
1.1.2 Oxidative Stress and Antioxidant Defense in Malaria Parasites 
Malaria parasites are continuously exposed to oxidative and nitrosative stress. Such 
stress might be classified as exogenous or endogenous. Exogenous stress is produced by the 
immune response of the host. Endogenous stress on the other hand could either be as a result 
of the high metabolic rate of the rapidly growing and multiplying parasite which generates 
large quantities of toxic redox active byproducts or degradation of host haemoglobin by the 
parasite [Becker et al., 2005]. Haemoglobin represents the major source of amino acids for 
Plasmodium, but its degradation in an acidic food vacuole results in the production of toxic 
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free haem (ferri/ferroprotoporphyrin IX; FP) and reactive oxygen species (ROS) [Tilley et al., 
2001]. Most of the FP is sequestered into a crystalline form, known as haemozoin or malaria 
pigment [Egan et al., 2002; Slater and Cerami, 1992]. Alternative detoxification pathways, 
including FP degradation [Zhang et al., 1992; Loria et al., 1999], reaction with glutathione 
[Ginsburg et al., 1998], and the binding to FP binding proteins [Harwaldt et al., 2002; 
Campanale et al., 2003], may also contribute to FP detoxification. However, even if a small 
amount (e.g. 0.5 %) of the FP escapes the neutralisation processes, it could cause redox 
damage to the host’s proteins and membranes, inhibit parasite enzymes and lyse erythrocytes 
[Tilley et al., 2001].  
In order to maintain a redox equilibrium, malaria parasites are equipped with a range 
of antioxidant defense mechanism namely a complete glutathione system comprising of 
NADPH highly active glutathione reductase (GR), glutathione (GSH) and different 
glutaredoxin like proteins [Becker et al., 2003; Becker et al., 2004] as well as a functional 
glutathione dependent glyoxylase system and a glutathione S-transferase (GST) with 
peroxidase activity. Besides this a complete thioredoxin (Trx) system comprising of NADPH 
thioredoxin reductase (TrxR), different thioredoxin like proteins and thioredoxin dependent 
peroxidase (TPx) [Rahlfs and Becker, 2001; Muller, 2004] is present. In addition to the 
thioredoxin and glutaredoxin systems, two functional superoxide dismutase (SOD) and two 
lipoamide dehydrogenase like proteins are also present [Becker et al., 2005]. Notably, 
Plasmodium possesses neither a classical catalase nor a classical glutathione peroxidase 
[Sztajer et al., 2001]. Some of the enzymes responsible for the maintenance of redox 
equilibrium have been studied in functional and structural detail over the last few years and 
represent promising targets for the development of novel antimalarial drugs [Becker et al., 
2004]. 
 
1.2 Rationale of the Study 
Science still has no magic bullet for malaria, the Plasmodium parasites are developing 
unacceptable levels of resistance to one drug after another and many insecticides are no 
longer useful against mosquitoes transmitting the disease. Years of vaccine research have 
produced few hopeful candidates and although scientists are redoubling the search, an 
effective vaccine is at best years away. In response to this dire situation I explored the pentose 
phosphate pathway of the malaria parasite P. falciparum in particular the bifunctional enzyme 
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase, the kynurenine pathway 
enzymes indoleamine 2,3-dioxygenase (1 and 2) and the thioredoxin networks in search for a 
new potential drug target and new drug alternatives.  
 
1.2.1 Glucose-6-Phosphate Dehydrogenase 
Glucose serves as the preferred energy source for mammalian cells and for many of 
the parasitic organisms they harbour. The Embden-Meyerhof-Parnas [EMP] or glycolytic 
pathway is responsible for oxidation of glucose to pyruvate with concomitant production of 
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ATP. Glucose is also metabolised by a second route, the pentose phosphate pathway [PPP] 
also known as the hexose monophosphate shunt [HMS]. The PPP occurs in the cytosol and is 
classically divided into two major branches: non-oxidative and oxidative. In the non oxidative 
branch the pathway catalyses the interconversion of three-, four-, five-, six- and seven carbon 
sugars in a series of nonoxidative reactions that can result in the synthesis of five carbon 
sugars for nucleotide biosynthesis or the conversion of excess five carbon sugars into 
intermediates of the glycolytic pathway. The oxidative branch on the other hand is involved in 
the generation of reductive equivalents in the form of NADPH and ribose 5-phosphate whose 
derivatives are components of RNA and DNA, as well as ATP, NADH and FAD. While the 
role of EMP has been extensively investigated in many parasites, the PPP has been relatively 
neglected although the pathway does play a crucial role both in the metabolism of P. 
falciparum and in its relationship with the human host. 
 
1.2.1.1 Glucose-6-Phosphate Dehydrogenase and the Pentose Phosphate Pathway 
Glucose-6-phosphate dehydrogenase (G6PD) is a cytoplasmic so called “house 
keeping” enzyme that catalyses the first and rate limiting step of the PPP [Ruwende and Hill, 
1998]. This pathway is an important source of NADPH that is required for several 
biosynthetic reactions and is essential for maintaining adequate intracellular levels of the 
reduced form of glutathione [Becker et al., 2004]. The reduced form of glutathione is essential 
for the reduction of hydrogen peroxide and oxygen radicals and the maintenance of 
haemoglobin and other red blood cell proteins in the reduced state [Cappellini and Fiorelli, 
2008]. Since red blood cells do not contain mitochondria, the PPP is their only source of 
NADPH; therefore, defence against oxidative damage is dependent on NADPH production by 
G6PD [Luzzatto et al., 2001].  
     
 
Figure 3: Pentose phosphate pathway and defence against oxidative stress in infected red blood cells [Becker et 
al., 2004]. 
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The HMS catalysed by G6PD is also an important source of ribose which is essential 
for production of nucleotide coenzymes, the replication of nucleic acids and therefore cell 
division [Sodiende, 1992]. The biological importance of G6PD is underlined by the fact that 
this enzyme is present in all cells, however its concentration varies in different tissues 
[Battistuzzi et al., 1985] and in the red blood cells (RBC) it operates at only 1-2 % of its 
maximum potential even under induced oxidative stress [Gaetani et al., 1974].  
 
1.2.1.2 G6PD Deficiency and Malaria 
The G6PD deficiency is the most common human enzyme defect which is widely 
distributed across the globe. A conservative estimate is that at least 400 million people carry a 
mutation in the G6PD gene causing the deficiency. Since 1967 when the WHO made an 
initial recommendation for the characterisation of the G6PD deficiency, more than 400 
biochemical variants of it have been characterised according to their physicochemical 
properties (such as thermostability and chromatographic behaviour), kinetic properties 
(involving substrates glucose-6-phosphate, NADP and substrate analogues) and pH 
dependence [Beutler, 1984]. These variants of the G6PD deficiency can be grouped into five 
classes according to their enzyme activity and clinical manifestations [WHO, 1989] or 
classified as sporadic or polymorphic [Luzzatto et al., 2001]. The G6PD deficiency can be 
caused by a reduction in the number of enzyme molecules, a structural difference in the 
enzyme causing a qualitative change, or both. Examination of G6PD variants shows that, in 
most cases, the G6PD deficiency is due to enzyme instability, implying that amino acid 
substitutions or mutations at different locations can destabilise the enzyme molecule. Many 
single point mutations or amino acid substitutions have been recorded repeatedly in different 
parts of the world, suggesting that their origin is unlikely to be from a common ancestor and 
that they are therefore probably new mutations that have arisen independently [Mason et al., 
1995; Hirono et al., 1997; Vulliamy et al., 1998]. 
 
                      
Figure 4: Human G6PD structure [Au et al., 2000]. 
 
The inheritance of the G6PD deficiency shows a typical X-linked pattern, which was 
identified through favism as having a higher incidence in males than in females, long before 
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the G6PD deficiency was identified as the cause. Males are hemizygous for the G6PD gene 
and can, therefore, have normal gene expression or be G6PD deficient. Females, who have 
two copies of the G6PD gene on each X chromosome, can have normal gene expression or be 
heterozygous. In some populations, in which the frequency of the G6PD deficient allele is 
very high, homozygous females are not rare. Heterozygous females are genetic mosaics as a 
result of X chromosome inactivation (in any cell, one X chromosome is inactive, but different 
cells randomly inactivate one chromosome or the other) and the abnormal cells of a 
heterozygous female can be as deficient for G6PD as those of a G6PD deficient male; 
therefore, such females can be susceptible to the same pathophysiological phenotype [Beutler 
et al., 1962]. Although heterozygous women have on average less severe clinical 
manifestations than G6PD deficient males, some develop severe acute haemolytic anaemia 
[Lim et al., 2005]. 
 
                
Figure 5: World distribution of G6PD deficiency [WHO, 1989]. 
 
The highest prevalence of G6PD deficiency is reported in Africa, southern Europe, the 
Middle East, Southeast Asia, and the central and southern Pacific islands; however, because 
of fairly recent migration, G6PD deficiency is nowadays quite prevalent in North and South 
America and in parts of northern Europe [Frank, 2005]. Two apparent exceptions to the 
geographical rule with clear explanations exist. These are southern Europe and North 
America. Whereas malaria was only eradicated in southern Europe during the 20th century; in 
North America, the defect is confined to immigrants from regions where malaria is found, and 
the descendants of these immigrants [Greene, 1993].  
The geographical distribution of malaria is remarkably similar to that of the G6PD 
deficiency. Based on this observation Motulsky [1961], Siniscalco et al., [1961], Allison 
[1960] and Allison and Clyde [1961] suggested over 45 years ago the malaria hypothesis of 
G6PD deficiency that states “G6PD deficiency is one of the polymorphisms that confers 
resistance to infection by P. falciparum malaria” a generally well accepted notion which has 
recently been supported by Luzzatto and Bienzle [1979] and Ruwende and Hill [1998]. This 
hypothesis has been verified through various studies: 
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a) Although epidemiologic evidence indicates that the highest G6PD deficiency gene 
frequencies are present among populations living where malaria disease is endemic 
[Luzzatto and Battistuzzi, 1985; Siniscalco et al., 1966], the relationships or 
connections between G6PD deficiency and malaria disease have been questioned 
[Luzzatto and Battistuzzi, 1985; Kidson and Gorman, 1962]. Early studies designed to 
assess this connection were somewhat contradictory and could not give conclusive 
evidence [Martin et al., 1979; Oo M et al., 1995; Bienzle et al., 1972; Guggenmoos-
Holzmann et al., 1981]. This led to the suggestion that an additional factor, perhaps 
oxidative stress [Greene, 1993; Martin, 1980], may be required for G6PD deficiency 
to confer immunity to malaria. The malaria parasite appears to be sensitive to 
oxidative stress [Becker et al., 2004] and it has been suggested that the eating of fava 
beans and the G6PD deficiency synergistically protects against malaria [Greene 1993; 
Clark et al., 1984; Golenser et al., 1988]. However it is difficult to explain protection 
against malaria on this basis in sub-Saharan Africa where fava beans are not 
cultivated.  
b) Decreased parasitemia among patients with G6PD deficiency when compared with 
normal individuals was originally reported by Allison [1960] and Allison and Clyde 
[1961] and has been confirmed in a number of studies [Luzzatto and Battistuzzi, 1985; 
Gilles et al., 1967; Kar et al., 1992]. A number of negative studies have also been 
reported but are considered to be flawed [Greene, 1993]. Although one study indicated 
that protection extended only to heterozygous females [Bienzle et al., 1972], this 
conclusion has not been borne out in other investigations and it seems likely that 
hemizygous males are also protected [Greene, 1993]. However, based on the disputed 
finding that it is heterozygotes that are resistant to malaria, an interesting explanation 
was devised. It was suggested that when deficient cells are parasitised, the parasite 
G6PD is eventually induced, but it requires several cycles in deficient host cells. 
Heterozygotes, who have a mixture of normal and deficient cells, would host the 
parasite in normal cells often enough to prevent the induction of the enzyme [Luzzatto 
et al., 1986; Usanga and Luzzatto, 1985]. However, subsequent data from the same 
group of investigators indicated that in reality, the G6PD activity of the host cells did 
not influence the expression of the parasite enzyme [Kurdi-Haidar and Luzzatto, 
1990]. Ruwende and colleagues have recently been able to reveal that the G6PDH A– 
allele (the most prevalent in Africa) is associated with a reduction in the risk of severe 
P. falciparum malaria, for female heterozygotes and male hemizygotes (46 % and 58 
%, respectively) [ Ruwende et al., 1995]. 
c) Studies in heterozygotes for G6PD deficiency, in which two populations of RBCs 
coexist, show that more parasites are present in the cells with normal enzyme activity 
than in the deficient cells. In an elegant investigation of the number of parasites in the 
RBCs of patients heterozygous for G6PD deficiency, Luzzatto et al., [1969] showed 
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that more parasites (2-80 times more) could be found in G6PD sufficient cells than in 
G6PD deficient ones. 
d) In vitro studies show that malaria parasite growth was slower in G6PD deficient than 
in normal cells [Luzzatto et al., 1986; Roth and Schulman 1988; Usanga and Luzzatto 
1985; Roth et al., 1983]. Cappadoro et al., [1998] were also able to show that G6PD 
deficient RBCs infected with parasites undergo phagocytosis by macrophages at an 
earlier stage of parasite maturation than do normal RBC with parasitic infection, 
which could be a further protective mechanism against malaria. 
At the molecular level the most likely explanation attributes the G6PD deficiency 
protection mechanism against malaria to reduced multiplication in deficient RBC, probably as 
a result of the intracellular accumulation of toxic oxidised substances such as oxidised 
glutathione and haemozoin [Turrini et al., 1993; Miller et al., 1984; Golenser et al., 1988]. 
However there is some evidence that infected RBCs are more susceptible to haemolysis as a 
result of increased methaemoglobin and release of ferriheme a known cytolytic agent [Janney 
et al., 1986], and that in addition they are more readily phagocytosed by cells of the 
reticuloendothelial system as a result of the RBC changes (i.e. methaemoglobin and heinz 
body formation, membrane damage) that are associated with oxidative stress imposed by the 
parasite infection [Turrini et al., 1993].    
 
                    
Figure 6: Possible protective mechanisms of the G6PD deficiency against severe malaria [Ruwende and Hill, 
1998]. 
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When a gene that has some potential for decreasing fitness achieves a high frequency 
in some populations, it is necessary to assume that in those populations it also confers a 
survival advantage. Thus, a balance is achieved between the advantage (resistance to malaria) 
and the disadvantage (lowered resistance to oxidative stress) conferred by a gene, and this is 
designated a balanced polymorphism. Evidence from a variety of sources has led to the 
conclusion that the advantage conferred by this gene is resistance to P. falciparum malaria 
[Beutler, 1994]. 
In most areas with a prevalence of the G6PD deficiency, several polymorphic alleles 
are found [Cappellini et al., 1996; Martinez di Montemuros et al., 1997]. Tropical regions of 
Africa where malaria is endemic are one exception, where the variant G6PD A– accounts for 
about 90 % of G6PD deficiency. G6PD A– is also frequent in North and South America, in 
the West Indies, and in areas where people of African origin are present [Martinez di 
Montemuros et al., 1997; Cappellini et al., 1994]. The second most common variant is G6PD 
Mediterranean, which is present in all countries surrounding the Mediterranean Sea [Luzzatto 
et al., 2001], and is also widespread in the Middle East, including Israel [Kurdi-Haidar et al., 
1990; Karimi et al., 2003]. In several populations, such as the countries around the Persian 
Gulf, G6PD A– and G6PD Mediterranean coexist at polymorphic frequencies [Bayoumi et 
al., 1996]. Other polymorphic variants are the Seattle and Union variants, which have been 
reported in southern Italy, Sardinia [Fiorelli et al., 1989; De Vita et al., 1989], Greece, the 
Canary Islands [Cabrera et al., 1996], Algeria, Germany, and Ireland. G6PD Union was also 
reported in China [Perng et al., 1992], and G6PD Maewo which by molecular analysis was 
shown to be G6PD Union is polymorphic in the corresponding island in the Vanuatu 
archipelago [Ganczakowski et al., 1995]. 
 
1.2.1.3 Glucose-6-Phosphate Dehydrogenase-6-Phosphogluconolactonase from 
             P. falciparum  
More than 41 years ago Langer et al., [1967] demonstrated the existence of G6PD 
activity in P. berghei, but the inability to confirm these findings through several subsequent 
investigations [Sherman, 1979] coupled with the clear documentation and reproducible 
findings on the existence of the second enzyme (6-phosphogluconolactonase) of the PPP 
[Fletcher et al., 1977] reaffirmed the theory that disputed the existence of the complete PPP in 
the Plasmodium parasite and suggested that the parasite made use of the host G6PD enzyme 
to carry out the initial step of the PPP [Eckman and Eaton, 1979]. The presence of P. 
falciparum G6PD activity was first reported 14 years later by Hempelmann and Wilson 
[1981]. A slow moving band on acrylamide gels which corresponded to a high molecular 
weight compared to the RBC G6PD was identified to be that of P. falciparum G6PD 
[Hempelmann and Wilson, 1981; Ling and Wilson, 1988; Kurdi-Haidar and Luzzatto, 1990]. 
Further studies on the enzyme lead not only to its identification and partial purification but 
also showed that the enzyme was present at similar levels in both G6PD deficient and normal 
host cells [Ling and Wilson, 1988; Kurdi-Haidar and Luzzatto, 1990]. Suggesting that parasite 
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G6PD activity was expressed independently from induction and adaptation to deficient cells 
[Kurdi-Haidar and Luzzatto, 1990].  
The nucleotide sequence encoding the enzyme has been cloned and sequenced 
[Shahabuddin et al., 1994; O’Brien et al., 1994]. The primary structure as predicted from the 
gene sequence was found to be remarkably different from any of the 50 or so other G6PDs 
whose structure is known or inferred. The deduced protein has a subunit molecular weight of 
107 kDa. The C- terminal part (residues 311-911) is clearly homologous to other described 
G6PDs [Jeffery et al., 1993]. The 310 amino acid protein sequence of the N-terminal region 
clearly differs from most eukaryotic and prokaryotic G6PDs and shows 6-
phosphogluconolactonase (6PGL) activity [Scopes et al., 1997]. Genes encoding very similar 
enzymes have also been found in four other Plasmodium parasites namely, P. berghei, P. 
yoelii, P. chabaudi and P. knowlesi [Clark et al., 2003]. Thus the first two steps of the PPP in 
Plasmodium are catalysed by a unique bifunctional enzyme named glucose-6-phosphate 
dehydrogenase-6-phosphogluconolactonase (GluPho) [Clark et al., 2001; Scopes et al., 1997] 
which is exclusively found in Plasmodium species.  
A unique feature of PfGluPho is the 62 amino acid insert (within the G6PD part) found 
between the structurally predicted NADP+ and G6P binding site that has no similarity found 
to date. Similar inserts which differ in size and sequence are present in other Plasmodium 
GluPho and have nevertheless been demonstrated to be essential for GluPho activity [Clark et 
al., 2003]. 
 
 
 
 
 
 
Figure 7: Sequence comparison of inserts within five Plasmodium GluPho proteins and human G6PD. 
Completely conserved amino acids are shaded black, highly conserved amino acids are shaded grey and insertion 
sequences are italicised. Potential N-glycosylation sites are underlined [Clark et al., 2003]. 
 
Further studies to determine if the unique structural features of PfGluPho have any 
biological significance may be useful in understanding the role PfGluPho plays in the PPP 
and in overcoming oxidative stress. Particularly because PPP activity in infected RBCs is 
greatly increased (78 fold) compared to non infected ones, and the parasite PPP is responsible 
for 82 % of this activity [Atamna et al., 1994]. RNA-mediated gene silencing of PfGluPho in 
cell culture has demonstrated an arrest of the parasite life cycle at the trophozoite stage. 
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Immediate transcript enhancement of thioredoxin reductase suggests that the PfGluPho plays 
a role in the response of the parasite to oxidative stress [Crooke et al., 2006].  
In the battle to eradicate malaria effectively, new drug targets are needed. An essential 
feature for a molecule to be considered as a potential drug target is that it must be 
distinguishable from its homologues in the human host. The enzyme PfGluPho might prove 
valuable in this respect, as mammals do not express this bifunctional enzyme and do not 
express insertion sequences within their two monofunctional proteins. 
 
1.2.2 Tryptophan Metabolism: Kynurenine Pathway 
Tryptophan is an essential amino acid that is required in several physiological 
processes in addition to protein synthesis. Dietary tryptophan enters the liver through the 
hepatic portal system, where it has been demonstrated to induce protein synthesis [Sidransky, 
1976]. Excess tryptophan can be delivered to the bloodstream, where it can be taken up by 
tissues and used in protein synthesis or in the synthesis of serotonin and melatonin. The 
dietary intake of tryptophan correlates with the ratio of tryptophan to large neutral amino 
acids in the plasma and with brain serotonin levels [Fernstrom and Wurtman, 1972]. Thus 
acute depletion of tryptophan has effects on mood and aggression through causing low 
serotonin levels [Young and Leyton, 2002]. An alternative fate for L-tryptophan is catabolism 
through the kynurenine pathway. Named after the pivotal metabolite kynureneine, the first 
and rate-limiting step in the pathway is the oxidative cleavage of the 2,3-double bond of the 
indole ring of tryptophan via the incorporation of molecular oxygen or a superoxide anion, a 
reaction that converts tryptophan to N-formylkynurenine, which is quickly catabolised to 
kynurenine [Shane and Stocker, 1999]. 
 
 
Figure 8: Initial steps of the kynurenine pathway. The heme containing enzymes TDO, IDO-1 and IDO-2 are 
capable of catalysing this reaction [Austin et al., 2008]. 
 
The first and rate limiting step in the kynurenine pathway is performed by either of the 
two enzymes, tryptophan 2,3 dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). 
The first of these, TDO an enzyme whose activity can be induced by dietary tryptophan and 
steroid hormones [Schimke et al., 1965; Knox, 1966], was first described in 1937 [Kotake and 
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Masayama, 1937]. It is a heme-containing protein mostly expressed in the liver and it is able 
to metabolise L- but not D-tryptophan [Schutz et al., 1972; Bender, 1989]. 
Indoleamine 2,3-dioxygenase (IDO-1) is the second enzyme able to open the indole 
ring of tryptophan. Its existence was suspected for a long time because a large percentage of 
patients with rheumatoid arthritis, tuberculosis, leukaemia, Hodgkin’s disease and bladder 
tumours excreted exceptionally large amount of kynurenine into the urine without having an 
induced TDO in the liver. The enzyme was firstly described by Hayaishi et al. in the early 
1960s in the rabbit intestine as a heme-containing protein (42,000 MW) able to catalyse the 
incorporation of superoxide anion into the pyrrole moiety of indole [Hayaishi et al., 1984]. 
The name indoleamine 2,3-dioxygenase originates from the proposed importance of the 
enzyme in the metabolism of the indoleamines 5-hydroxytryptamine (5-HT), tryptamine and 
melatonin [Hirata and Hayaishi, 1975; Yoshida and Hayaishi, 1987]. 
In fact, while TDO specifically acts on L-tryptophan, IDO-1 may open the indole ring 
of the amines, D-tryptophan, L- or D-5-OH-tryptophan, but it is not active on scatole, indole 
or indole acetic acid. Furthermore, while 
TDO is predominantly located in the liver, 
IDO-1 is present in most mammalian organs, 
including intestine, placenta, lung, blood 
mononuclear phagocytes, epididymis, 
endocrine and central nervous systems 
[Watanabe et al., 1981]. IDO-1 is normally 
highly expressed in inflammatory states with 
interferon-gamma (IFNγ) and tumor necrosis 
factor (TNF) playing key mediatory roles in 
its expression [Takikawa et al., 1999; 
Fujigaki et al., 2001]. Induction of IDO-1 in 
endothelial cells by IFNγ has been shown to 
inhibit the growth of various infectious 
agents, including Toxoplasma gondi, 
Clamydia psittaci, C. trachomatis, 
Enterococci, Staphylococcus aureus, herpes 
simplex virus, measles virus and 
cytomegalovirus [MacKenzie et al., 2007; 
Schroten et al., 2001; Daubener et al.,         
2001; Pfefferkorn, 1984] through tryptophan 
depletion.        
The expression of IDO-1 also has an 
immunomodulatory role in inducing tolerance  
Figure 9: Kynurenine pathway of tryptophan metabolism 
[Ball et al., 2008]. 
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by suppressing T-lymphocyte proliferation via tryptophan depletion with far implications in 
many fields of medicine, including fetal rejection and organ transplant survival [Munn et al., 
1999]. The downstream metabolites of the kynurenine pathway can have physiological or 
patho-physiological activities, and it is not always clear whether the induction of this pathway 
exerts its effects through tryptophan depletion, by production of kynurenine and/or 
kynurenine derived metabolites or a combination of these two processes.  
For example, the proliferation of T-lymphocytes is inhibited by downstream 
catabolites of the kynurenine pathway [Frumento et al., 2002]. Two of the major metabolites 
formed by the pathway are kynurenic acid (KA) and quinolinic acid (QA), both of which can 
bind to glutamate receptors activated by N-methyl-D-aspartate (NMDA). Kynurenic acid acts 
as an antagonist for NMDA receptors whereas QA is an agonist and may be neuroexcitotoxic 
at physiological concentrations [Perkins and Stone, 1982; Schwarcz et al., 1983].  
Quinolinic acid acts through the excitatory amino acid acceptor site on the NMDA 
receptor [Schurr and Rigor, 1993; Stone et al., 2001], whereas kynurenic acid acts through the 
glycine binding site to inhibit the excitatory actions of glutamate, NMDA and kainic acid 
[Perkins and Stone, 1982; Stone et al., 2003]. Thus, the kynurenine pathway of tryptophan 
metabolism generates both a potential neuroexcitotoxin quinolinic acid and a neuroprotectant 
kynurenic acid and the balance between the levels of these molecules is critical in determining 
the consequences of activation of this pathway. The (neuroexcitotoxin : neuroprotectant) QA: 
KA ratio as well as IDO-1 activity have been found to be increased in experimental celebral 
malaria mouse implying that this imbalance contributes to the neurological symptoms and 
perhaps the morbidity of celebral malaria [Sanni et al., 1998]. 
The accumulation of QA within the brain has also been reported to occur in a broad 
spectrum of patients or experimental animals with inflammatory neurological diseases such as 
acquired immunodeficiency (AIDS) dementia complex caused by an infection of 
immunodeficiency virus type 1 (HIV-1) [Heyes et al., 1991], poliovirus brain infection, and 
isechemic brain injury [Saito et al., 1993]. The cerebrospinal fluid levels of QA correlated 
well with the severity of the neurological defects thus suggesting that QA plays a direct role 
in the pathogenesis of neurodegenerative disorders. The production of QA closely reflects the 
induction of the first and rate limiting enzyme IDO-1 in the kynurenine pathway within the 
central nervous system [Heyes et al., 1991]. Therefore the upregulation of IDO-1 in the brain 
leads to an accumulation of QA and results in neural degeneration. 
Since the 1970s it has been believed that the first and rate limiting step in the 
kynurenine pathway is performed by either of two enzymes, tryptophan 2,3-dioxygenase 
(TDO) or indoleamine 2,3-dioxygenase (IDO-1), depending on the tissue and cell type. 
Although Shimizu et al., [1978] demonstrated in their work the existence of 3 various forms 
of IDO which differed in their isoelectric points; it was still believed that only IDO-1 and 
TDO were responsible for catalysing the first and rate-limiting step in the kynurenine 
pathway. This paradigm was overturned recently when a gene with homology to IDO was 
reported [Murray, 2007] and then subsequently demonstrated by three groups to encode an 
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enzyme with the ability to catabolise tryptophan [Ball et al., 2007; Metz et al., 2007; Yuasa et 
al., 2007]. The enzyme has been referred to as indoleamine 2,3-dioxygenase like protein, 
indoleamine 2,3-dioxygenase-2 or proto indoleamine 2,3-dioxygenase (INDOL1, IDO-2, 
IDO2, protoIDO) on the basis of its structural similarity to IDO-1 and its enzymatic activity. 
In mice, IDO-2 is predominantly expressed in the kidney followed by epididymis, testis and 
liver [Ball et al., 2007] as well as in the ovary and uterus. Although both IDO proteins are 
expressed in some tissues, e.g. epididymis, immunohistochemistry demonstrated that IDO-1 
and IDO-2 are expressed in distinct cell types suggesting they are not functionally redundant. 
For example, IDO-1 was found in the principal and apical cells of the mouse caput 
epididymidis whilst IDO-2 is expressed in the tails of spermatozoa [Ball et al., 2007]. In 
addition, expression of the proteins in response to stimuli differs. For example, IDO-1 is 
induced systemically in endothelial cells during murine malaria infection, and this induction is 
dependent on the presence of interferon gamma [Hansen et al., 2004], whereas IDO-2 mRNA 
expression is unchanged or down-regulated [Ball et al., 2007]. The tryptophan catabolising 
activity of IDO-2 expressed in intact mammalian cells has been demonstrated [Ball et al., 
2007; Metz et al., 2007]. The depletion of tryptophan by IDO-1 and IDO-2 activity also 
triggered signalling pathways such as phosphorylation of the translation initiation factor eIF-
2α and translation of liver enriched inhibitory protein (LIP), an inhibitory isoform of CEPBβ 
transcription factor [Metz et al., 2007]. As the discovery of the IDO-2 enzyme is so recent, its 
biological role is still yet to be defined but its expression pattern in the kidney, reproductive 
system and a dendritic cell line suggest its involvement in kidney function, fertility and 
immunomodulation [Ball et al., 2008]. 
 
1.2.3 Thioredoxin Networks: Glutaredoxin, Thioredoxin and Plasmoredoxin 
Plasmodium parasites posses a number of proteins belonging to the thioredoxin 
superfamily which are characterised by a specific active site Cys-X-X-Cys motif [Rahlfs et 
al., 2003]. Despite the low degree of similarity between their primary sequences, the proteins 
are structurally related and they all posses the so called thioredoxin fold and have similar 
functions within the cell [Fernandes and Holmgreen, 2004]. They are considered to be redox 
messengers that interact with a variety of redox active proteins and metabolites such as 
ribonucleotide reductase, transcription factors, peroxidases, cyclophilins and low molecular 
weight thiols [Fernandes and Holmgreen, 2004]. 
Plasmodium falciparum possesses one classical glutaredoxin with the typical CPYC 
redox active site [Rahlfs et al., 2001]. This active site motif allows glutaredoxin to interact 
with proteins containing sulphydryl groups that need to be either oxidised or reduced, 
depending on their distribution, the redox state of the cell and their abundance. Plasmodium 
glutaredoxin has the ability to reduce ribonucleotide reductase and acts as an efficient 
reductant for plasmoredoxin, another member of the thioredoxin superfamily [Rahlfs et al., 
2001; Becker et al., 2003]. 
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Plasmoredoxin itself appears to be unique to Plasmodium parasites and contains a 
unique active site WCKYC motif [Rahlfs et al., 2001; Becker et al., 2003]. Its precise 
function in Plasmodium remains to be elucidated but it has been found to also reduce 
ribonucleotide reductase. In addition, Plasmodium possesses a genuine thioredoxin (Trx) 
[Kanzok et al., 2000; Rahlfs et al., 2002] which is reduced by thioredoxin reductase (PfTrxR) 
and confers reduction of the 2-Cys containing peroxiredoxin, ribonucleotide reductase and 
GSSG [Rahlfs et al., 2001; Rahlfs et al., 2003; Kanzok et al., 2000]. Thus all three members 
of the thioredoxin superfamily have overlapping functions in Plasmodium. 
Plasmodium also possesses thioredoxin and glutaredoxin like proteins which are 
thought to be involved in the reduction of protein-GS-mixed disulphides that are inevitably 
formed during exposure to ROS and generally lead to a reversible inactivation of protein 
functions [Rahlfs et al., 2001; Rahlfs et al., 2003]. 
 
1.3 General Objective 
Plasmodium parasites are developing unacceptable levels of resistance to one drug 
after another and science still has no magic bullet for malaria. Therefore there is need for 
identification of new drug targets and alternative antimalarial regimes. The study aimed at 
evaluating PfGluPho as a new drug target, understanding tryptophan metabolism and 
unravelling more knowledge about the thioredoxin system networks. 
 
1.3.1 Specific Objectives 
1.3.1.1 Glucose-6-phosphate Dehydrogenase-6-Phosphogluconolactonase from  
P. falciparum 
PfGluPho is a unique bifunctional enzyme which is exclusively found in Plasmodium 
species and catalyses the first two steps of the PPP. In spite of the importance of the role this 
enzyme plays in the parasites PPP as well as in overcoming oxidative stress, studies using 
PfGluPho have so far been restricted to the enzyme purified from parasite extract which is not 
only limiting in terms of the quantity of the enzyme required for inhibitor testing, crystal 
screening and biochemical characterisation of the enzyme, but also contains a high excess of 
the RBC G6PD. The desire and difficulties in cloning PfGluPho have also been reported 
[O’Brien et al., 1994; Clark et al., 2001] thus making it impossible to heterologously 
overexpress PfGluPho. This study aimed at cloning, heterologous overexpression and 
purification to homogeneity of PfGluPho in order to obtain the purified enzyme in mg 
quantities. This would enable us to perform biochemical characterisation of the enzyme, 
screen for novel inhibitors and attempt to elucidate the three dimensional structure of the 
enzyme through crystallisation and x-ray diffraction analysis. 
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1.3.1.2 Tryptophan Metabolism 
Indoleamine 2,3-dioxygenase, the first and rate-limiting enzyme in tryptophan 
metabolism, has been implicated in the pathogenesis of many diseases. The discovery of IDO-
2 has not helped the situation but has demonstrated that the kynuenine pathway could be 
implicated in the pathogenesis of many other diseases than earlier thought. Inhibition of IDO 
has been targeted for the therapy of diseases such as cancer, neurological disorders and most 
notably cerebral malaria. Although IDO inhibitors exist, most of them exhibit their inhibitory 
activities at micromolar Ki values. As a result there is need for more potent IDO inhibitors. It 
would be highly advantageous to have access to large quantities of recombinant IDO-1 and 
IDO-2 to allow for development of more potent IDO inhibitors and allow for further studies 
on the enzymes. This study aims at heterologous overexpression and purification of mouse 
IDO-1 and IDO-2 to homogeneity. This would enable us to obtain sufficient amounts of the 
enzyme for biochemical characterisation (e.g. oligomerisation studies, kinetic 
characterisation), crystallisation trials and finally screen for more potent novel inhibitors for 
IDO. We also intend to test the antimalarial activity in P. falciparum cell culture for the IDO 
inhibitors that will be identified.   
 
1.3.1.3 Thioredoxin Networks: Glutaredoxin, Thioredoxin and Plasmoredoxin 
The P. falciparum parasite is endowed with a complex network of interacting enzymes 
which together form the redox metabolism network. Some of the members of this network 
have been demonstrated to have overlapping functions e.g. members of the thioredoxin 
superfamily. Their active site motifs allow them to interact with proteins containing 
sulphydryl groups that need to be either oxidised or reduced, depending on their distribution, 
their redox potential, the redox state of the cell and their abundance. More than 50 % of all the 
predicted parasite proteins functions are still unknown. Therefore the possibility that members 
of the thioredoxin super family could be interacting with novel proteins is rather high. This 
study aimed at identifying proteins which interact with and might be regulated by members of 
the thioredoxin superfamily namely glutaredoxin, plasmoredoxin and thioredoxin in 
Plasmodium parasites. 
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2 Materials  
2.1 Chemicals 
All chemicals used were of the highest available purity and were obtained from Roth 
(Karlsruhe, Germany), Merck (Frankfurt am Main, Germany) or Sigma-Aldrich (Steinheim, 
Germany). 
 
Chemical Source 
Acetic acid Roth, Karlsruhe 
Acrylamide solution BioRad, München 
Ampicillin Sigma, Steinheim 
Ascorbic acid Sigma, Steinheim 
Bacto Agar Roth, Karlsruhe 
Boric acid Roth, Karlsruhe 
Bovine serum albumin Roth, Karlsruhe 
Bromophenol blue Sigma, Steinheim 
Carbenicillin Roth, Karlsruhe 
Chloramphenicol Roth, Karlsruhe 
Coomassie brilliant blue R250 Sigma, Steinheim 
Cystatin Roth, Karlsruhe 
Ethidium Bromide Sigma, Steinheim 
Ethylenediaminetetraacetate (EDTA) Roth, Karlsruhe 
Gentamycin Gibco, Karlsruhe 
Glucose-6-phosphate Na-salt Sigma, Steinheim 
Glucoseamine-6-phosphate Sigma, Steinheim 
Deoxyglucose-6-phospate Sigma, Steinheim 
Glycerin    Roth, Karlsruhe 
Hypoxanthin Sigma, Steinheim 
Imidazole Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
Isopropylthiogalactoside (IPTG) Roth, Karlsruhe 
K2HPO4 Roth, Karlsruhe 
Kanamycin Roth, Karlsruhe 
KH2PO4    Roth, Karlsruhe 
Lipid rich bovine serum albumin (Albumax) Gibco, Karlsruhe 
Magnesium chloride Roth, Karlsruhe 
Mercaptoethanol Sigma, Steinheim 
Methyl tryptophan Sigma, Steinheim 
Methylene blue Roth, Karlsruhe 
Milk powder BioRad, München 
NADP Biomol 
NADPH Biomol 
Nickel-nitrilotriacetic acid (Ni-NTA)  Qiagen, Hilden 
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p-Dimethylaminobenzaldehyde (p-DMAB) Sigma, Steinheim 
Pepstatin Sigma, Steinheim 
Phenylmethylsulfonylfluoride (PMSF) Sigma, Steinheim 
Rhamnose Promega. Mannheim 
Sodium chloride Roth, Karlsruhe 
Sodium dodecyl sulphate (SDS) Merck, Darmstadt 
Sorbitol Roth, Karlsruhe 
TEMED Sigma, Steinheim 
Trichloroacetic acid Sigma, Steinheim 
Tris Roth, Karlsruhe 
Trypton Roth, Karlsruhe 
Tryptophan Merck, Darmstadt 
Tween 20 Merck, Darmstadt 
Yeast  Extract Oxoid LTD, U.K 
δ-Aminolevulinic acid hydrochloride (ALA) Sigma, Steinheim 
 
2.2 Antibodies 
Antibody Source 
Mouse anti-histidine tag antibodies Qiagen, Hilden 
Anti-mouse antibody Pearce 
Anti-rabbit antibody Pearce 
Glucose-6-phosphate dehydrogenase peptide specific antibody Eurogentech, Belgium 
6-phosphogluconolactonase peptide specific antibody Eurogentech, Belgium 
 
2.3 Enzymes 
Enzymes Source 
Catalase Sigma, Steinheim 
DNase 1 Roche, Mannheim 
Pfu Polymerase Promega, Mannheim 
Quick DNA ligase New England Biolabs, U.K 
Red Taq polymerase Sigma, Steinheim 
Restriction enzymes MBI, Fermentas 
Yeast Glucose-6-phosphate dehydrogenase Sigma, Steinheim 
Yeast Phosphogluconate dehydrogenase Sigma, Steinheim 
 
2.4 Antibiotics Concentrations 
 Antibiotic                           Stock solution Working concentration 
Carbenicillin                   50 mg/ml in 50 % ethanol 100 µg/ml 
Kanamycin                      25 mg/ml in water   50 µg/ml 
Chloroamphenicol           25 mg/ml in 100% ethanol   25 µg/ml 
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2.5 Kits 
Kit Source 
Amine coupling kit and chip Biacore AG, Sweden 
Bradford kit Biorad, München 
Crystallisation kit (crystal screen 1& 2) Hampton Research, Laguna 
Niguel, U.S.A 
Primers  MWG-Biotech AG, Ebersberg 
QIAprep spin mini prep kit  Qiagen, Hilden 
QIAquick PCR purification kit  Qiagen, Hilden 
Western lightning chemiluminescence reagent Perkin Elmer, Boston, U.S.A 
 
2.6 Biological Materials 
2.6.1  Plasmids 
Plasmids Antibiotic Resistance  Source 
pDest 17 Carbenicillin Invitrogen 
pRARE I & II Chloroamphenicol Novagen, Darmstadt 
pET-28a Kanamycin Novagen, Darmstadt 
pSK Carbenicillin Stratagen 
pRIG Chloroamphenicol, tRNAs for R, I and G Wim Hol, (Baca & Hol, 2000) 
 
2.6.2 Escherichia coli Cells 
E. coli strain Genotype Source 
KRX  [F’, traD36, ∆ompP, proA+B+, lacIq, ∆(lacZ)M15] 
∆ompT, endA1, recA1, gyrA96 (Nalr), thi-1, hsdR17 
(rk-, mk+), e14- (McrA-), relA1, supE44, ∆(lac-proAB), 
∆(rhaBAD): T7 RNA Polymerase 
Promega, 
Mannheim 
Rosetta BL21 lacYZ deletion, Lacks Ion and ompT protease Novagene 
Novablue endA1, hsdR17, (rk12- mk12), supE44, thi-1, recA1, 
gyrA96, relA1, lacF’[proAB, lacI qZM15, Tn10 (Tetr)] 
(DE3-λcIst857, ind1, sam7, nin5, lacUV5-T7 gene1) 
Novagene 
C41 Miroux and Walker 1996 Avidis 
PD2000 (G6PD 
mutant cells)  
garB10, fhuA22, ompF627(TR2), zwf-2, fadL701(TR2), 
relA1, pit-10, spoT1, rrnB-2, pgi-2, mcrB1, creC510 
Fraenkel, D 
Yale University 
 
2.6.3 Plasmodium falciparum Strains 
Strain Origin  Source 
K1 (Chloroquine-resistant strain) South-East Asia AG Prof. Lanzer, Heidelberg 
Dd2 (Chloroquine-resistant strain) Indochina AG Prof. Lanzer, Heidelberg 
HB3 (Chloroquine-sensitive strain) Honduras AG Prof. Lanzer, Heidelberg 
3D7 (Chloroquine-sensitive strain) Netherlands AG Prof. Lanzer, Heidelberg 
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2.7 Buffers and Solutions 
2.7.1 Buffers for Determination of Enzyme Activity  
G6PD assay buffer 100 mM Tris 
 10 mM  MgCl2 
 0.5 mM EDTA 
 pH 8.0  
G6PD assay buffer for intact red blood cells 100 mM Tris 
 10 mM MgCl2 
 0.5 mM EDTA 
 0.03 mM Digitonin 
 pH 8.0  
IDO assay buffer 100 mM Potassium phosphate 
 100 mM KCl 
 20 mM Ascorbic acid 
 200 µg/ml Catalase 
 10 µM Methylene blue 
 pH 6.5  
 
2.7.2 Buffers and Solutions for DNA Electrophoresis 
10 × TBE 1 M Tris 
 1 M Boric acid 
 20 mM EDTA 
 pH 8.0 with acetic acid 
DNA sample buffer 0.1 % Bromophenolblue 
 1 mM   Tris 
 60 % Saccharose 
 pH 8.3 with HCl 
 
2.7.3 Buffer for Extraction of P. falciparum Parasites from Red Blood Cells 
Saponin lysis buffer 0.02 % 
(w/v) 
Saponin 
 7 mM K2HPO4 
 1 mM NaH2PO4 
 11 mM NaHCO3 
 58 mM KCl 
 56 mM NaCl 
 1 mM MgCl2 
 14 mM Glucose 
 pH 7.4 using HCl 
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2.8 Protease Inhibitors 
Inhibitor                           Stock solution Working concentration 
PMSF 100 mM in ethanol 10 µl /10 ml US buffer 
Pepstatin A 0.3 mM in DMSO   5 µl /10 ml US buffer 
Cystatin 40 µM in US buffer 10 µl /10 ml US buffer 
 
2.9 Medium for E. coli Culture 
Luria-Bertani (LB) 5 g  Trypton 
 10 g  Yeast extract 
 5 g  NaCl 
                                 ad 1000 ml bidistilled H2O and autoclave 
Terrific Broth (TB) 12 g Trypton 
 24 g  Yeast extract 
 9.4 g K2HPO4 
 2.2 g KH2PO4 
 4 ml Glycerol 
                                                         ad 1000 ml bidistilled H2O, autoclave and pH 7.0 ± 0.2 
2 x YT 16 g Trypton 
 10 g Yeast extract 
 5 g NaCl 
                                                         ad 1000 ml bidistilled H2O and autoclave 
 
2.10 Instruments 
Instrument Company 
Analytical Balance Scaltec Instruments, Göttingen 
Beckmann Spectrophotometer DU® 650 Beckman, München 
Biacore X Biacore AG, Sweden 
Biophotometer Eppendorf, Hamburg 
Infinite M200 multiplate reader Tecan 
ÄKTA/ Unicorn- FPLC system Amershan Pharmacia Biotech 
Hitachi Spectrophotometer U-2001 Hitachi Ltd, Tokyo 
Incubator shaker Thermo Life Sciences, Egelsbach 
Microscope Axiostar Zeiss, Jena 
Mini-Spin Table Centrifuge Eppendorf, Hamburg 
OptimaTM TLX Ultracentrifuge Beckman, München 
PCR – Normal and – Gradient cyclers Eppendorf, Hamburg 
pH-Meter (Φ 350 pH/ Temp/ mV Meter) Beckman, München 
Quarz cuvettes Hellma, Müllheim 
Salvant, SpeedVac, Vacuum centrifuge Thermo Life Sciences, Egelsbach 
Sonicator Bandelin Electronics, Berlin 
Sorvall Centrifuge RC5C Du Pont Company, Wilmington 
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3 Methods 
3.1  General Methods 
3.1.1 Preparation of Competent E. coli Cells  
LB media (3 ml) containing the right antibiotic was inoculated with a small amount of 
E. coli cells glycerine storage culture and grown overnight in a shaking incubator at 37 oC. 
100 ml of LB media containing the right antibiotic was then inoculated with the overnight 
culture and left to grow in a shaking incubator at 37 oC until an O.D600 value of between 0.6-
0.8 was achieved. The culture was then put into 4 Falcon tubes (25 ml into each) and placed 
on ice for 10 minutes. The culture was then centrifuged at 4000 rpm at 4 oC for 10 minutes to 
obtain a pellet, which was resuspended in 10 ml of ice cold 0.1 M CaCl2 containing 10 % 
glycerine and left to stand on ice for 15 minutes. The resuspended pellet was again 
centrifuged at 4000 rpm at 4 oC for 10 minutes to obtain a pellet. The pellet was this time 
quickly resuspended in 1 ml of ice cold 0.1 M CaCl2 containing 10 % glycerine. Into clearly 
labelled Eppendorf tubes, the resuspension was quickly aliquoted (50 µl into each), placed 
into liquid nitrogen for 2-5 minutes and then stored at -80 oC. The cells were competent and 
ready for use. 
 
3.1.2 Preparation of Competent E. coli Cells Containing pRARE or pRIG Plasmid  
Competent E. coli cells were transformed with the pRARE or pRIG plasmid as 
outlined under 3.1.3 transformation of competent E. coli cells. After colonies appeared on the 
LB agar plates containing the right antibiotic, one colony was picked and used to inoculate 3 
ml of LB media containing antibiotic and grown in a shaking incubator overnight at 37 oC. 
100 ml of LB media containing the right antibiotic was then inoculated with the overnight 
culture and the competent cells were then prepared as outlined in 3.1.1. 
 
3.1.3 Transformation of Competent E. coli Cells 
To 50 µl of competent E. coli cells 2 µl of the plasmid was added and mixed 
thoroughly by use of a pipette and left to stand on ice (4 oC) for 30 minutes. After 30 minutes 
heat shock was induced for 90 seconds at 42 oC and the cells were then placed on ice again for 
2 minutes. Approximately 400 µl of LB media was added to the cells and stood for 1 hour at 
37 oC, after which the cells were plated on LB agar plates containing the right selection 
marker or antibiotics. The plates were incubated overnight in an incubator at 37 oC and 
colonies were observed the next day.  
 
3.1.4 SDS-Polyacrylamide Gel Electrophoresis 
Sample buffer 62.5 mM Tris-HCL 
 25 % Glycerol 
 2 % SDS 
 0.01 % Bromophenolblue 
 5 % Mercaptoethanol 
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Separating gel 7.5 % (15.1 ml)  3.75 ml 1.5 M  Tris pH 8.8 
 3.75 ml Acrylamide (Rotiphorese® gel 30)* 
 0.15 ml SDS (10 % in water) 
 7.35 ml H2O 
 75 µl APS (10 % in water) 
 7.5 µl TEMED 
   
Sample gel 4 % (5 ml)  1.25 ml 0.5 M  Tris pH 6.8 
 0.65 ml Acrylamide (Rotiphorese® gel 30) 
 0.05 ml SDS (10 % in water) 
 3.05 ml H2O 
 25 µl APS (10 % in water) 
   5 µl TEMED 
   
Electrophoresis buffer 25 mM   Tris 
 192 mM Glycine 
 0.1 %   SDS 
   
Coomassie staining solution 0.2 %   Coomassie Brillant Blue R250 
 10 % Acetic acid 
 40 % 2-Propanol 
   
Coomassie destaining solution 10 % Acetic acid 
 8 % Ethanol 
* various amounts of acrylamide (Rotiphorese® gel 30) 3.75, 4.95, 6, 7.5 ml for 7.5 %, 10 %, 12 %, and 15 % 
SDS-polyacrylamide gels respectively. 
 
SDS-PAGE was performed according to Laemmli [1970]. In brief the proteins were 
mixed in a volume ratio of 1:1 with sample buffer and heated at 95 oC for 5 minutes to 
denature the proteins. The denatured proteins were then loaded on to pre-cast discontinuous 
polyacrylamide gels 10 % consisting of 2 parts namely; sample gel (Tris buffer pH 6.8, 4 % 
acrylamide, 1 % SDS) containing pockets on which the samples were loaded. The second part 
is the separating gel (Tris buffer pH 8.8, 7.5-15 % acrylamide, 10 % SDS) on which the 
proteins are separated according to their molecular weight. The gels were run at a voltage of 
200 in an electrophoresis tank containing an electrophoresis buffer. Once the separation 
process was complete, the gel electrogram was stained with Coomassie stain and destained 
with Coomassie destaining solution until protein bands were clearly visible. Just in case the 
gel electrogram was required for Western blot, it was not stained with Coomassie rather it was 
immediately soaked into the cathode buffer. 
 
3.1.5 Western Blot 
Anode buffer I 300 mM  Tris 
   
Anode buffer II 25 mM   Tris 
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Cathode buffer 40 mM   6 –Aminohexanoic acid 
   
Blocking buffer 5 % Milk powder in TBS buffer 
  
TBS buffer 10 mM   Tris 
 155 mM  NaCl 
 pH 8.0 with HCl 
  
TBST buffer 0.05 %  Tween 20 in 1000 ml TBS buffer 
  
Ponceau staining solution 1 %   Ponceau S 
 1 %  Acetic acid 
   
Ponceau destaining solution 1 %   Acetic acid 
 
Semi dry Western blot was performed according to Towbin et al., [1979]. A sample of 
the protein of interest was subjected to SDS-PAGE. The completed gel electrogram was 
blotted onto a sheet of PVDF (polyvinyl difluoride) membrane that had been activated by 
briefly soaking in methanol then quickly transferring it into anode buffer II solution. The 
transfer set up was made up of a cathode graphite plate onto which 5 filter papers and the gel 
electrogram pre-soaked in cathode buffer had been laid. The PVDF membrane was laid onto 
the gel electrogram followed by 2 filter papers pre-soaked in anode buffer II. Then 3 more 
filter papers pre-soaked in anode buffer I followed. Finally an anode graphite plate was laid 
on top of the set up to complete the transfer cassette. The transfer process was carried out at 
0.8 mA / cm2 of gel electrogram for 55 minutes.   
To check for the efficiency of the transfer process, the PVDF membrane was stained for 30 
seconds with Ponceau staining solution and immediately de-stained with 1 % acetic acid until 
clear protein bands were visible. The PVDF membrane bound proteins strongly and 
unspecifically. The excess adsorption sites on the PVDF were blocked using 5 % milk powder 
in TBS buffer so as to prevent non specific adsorption of antibodies. The membrane was 
rinsed 3 times for 10 minutes each with TBST and incubated with the primary antibody or the 
antibody for the protein of interest (e.g. anti-histidine IgG) for 1 hour. After washing away the 
unbound primary anti-body with TBST (3 times for 10 minutes each), the blot was incubated 
for 1 hour with a secondary antibody (e.g. anti-mouse in case anti-histidine is the primary 
antibody) directed against the primary antibody to which the protein of interest had been 
covalently linked. After washing away the unbound secondary antibody (3 times for 10 
minutes each) with TBST, immunostaining of the membrane was performed by exposing the 
membrane to an enhanced chemiluminescence mixture for 1 minute. The membrane was then 
wrapped in a transparent foil paper and exposed to X-ray film for a period of between 30 
seconds to 15 minutes. The final development of the X-ray film was performed using an X-
ray film exposure machine. 
 
Mailu B M Methods  
 28
3.1.6 Gel Filtration 
The molecular mass of the recombinant protein was determined by native gel 
chromatography on a 16/60 superdex 200 prep grade column which was connected to an 
ÄKTA/ Unicorn- FPLC system (Amersham Pharmacia Biotech). Calibration of the column 
was performed using a gel filtration standard (Amersham Pharmacia Biotech) containing 
ferritin, aldolase, albumin, ovalalbumin and chymotrypsinogen as reference proteins. One 
millilitre of a 1 mg/ml protein solution was applied to the column that had previously been 
equilibrated with the appropriate buffer. Protein-containing fractions were detected 
spectrophotometrically at 280 nm and were collected at a flow rate of 1.0 ml/min. The peak 
areas and KAV values were evaluated using the UNICORN 4.11 software. Protein-containing 
fractions were also analysed on SDS-PAGE. The pure protein fractions obtained after gel 
filtration (FPLC machine) were then concentrated using a 50 kDa viva spin column. Protein 
concentration was determined using the Bradford protein assay [Bradford, 1976] and a 
standard curve of bovine serum albumin, ranging in concentration from 0 to 1 mg/ml. 
 
3.1.7 Protein Crystallisation 
The hanging drop method was used for crystal screening. The principle of this method 
is basically the vaporisation between a micro drop of mother liquor and a much larger highly 
concentrated reservoir solution thereby causing a slow precipitation of the protein in a 
controlled manner. The protein molecule is normally initially dissolved in a buffered solution 
usually containing a mixture of solvents and salts. The sample solution is physically separated 
from a larger volume called a reservoir (Figure 10). The sample and reservoir are kept in a 
closed system, and as the solvent or salts vaporise from the drop (or sometimes are added to 
the drop) the precipitant concentration increases to a level optimal for crystallisation. Since 
the system is in equilibrium, these optimum conditions are maintained until the crystallisation 
is complete [Fairall et al., 1993, Shaw et al., 1993]. 
 
 
 
 
 
 
 
                                   Figure 10: Hanging drop method of protein crystallisation. 
 
In order to crystallise our protein of interest 2 µl drops of the protein were mixed with 
a similar volume of precipitant solution on a siliconised microscope glass slip. The glass slip 
was then placed over a small well (of a multiwell crystallisation plate) containing 800 µl of 
the precipitant solution. To make sure that the system was totally sealed silicon oil was added 
to the sides of the glass slip. Over 100 different solutions which varied in terms of pH, buffer, 
ionic strength, metallic content and precipitant were tested by use of Hampton research 
crystallisation kits (crystal screen I and II). 
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3.2 PfGluPho Methods 
3.2.1 Cloning of PfGluPho 
The gene of PfGluPho was identified on chromosome 14. By polymerase chain 
reaction (PCR) on a P. falciparum 3D7 cDNA library, the whole PfGluPho gene was 
amplified. The forward primer was designated to introduce a BamHI restriction site (5′-CGC 
GGG ATC CGA TTA TGA GAA TTT TGT AAA AAG TGC AG-3′) and the reverse primer 
to introduce a HindIII restriction site (5′-GCG CAA GCT TTC AAT TAA TAT CTA ACA 
AAT CGT CTT C-3′). The PCR conditions as well as the PCR mix was as follows: 
 
PCR mixture The PCR programme used 
Volume in µL  Time in Seconds Temperature in oC 
5.0 Buffer 300     94 
4.0 dNTP 30     94 
1.0 Primer (100 pmol/µl) 30     55 
1.0 Primer (100 pmol/µl) 180     60  (35 cycles) 
1.0 Template 480     60 
          35.5 H2Odd autoclaved ∞       8 
2.5 Red Taq Polymerase 
Total 50.0 
 
The amplified PCR product was cleaned using the QIAquick PCR purification kit, restricted 
with the corresponding restriction enzymes, purified again using the QIAquick PCR 
purification kit but could not directly be cloned into the pSK vector. 
Since no native useful restriction site is present within PfGluPho, we decided using a 
silent mutation to create a SacI restriction site within the PfGluPho gene. This would enable 
us to amplify the gene in two separate parts of 1000 and 1733 base pairs, which could later be 
combined by ligation to form the complete PfGluPho gene. We emphasise the mutation was 
silent in that the amino acid sequence of the protein was not altered by our cloning strategy.  
 
901 - AATACCACTGTTATATCTTGTGGTTATGAAAATTATACAAAATCTATTGAAGAAATTTAT - 960  
      - N  T  T  V  I  S  C  G  Y  E  N  Y  T  K  S  I  E  E  I  Y- GAGCTC    
961 - GATTCTAAATATGCTCTATCTCTTTATTCTAATAGTTTGAATAAAGAAGAATTATTAACT -1020  
      - D  S  K  Y  A  L  S  L  Y  S  N  S  L  N  K  E  E  L  L  T   SacI 
1021 - ATAATAATTTTTGGCTGTTCAGGTGATTTAGCCAAAAAAAAAATATATCCAGCTTTATTT - 1080  
       - I  I  I  F  G  C  S  G  D  L  A  K  K  K  I  Y  P  A  L  F-    
 
Figure 11: Silent mutation introduced in the PfGluPho gene in order to creat a SacI restriction site 
 
The first part was amplified using the same BamHI forward restriction site primer and a 
reverse primer containing a SacI restriction site (5′-GCG CGA GCT CTT CTT TAT TCA 
AAC TAT TAG AAT AAA GAG-3′). The second part was amplified using a SacI restriction 
site primer (5′-GCG CGA GCT CTT AAC TAT AAT AAT TTT TGG CTG TTC AG-3′) and 
the same reverse primer containg a HindIII restriction site. The PCR conditions and mixture 
was as follows: 
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PCR mixture The PCR programme used 
Volume in µl  Time in Seconds Temperature in oC 
 5.0 Buffer 300        94 
4.0 dNTP 30        94 
1.0 Primer (100 pmol/µl) 30        55 
1.0 Primer (100 pmol/µl) 120   60 (35 cycles) 
1.0 Template 240        60 
          35.5 H2Odd autoclaved ∞          8 
2.5 Polymerase 
Total  50.0 
 
The amplified PCR products were restricted with the corresponding restriction enzymes, 
cleaned using the QIAquick PCR purification kit and ligated into a pSK vector which had also 
been restricted with the corresponding restriction enzymes. We chose to use the pSK vector 
which allows for the α-complementation test or blue and white screening in the presence of 
chromogenic X-gal (Davies and Jacob, 1968). The restriction enzyme reactions were 
performed overnight at room temperature and the reaction mixtures as well as the ligation 
reaction mixtures were as follows: 
 
Restriction Enzyme Reactions Mixtures 
Volume in µl  Volume in µl  
          25.0 PCR products              10.0 pSK plasmid 
 5.0 Buffer (yellow) 3.0 Buffer (yellow) 
1.5 BamHI or HindIII  1.0 BamHI or HindIII 
1.5 SacI 1.0 SacI 
          17.0 H2Odd autoclaved              15.0 H2Odd autoclaved 
Total  50.0   Total    30.0  
 
Ligation Reaction Mixture 
Volume in µl  
8.0 Digested PCR product (BamHI-SacI or SacI-HindIII) 
2.0 pSK (BamHI-SacI or SacI-HindIII) 
          10.0 Buffer  
1.0 Quick ligase 
Total  21.0  
 
The ligation mix was mixed thoroughly and incubated at room temperature for 6-7 minutes. 
25 µl of competent E. coli Novablue (Novagene) cells were then transformed (as outlined 
under 3.1.3 transformation of E.coli cells) separately with 2 µl of the pSK / BamHI-SacI and 
pSK / SacI-HindIII ligation mixture, plated onto X-gal LB (LAXI) plates and stood over night 
in an incubator at 37 oC. Blue (empty colonies) and white colonies (probably containing the 
insert of interest) were observed the next day. The white colonies were used to inoculate 3 ml 
of LB media tubes containing carbenicillin (100 µg/ml) and the culture was grown overnight. 
The next morning the culture was centrifuged at 10,000 x g to obtain a pellet. The supernatant 
was discarded and the pellet used for mini plasmid preparations using the QIAprep kit and 
spin columns. The prepared plasmids together with an empty pSK plasmid (control) were then 
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subjected to 1 hour of restriction cleavage at 37 oC using the respective restriction enzymes 
(BamHI /SacI or SacI / HindIII). The restriction reaction mixture was as follows: 
 
Restriction Enzyme Reactions Mixture 
Volume in µl  
25.0 Plasmid prep 
  5.0 Buffer (Yellow) 
  1.5 BamHI or HindIII 
  1.5 SacI 
17.0 H2Odd autoclaved 
            Total     50.0  
 
The restricted plasmids were then analysed against the control plasmid using agarose gels 
stained with ethidium bromide. The plasmid containing the right size of insert and the right 
size of restricted plasmid in comparison to the marker and control were used for further 
verification of the insert by sequencing. 
 
3.2.2 Mutagenesis PCR 
Comparing our sequence results with the sequence present in the data bank (Gene 
Bank AAN37124, PlasmoDB PF14_0511) revealed the presence of the following mutations 
 
pSK/ BamHI-SacI   S315 changed to Y315 
 
pSK/ SacI-HindIII  N415 changed to S415   
 
Since we had different clones sequenced each with different mismatches to the database 
sequence we thought these were mutations derived from the Taq-Polymerase used. We 
therefore performed mutagenesis PCR in order to back mutate these mutations so that our 
gene sequence could conform to that present in the data bank. The PCR conditions and the 
mixture were as follows: 
 
PCR mixture The PCR programme used 
Volume in µl  Time in Seconds Temperature in oC 
5.0 10x Pfu Buffer 180        94 
4.0 dNTP 30        94 
1.0 Primer I 30        55 
1.0 Primer II 510        60 (2 min/kb template) 
1.0 Template (50 ng/µl) 510        60 
2.5 DMSO ∞          8 
          34.5 H2Odd autoclaved 
1.0 Pfu Polymerase 
Total 50.0  
 
After the mutagenesis PCR, the products were cleaned using the Qiaquick PCR purification 
kit and restricted for 1 hour at 37 oC using DpnI restriction enzyme. The reaction mixture was: 
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DpnI Restriction Enzyme Reactions Mixtures 
Volume in µl  
42.0 PCR product 
  5.0 10x Buffer B 
  0.5 BSA (10 mg/ml) 
  2.5 DpnI 
Total              50.0  
 
The restricted PCR product was then transformed into Novablue competent cells, plated on 
LAXI plates and stood overnight in an incubator at 37 oC. The next day colonies probably 
containing the gene of interest were observed which were used to inoculate 3 ml of LB media 
tubes containing carbenicillin (100 µg/ml) and the culture was grown overnight in a shaking 
incubator at 37 oC. The next morning the culture was used for plasmid preparation using 
Qiaprep kit and spin columns. The plasmid inserts were verified by sequencing and by 
comparison of the sequences to those present in the data bank. 
The DpnI restriction reaction performed after the mutagenesis PCR is important 
because DpnI is a restriction enzyme that targets methylated DNA. Since the template used in 
the mutagenesis PCR was a plasmid prep which had been prepared after transformation in E. 
coli cells, this meant it was methylated and therefore cleaved or destroyed leaving only the 
mutagenesis PCR product plasmid.  
Once it was established that our 2 clones had the right sequence, we decided to cleave 
them out of the pSK plasmid and insert them into the expression vector pET-28a while 
combining them to form the bifunctional gene of PfGluPho. This was performed in two steps: 
the first step was to insert the clone Sac/ Hind then followed by the Bam/ Sac clone as the 
second step. The pSK plasmid containing the Sac/ Hind clone and the pET-28a plasmid where 
the clone was to be inserted were subjected to restriction enzyme reaction under the following 
conditions: 
        
Restriction Enzyme Reactions Mixtures 
pSK Sac / Hind pET-28a 
Volume in µl  Volume in µl  
4.0 Buffer   5.0 Buffer 
2.0 Hind III   2.0 HindIII 
2.0 SacI   2.0 SacI 
7.0 pSK SacI-HindIII 25.0 pET-28a 
5.0 H2Odd autoclaved 16.0 H2Odd autoclaved 
Total    20.0  50.0  
 
The restriction cleavage reaction mixtures were mixed thoroughly and stood at 37 oC for 1 
hour after which they were cleaned using the Qiagen PCR purification kit. Agarose gel 
electrophoresis was performed to check for the integrity of the restriction reaction. The next 
step was to try and insert the Sac/ Hind clone into pET-28a. This was achieved by ligating the 
Sac/ Hind clone into the pET-28a vector using the following ligation mixture: 
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Ligation Reaction Mixture 
Volume in µl  
 6.0 pSK Sac/ Hind 
 4.0 pET-28a Sac/ Hind 
10.0 Buffer 
 1.0 Quick Ligase 
Total                 21.0  
  
The reaction mixture was incubated for 6-7 minutes at room temperature, transformed into 
Novablue competent E. coli cells, plated on LB plates containing kanamycin (50 µg/ml) and 
stood overnight in an incubator at 37 oC. The next day colonies were observed which showed 
that the ligation reaction was successful, but to be sure we had the right clones, we inoculated 
3 ml of LB medium containing kanamycin (50 µg/ml) using these colonies and grew them 
overnight. The next morning we performed plasmid preparations using the Qiaprep kit and 
spin columns. The prepared plasmids were then subjected to restriction cleavage using SacI 
and HindIII restriction enzymes and the restriction products analysed using agarose gel 
stained with ethidium bromide. We were able to obtain the right band of interest and therefore 
we were sure we had the SacI-HindIII clone within the pET-28a vector.  
The next challenge was to insert the BamHI-SacI clone into the pET-28a vector 
containing the SacI-HindIII clone. The BamHI-SacI clone was inserted into the pET-28/ SacI-
HindIII clone as follows; restriction reaction was performed on the pSK/ BamHI-SacI and 
pET-28a/ SacI-HindIII plasmids in a reaction mixture of the following composition: 
 
Restriction Enzyme Reactions Mixtures 
pSK/ BamHI-SacI pET-28a/ SacI-HindIII 
Volume in µl  Volume in µl  
 5.0 Buffer   5.0 Buffer 
 1.0 BamHI   1.0 BamHI 
 2.0 SacI   1.0 SacI 
20.0 pSK/ BamHI-SacI 20.0 pET-28a/ SacI-HindIII 
22.0 H2Odd autoclaved 22.0 H2Odd autoclaved 
Total  50.0           50.0  
 
The restriction reaction was performed at 37 oC for 1 hour after which the plasmids were 
cleaned using the Qiagen PCR purification kit. An agarose gel electrophoresis was performed 
to check the integrity of the restriction reaction. The cleaned restriction reaction products 
were then ligated together in a reaction composition as follows: 
 
Ligation  Reaction Mixture 
Volume in µl  
6.0 pSK BamHI-SacI 
3.0 pET-28a/ SacI-HindIII 
1.0 H2Odd autoclaved 
                                 10.0 Buffer 
1.0 Quick Ligase 
Total                         21.0  
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The ligated products were transformed using Novablue competent E. coli cells, plated on LB 
plates containing kanamycin (50 µg/ml) and stood in an incubator at 37 oC overnight. The 
next day colonies were observed which showed that the ligation reaction was successful, but 
to be sure we had the right clones, we inoculated 3 ml of LB medium containing Kanamycin 
(50 µg/ml) using these colonies and grew them overnight. The next morning we performed 
plasmid preparations using the Qiaprep kit and spin columns. The prepared plasmids were 
then subjected to restriction cleavage using BamHI and HindIII restriction enzymes and the 
restriction products analysed using agarose gel stained with ethidium bromide. We were able 
to obtain the right band of interest and therefore we were sure we had the BamHI-HindIII 
clone in the pET-28a vector and therefore we had the complete PfGluPho clone. 
Further confirmatory tests were performed to ascertain that we had the complete 
PfGluPho clone. We performed a PCR using two sets of primers capable of amplifying the 
complete PfGluPho gene; the BamHI and HindIII primers which had been used earlier and 
another set of primers without the restriction site designated as N primer (5′-ATT ATG AGA 
ATT TTG TAA AAA GTG CAG-3′) and C primer (5′-TCA ATT AAT ATC TAA CAA ATC 
GTC TTC-3′). Once again when the PCR product was analysed on the agarose gel we were 
able to obtain the right band of interest. The inserts were further verified by sequencing and 
comparison of the sequences to those present in the data bank. The sequencing results 
revealed that we had the right clone and our cloning strategy was very successful. The 
pET28a vector would thus place a hexahistidyl tag at the N-terminus of the recombinant 
protein. 
 
3.2.3 Heterologous Overexpression of PfGluPho 
E. coli KRX pRAREII cells were transformed with the pET-28a/ PfGluPho plasmid. 
Cultures of transformed cells were grown in 1 Litre of Terrific Broth (TB) medium 
[containing kanamycin (50 µg/ml) and chloramphenicol (25 µg/ml) antibiotics] until an OD600 
of between 0.3 and 0.4 was achieved. The cultures were then transferred to room temperature 
and grown further to an OD600 of between 1.0 and 1.5. Rhamnose (20% stock solution) was 
then added to a final concentration of 0.1% and the culture was further grown overnight. Cells 
were collected as a pellet by centrifugation at 8,000 g for 15 minutes at 4 oC and resuspended 
in 100 mM Tris buffer pH 7.8, 500 mM NaCl. After addition of protease inhibitor cocktail 
consisting of pepstantin, cystantin and PMSF, the pellet was stored at -20 oC.  
 
3.2.4 Optimisation of the Heterologous Overexpression of PfGluPho 
The optimisation of the heterologous overexpression of PfGluPho was performed 
using different E. coli cell lines (G6PD deficient cells PD2000 and other non deficient cells) 
as well as varying the different expression parameters as summarised in Table 3.  
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3.2.5 Purification of PfGluPho 
A small amount of DNase as well as lysozyme (4 mg/g pellet) was added to the 
thawed pellet and stirred over ice for 1 hour. The cells were sonicated 3 times for 30 seconds 
each at maximum power and centrifuged at 16,000 g for 30 minutes. The clear supernatant 
was then applied to a 1 ml Ni-NTA column, washed with 5 ml of 100 mM Tris buffer, pH 7.8, 
500 mM NaCl and eluted using a stepwise imidazole concentration gradient. The pure 
fractions as observed on the SDS gel were pooled together, concentrated using a 50 kDa viva 
spin column and further purified by gel filtration using an ÄKATA/ Unicorn FPLC system as 
outlined in 3.2.7. 
 
3.2.6 Optimisation of the Purification of PfGluPho 
The purification process was optimised using two column materials namely: the Ni-
NTA and the 2’ 5’ ADP Sepharose 4B in combination with gel filtration using an FPLC 
machine (Table 2). Different buffers, pH and salt concentrations were also optimised for the 
purification process (Table 3).  
 
3.2.7 Gel Filtration of PfGluPho 
Gel filtration was performed as outlined in Section 3.1.6 with a minor modification. 
The buffer used for gel filtration was 100 mM Tris buffer, pH 7.8, 500 mM NaCl. The protein 
containing fractions obtained after gel filtration (FPLC machine) were analysed on SDS-
PAGE and then concentrated using a 50 kDa viva spin column. Protein concentration was 
determined using the Bradford protein assay [Bradford, 1976] and a standard curve of bovine 
serum albumin, ranging in concentrations from 0 to 1 mg/ml. 
 
3.2.8 Western Blot Using PfGluPho Specific Antibody and P. falciparum Proteins 
The Western blot using peptide specific antibodies for PfGluPho produced from 
rabbits which had been immunized with synthetic peptides of PfGluPho (N-teminal peptide 
composed of aa 118-133: KEQLYKPDTTKSIVDC and C-terminal peptide composed of aa 
896-910: CVRKSSFYEDDLLDIN) (Eurogentec, Seraing, Belgium) was performed as 
outlined in 3.1.5 but with a few modifications. The primary antibody was PfGluPho specific 
antibody diluted using 5 % milk powder in TBST (1:5,000). The secondary antibody was anti-
rabbit diluted in TBST. The SDS-PAGE (7.5 %) was performed using P. falciparum proteins 
(concentrations loaded on the gel 45, 70, 105 µg) as well as recombinant PfGluPho. The P. 
falciparum proteins were prepared as outlined in 3.6.4.  
 
3.2.9    PfGluPho’s G6PD Assays 
3.2.9.1    Determination of Km Values for G6P, NADP+ and Steady State Kinetics 
The standard two substrate G6PD assay which measures the reduction of NADP+ to 
NADPH at 340 nm was performed at 25 oC according to Beutler, [1984]. In brief the standard 
reaction mixture for measurement of the Km for G6P on PfGluPho’s G6PD was composed of 
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100 µM NADP+, the standard G6PD assay buffer (100 mM Tris, 0.5 mM EDTA, 10 mM 
MgCl2, pH 8.0), PfGluPho enzyme and varying amounts of G6P (200-5 µM) which was 
added to start the reaction. The total reaction volume was 500 µl. Measurement of the Km for 
NADP+ on PfGluPho’s G6PD on the other hand was performed by varying the concentrations 
of NADP+ (200-2 µM) and fixing the concentration of G6P at 100 µM. The same method was 
also used for the determination of the kinetic parameters (Km for G6P and Km for NADP+) for 
yeast G6PD as an internal control. The steady state kinetics of  PfGluPho’s G6PD for G6P 
were performed by holding the concentration of NADP+ at the Km value while varying the 
concentration of G6P (100-5 µM). Likewise the steady state kinetics for NADP+ were 
performed by holding the concentration of G6P at Km value while varying the concentration 
of NADP+ (50-2 µM).  
 
G6P + NADP+  ⎯⎯ →⎯ PDG 6  6PGL + NADPH + H+ 
G6PD assay (340 nm): 
          G6PD assay buffer :  480 - x µl 
                (100 mM Tris, 0.5 mM EDTA, 10 mM MgCl2, pH 8.0) 
             NADP+ (10 mM) :    10.0  µl    (ad 200 µM)      
                               G6PD :     x µl 
         ⎯⎯⎯⎯⎯⎯⎯⎯ Baseline ⎯⎯⎯⎯⎯⎯⎯⎯ 
               G6P (4 mM) :    25 µl    (ad 200 µM) 
 
       εNADPH = 6.22 mM-1*cm-1 
       VA =
Vi
VoA
*22.6
min*/∆
 [U/ml]  where Vo  is the total volume of assay and  
Vi is volume of enzyme used.  
 
The stability of the baseline was determined before the assays were carried out in order to 
check for background reactions that could affect the integrity of our assays. Such background 
reactions could be from E. coli proteins that could be co-purified with PfGluPho. A standard 
reaction mixture for the G6PD assay was prepared as outlined above in the presence of 
PfGluPho but the reaction was not started by adding G6P. Instead the stability of the baseline 
was checked by measuring the absorbance at 340 nm. In a similar set up an expression was 
performed using KRX pRAREII cells without PfGluPho and purified as outlined for 
PfGluPho. The fractions that normally contain positive bands for PfGluPho were then used to 
check for the stability of the baseline as outlined.  
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3.2.9.2 PfGluPho’s G6PD Assays with the Substrate Analogue 2-Deoxyglucose-6- 
  Phosphate 
The steady state kinetics of PfGluPho’s G6PD using the substrate analogue 2-
deoxyG6P were performed by holding the concentration of NADP+ at the Km value while 
varying the concentration of 2-deoxyG6P (100-0.1 mM). Likewise the steady state kinetics 
for NADP+ was performed by holding the concentration of 2-deoxyG6P at Km value while 
varying the concentration of NADP+ (50-2 µM). 
 
3.2.9.3   PfGluPho’s G6PD Inhibition with NADPH, Glucoseamine-6-Phosphate  
   and ATP-Ribose  
In product inhibition studies, the initial rates were measured for a series of NADPH 
concentrations (0-20 µM) by holding the concentration of G6P at the Km value while varying 
the concentration of NADP+ (2-50 µM). A similar experiment was carried out by use of the 
same series of NADPH concentration (0-20 µM) by holding the concentration of NADP+ at 
the Km value while varying the concentration of G6P (5-100 µM). In analogous fashion, 
glucoseamine-6-phophate and ATP-ribose were used as inhibitors covering the same 
combination and ranges of substrate concentrations as used in the experiments with NADPH. 
 
3.2.9.4  PfGluPho’s G6PD Assays with GSSG, GSH and PfGR 
To check if PfGluPho activity is regulated through the interaction with PfGR or 
undergoes allosteric regulation in the presence of GSH or GSSG, the G6PD assay was 
performed in the presence of either; 2 mM GSH, 1 mM GSSG, PfGR 10 mU/ml or in the 
presence of both 10 mU/ml PfGR and 2 mM GSH. 
 
3.2.9.5  PfGluPho’s G6PD pH, Buffers and Salt Profile 
Several buffers as outlined below were tested in order to determine the best buffer, pH 
and salt conditions optimum for PfGluPho activity: 
 
Buffer pH range  Salts 
Na-phosphate buffer 25 mM 6.2 - 8.8 NaCl  0 - 300 mM 
Tris buffer 100 mM  6.6 - 8.8 NaCl  0 - 500 mM, MgCl2 0 - 500 mM 
Hepes buffer 6.6 - 8.2 MgCl2 0 - 100 mM 
 
3.2.9.6  Test for G6PD Activity in Full Blood 
G6PD activity in fresh full blood samples obtained from three donors from our labs 
was determined according to the standard G6PD assay (as outlined in 3.2.10.1) but with a few 
modifications. The standard G6PD assay for measuring Km values for G6P and NADP+ was 
set up as earlier outlined but the standard assay buffer contained in addition 0.03 mM 
Digitonin for red blood cell lysis.  
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3.2.10   PfGluPho’s 6-PGL Assays  
3.2.10.1 Determination of the Km for  6-PGL   
The analysis of PfGluPho’s 6-PGL activity was performed using a time course study. 
The assay system consisted of a 500 µl solution composed of 200 µM NADP+, the standard 
G6PD assay buffer (100 mM Tris, 0.5 mM EDTA, 10 mM MgCl2, pH 8.0), PfGluPho enzyme 
and 150 µM of G6P which was added to start the reaction. After a given period of time (1, 2, 
4, 6, 8, 10, 12, 15 and 20 minutes) 6-phosphogluconate dehydrogenase (6-PGD) (yeast, 
Sigma) was added to the reaction mixture and the reaction allowed to continue for a further 3 
minutes. The reaction was performed at 25 oC and absorbance readings taken at 340 nm. The 
absolute and linear changes in absorbance indicating the consumption of G6P and therefore 
production of 6-phosphoglucono-δ-lactone (6-PG-δ-L) were determined at each time point 
before and after addition of 6-PGD. The difference between these values were used for the 
calculation of 6-PGL activity.  
Hydrolysis of 6-PG-δ-L by the enzyme 6-PGL leads to the formation of 6-
phosphogluconate (6-PGn) which is converted by the action of the enzyme 6-PGD to ribose-
5-phosphate. In order to estimate the amount of 6-PGn available to 6-PGD after 6-PG-δ-L 
hydrolysis by PfGluPho’s 6-PGL, 6-PGD assays in the absence of PfGluPho were performed 
and used as a calibration curve. The assay consisted of 200 µM NADP+, assay buffer (100 
mM Tris buffer, 0.5 mM EDTA, 10 mM MgCl2, pH 8.0), 6-PGD (Yeast, Sigma) (0.08 U/ml) 
and varying amounts of 6-PGn (100-5 µM). The total volume of the assay was 500 µl and the 
reaction was performed at 25 oC with absorbance readings being taken at 340 nm. Prior to 
experiments involving yeast 6-PGD, the approximate Km values for both substrates (NADP+ 
and 6-PGn) were determined. The standard two substrate 6-PGD assay which measures the 
reduction of NADP+ to NADPH at 340 nm was performed at 25 oC. In brief the standard 
reaction mixture for measurement of the Km for 6-PGn on 6-PGD was composed of 200 µM 
NADP+, the standard G6PD assay buffer (100 mM Tris, 0.5 mM EDTA, 10 mM MgCl2, pH 
8.0), yeast 6-PGD enzyme (0.08 U/ml) and varying amounts of 6-PGn (200-5 µM) which was 
added to start the reaction. The total reaction volume was 500 µl. Measurement of the Km for 
NADP+ on 6- PGD on the other hand was performed by varying the concentrations of NADP+ 
(200-2 µM) and fixing the concentration of 6-PGn at 100 µM.  
 
3.2.10.2  PfGluPho’s 6-PGL Assays in the Presence of GSSG and GSH 
The standardised PfGluPho’s 6-PGL assay was performed in the presence of either 5 
mM GSSG, 5 mM GSH, 5 mM GSSG plus 10 µM Glutathione reductase (GR), 5 mM GSH 
and 5 mM GSSG plus 10 µM GR. The reaction was performed for 10 minutes before the 
addition of 6-phosphogluconate dehydrogenase and then allowed to continue further for 3 
minutes. Data collection was performed as outlined in 3.2.10.1. 
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3.2.11 PfGluPho Crystal Screening 
Crystal screening was performed as outlined in 3.1.7. In order to crystallise PfGluPho 
2 µl drops of the protein were mixed with a similar volume of precipitant solution on a 
siliconised microscope glass slips. The glass slip was then placed over a small well (of a 
multiwell crystallisation plate) containing 800 µl of the precipitant solution. To make sure that 
the system was totally sealed silicon oil was added to the sides of the glass slip. Over 100 
different solutions which varied in terms of pH, buffer, ionic strength, metallic content and 
precipitant were tested by use of Hampton research crystallisation kits (crystal screen I and 
II). We also tested various solutions from the published G6PD structures [Cosgrove et al., 
1998; Cosgrove et al., 2000; Au et al., 2000; Delarue et al., 2007]. PfGluPho obtained after 
gel filtration (FPLC purification) was used for the crystallisation trials. The concentration of 
the protein was 15 mg/ml from a total of 25 litres of culture.  
 
3.2.13 PfGluPho Inhibitor Screening  
The standard G6PD assay method was optimised for the first time for screening of 
PfGluPho G6PD inhibitors using an Infinite M200 (Tecan) multiwell plate reader with 
monochromator. In brief the method involved a 20 ml master mix composed of standard 
G6PD buffer, NADP+ (200 µM) and PfGluPho (32 µg/ml). The assay was performed by 
mixing together G6PD buffer (79 µl), inhibitor 5 µg/ml (1 µl of 1 mg/ml) and 100 µl of the 
master mix (final concentration NADP+ 100 µM, PfGluPho 16 µg/ml). The assay was started 
by adding G6P (20 µl) 100 µM and the absorbance measured at 340 nm. Total volume for the 
assay was 200 µl. A total of 2,000 compounds were screened and IC50 values determined. The 
best compounds were further tested to determine the inhibition mechanism. 
 
Buffer:   100 mM Tris, 0.5 mM EDTA, 10 mM MgCl2, pH 8.0 
PfGluPho:   0.91 mg/ml 
NADP+:  10 mM (8.37 mg/ml) 
G6P:   1 mM (0.282 mg/ml) 
 
Master Mix: Buffer 18.424 ml 
 NADP+ (200 µM)   0.390 ml (add 100 µM) 
 PfGluPho  0.686 µl (add 16 µg) 
   
Assay mix:  Buffer   79 µl 
 Inhibitor (1 mg/ml)    1 µl (add 5 µg/ml) 
 Master mix        100 µl 
                                              Mix thoroughly 
 G6P (1 mM) 20 µl  (add 100 µM) 
Measure absorbance at 340 nm 
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3.3 Human 6-PGL Methods  
3.3.1 Heterologous Overexpression of Human 6-PGL 
Expression of human 6-PGL was performed using E. coli KRX pRAREII cells 
transformed with pET-28a human 6-PGL plasmid. The expression was performed as outlined 
in 3.2.3 with minor modifications. The expression was performed for a total time period of 4 
hours from onset of induction with rhamnose. The temperature on the other hand was 
maintained at 37 °C throughout the expression. 
 
3.3.2 Purification of Heterologously Overexpressed Human 6-PGL 
Purification of human 6-PGL was performed as outlined in 3.2.5 in a method 
incorporating both the Ni-NTA column material and gel filtration using an ÄKATA/Unicorn 
FPLC system (3.2.7).  
 
3.3.3 Human 6-PGL Assay  
The human 6-PGL activity was performed using a time course study as described for 
PfGluPho’s 6-PGL (3.2.10.1) with a few modifications. As opposed to assays involving the 
bifunctional PfGluPho which contains G6PD activity, in this assay yeast G6PD was used for 
the enzymatic generation of 6-PG-δ-L which is the substrate for 6-PGL. The assay system 
consisted of a 500 µl solution composed of 200 µM NADP+, the standard G6PD assay buffer 
(100 mM Tris, 0.5 mM EDTA, 10 mM MgCl2, pH 8.0), G6PD (Yeast Sigma) human 6-PGL 
and 150 µM of G6P which was added to start the reaction. Data collection was performed as 
outlined in 3.2.10.1. 
 
3.4 MouseIDO-1 and MouseIDO-2 Methods 
3.4.1 Heterologous Overexpression of Recombinant Mouse IDO-2 (mIDO-2)  
E. coli KRX cells were transformed with the pDEST 17/ mIDO-2 plasmid. Cultures of 
transformed cells were grown in 1 litre of Terrific Broth (TB) medium containing 
carbenicillin (50 µg/ ml) at 37 oC until an OD600 of 0.8. The cultures were then transferred to 
room temperature and grown further to an OD600 between 1.0 and 1.5. rhamnose (20 %) and 
δ-aminolevulinic acid (ALA) hydrochloride (250 mM) were then added to final 
concentrations of 0.1 % and 0.5 mM, respectively and the cultures were further grown 
overnight. Cells were collected as a pellet by centrifugation at 8,000g for 15 minutes and 
resuspended in 25 mM Tris (hydroxymethyl) methylamine  buffer pH 7.4, 150 mM NaCl. 
 
3.4.2 Optimisation of Rhamnose for Heterologous Overexpression of Mouse IDO-2 
The KRX/ pDEST 17-IDO-2 cells were grown according to the general method 
outlined. Concentrations of rhamnose were varied at the time of induction stage using final 
concentrations of between 0.05 % and 0.1 % (recommended maximum). The growth trials 
were performed in 500 ml TB medium and LB medium. 
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3.4.3 Purification of Heterologously Overexpressed Mouse IDO-2 
After resuspension the pellet was sonicated 3 times for 20 seconds each at maximum 
power and centrifuged at 16,000g for 30 minutes. The clear supernatant was then applied to a 
1 ml Ni-NTA column, washed with 5 ml of 25 mM Tris buffer, pH 7.4, 150 mM NaCl and 
eluted using a stepwise imidazole concentration gradient. 20 % glycerol was immediately 
added to the eluted fractions.  
 
3.4.4 Heterologous Overexpression of Recombinant Mouse IDO-1 (mIDO-1) 
E. coli Rosetta cells were transformed with the pDEST 17/ mIDO-1 plasmid. Cultures 
of transformed cells were grown in 1 litre of LB medium containing carbenicillin (50 µg/ml) 
and chloroamphenicol (35 µg/ml) at room temperature until an OD600 between 0.3 and 0.4.   
Isopropyl-β-D-thiogalactopyranoside (IPTG) (1 M) and δ-Aminolevulinic acid (ALA) 
hydrochloride (250 mM) were then added to final concentrations of 0.025 mM and 0.5 mM, 
respectively and the cultures were further grown overnight. Cells were collected as a pellet by 
centrifugation at 8,000g for 15 minutes, resuspended in 25 mM Tris buffer pH 7.4, 150 mM 
NaCl. Purification of IDO-1 was as outlined for IDO-2 in 3.3.3. 
 
3.4.5 IDO Assay Methylene Blue/ Ascorbic Acid Method 
Unless otherwise stated the assays were performed using freshly prepared samples. 
IDO-2 activity was determined as described by Takikawa et al. [1988] with minor 
modifications. In brief, the standard reaction mixture (200 µl) contained 100 mM potassium 
phosphate buffer pH 6.5, 100 mM KCl, 20 mM ascorbic acid (neutralised with NaOH), 200 
µg/ml catalase, 10 µM methylene blue, 30 mM L-tryptophan, and purified IDO-2. The 
reaction was carried out at 37 oC for 60 min and stopped by the addition of 40 µl of 30 % 
(w/v) trichloroacetic acid. After heating at 65 oC for 15 min, the reaction mixtures were 
centrifuged at 11,500 g for 7 minutes. The supernatant (125 µl) was transferred into a well of 
a 96-well microtitre plate and mixed with 125 µl of 2 % (w/v) p-dimethylaminobenzaldehyde 
(p-DMAB) in acetic acid. The yellow pigment derived from kynurenine was measured at 480 
nm using a microtitre plate reader. A standard curve of L-kynurenine was used, ranging in 
concentration from 0 to 500 µM. The kinetic parameters (Km, Vmax) were determined using 
the same method by varying the substrate (L-tryptophan concentration between 0 and 60 
mM). The assays involving IDO-1 were performed as outlined with the substrate L-
tryptophan concentration being maintained at 400 µM and varied between 0 to 200 µM for the 
determination of kinetic parameters (Km, Vmax). Protein concentration was determined using 
the Bradford protein assay [Bradford, 1976] and a standard curve of bovine serum albumin, 
ranging in concentration from 0 to 1 mg/ml. 
 
3.4.6 IDO Assay Cytochrome b5/ Cytochrome P450 Method 
The reduction of mouse IDO by cytochrome b5 was performed as outlined by 
Maghzal et al. [2008]. In brief the reaction involved the addition of mouse IDO to a reaction 
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mixture purged with argon gas and containing 0.2 µM human recombinant cytochrome b5, 2 
µM of human NADPH: cytochrome P450 reductase, 56 units of G6PD, 375 units of bovine 
catalase, 20 mM G6P, 4 mM NADP+, and 200 µM diethylene triamine pentaacetic acid in 100 
mM phosphate buffer, pH 7.4. The reaction was carried out at 25 °C in a septum sealed 
cuvette thoroughly purged with argon gas. Difference spectra were recorded every 30 s from 
380 to 680 nm against a reference sample containing the reaction mixture without mouse 
IDO, using a spectrophotometer. Experiments were performed in the absence and presence of 
CO (approximately 1 mM), by thoroughly purging the reaction mixture and the cuvette with 
CO gas.  
 
3.4.7 Determination of pH and Salt Profiles 
The pH stability test was carried out in a standard reaction mixture containing 100 mM 
potassium phosphate buffer, 100 mM KCl. The pH was varied by increments of pH 0.2 within 
a range of pH 6-9. For salt stability tests the standard reaction mixture contained 100 mM 
potassium phosphate buffer, pH 7.4 with salt concentrations being varied within a range of 0-
300 mM. 
 
3.4.8 Gel Filtration of Heterologously Overexpressed Mouse IDO-1 and Mouse IDO-2 
Gel filtration was performed as outlined in 3.1.6 with minor a modification. The buffer 
used for gel filtration was 50 mM Tris pH 7.6, 300 mM NaCl. The protein containing 
fractions obtained after gel filtration (FPLC machine) were analysed on SDS-PAGE and then 
concentrated using a 50 kDa viva spin column. Protein concentration was determined using 
the Bradford protein assay [Bradford, 1976] and a standard curve of bovine serum albumin, 
ranging in concentrations from 0 to 1 mg/ml. 
 
3.4.9 Protein Modelling of Mouse IDO-2 
The structural model for mouse IDO-2 was predicted using “Swiss-Model” [Peitsch, 
1995]. The preparation of the homology project was carried out in the web-interface of the 
programm SWISS-PDB VIEWER. At the beginning the FASTA amino acid sequence of 
mouse IDO-2 was loaded into the interface. Then suitable template structures based on their 
sequence similarity to IDO-2 were identified. With Swiss-Model this is achieved by 
comparing the target sequence with all entries of the ExPDB sequence database using blastp.  
Suitable templates were sorted by statistical significance and could be downloaded readily.  
For the sequence of mouse IDO-2 only two templates were listed: i) the cyanide bound form 
of the 4-phenylimidazole and ii) the cyanide bound form of the human IDO-1.  A comparison 
of the amino acid sequences of the human IDO-1 and the IDO-2 of mouse revealed an 
indentity of 43 %. So the structural model was built in homology to the homodimeric crystal 
structure of human IDO-1 (PDB-ID: 2D0T). With the “Magic fit” tool of the program, an 
initial alignment of both sequences was made and then improved by manual alterations. In 
parallel the backbone of the target protein was built up based on the localisation of accordant 
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atoms in the template structure. The entire project was submitted to SWISS-MODEL, where 
extensive optimisation and minimisation steps were carried out by the GROMOS 96 
forcefield [Fraternali and Van Gunsteren, 1996]. The model’s coordinates and all intermediate 
analysis results are then returned to the user by e-mail.  
 
3.4.10 Inhibitor Screening for Mouse IDO-1  
The inhibitor assays were performed in a 96 well microtitre plate as described by 
Takikawa et al. [1988] with minor modifications. In brief, the standard reaction mixture (200 
µl) contained 100 mM potassium phosphate buffer pH 6.5, 100 mM KCl, 20 mM ascorbic 
acid (neutralised with NaOH), 200 µg/ml catalase, 10 µM methylene blue and purified IDO-1 
optimised based on its activity. The reaction mixture was added to the substrate L-tryptophan 
and the inhibitor. The L-tryptophan was serially diluted from 200 to 25 µM and the inhibitor 
was tested at concentrations between 0.01-0.08 µg/ml.The reaction was carried out at 37 oC 
for 60 min and stopped by the addition of 40 µl of 30 % (w/v) trichloroacetic acid. After 
heating at 65 oC for 15 min, the reaction mixtures were centrifuged at 11,500 g for 7 min. The 
supernatant (125 µl) was transferred into a well of a 96 well microtitre plate and mixed with 
125 µl of 2 % (w/v) p-dimethylaminobenzaldehyde (p-DMAB) in acetic acid. The yellow 
pigment derived from kynurenine was measured at 480 nm using a microtitre plate reader. A 
standard curve of L-kynurenine was used, ranging in concentration from 0 to 500 µM.  
 
Pipetting scheme: 
 
50 mM potassium phosphate buffer, pH 6.5              166.5 – x µl 
Master Mix         22.5 µl 
{Ascorbic acid (neutralised with NaOH) 400 mM 10 µl 
Catalase 4 mg/ml     10 µl 
Methylene blue 800 µM                 2.5 µl} 
L-Kynurenine or IDO1       x µl 
Inhibitor          1 µl 
 
Cover the plate with a foil paper 
________________________stand at room temperature 10 min________________________ 
Add tryptophan 8 mM      10 µl 
_______________________37 °C, 60 min__________________________ 
Add trichloroacetic acid 30%      40 µl 
_______________________65 °C, 15 min__________________________ 
Centrifuge at 11500 x g (2800 rpm), for 7 min 
 
To 100 µl of the supernatant add 100 µl 2 % p-DMAB in acetic acid 
 
Measure absorbance at 480 nm (or 450 nm) using a multiwell plate reader  
 
Master Mix per Plate  
Buffer             17.215 ml 
Ascorbic acid     1.1     ml 
Catalase     1.1     ml 
Methylene blue  0.275 ml  
            19.69 ml              then use 179 µl/well 
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3.5 Thioredoxin Networks Methods 
3.5.1 Site Directed Mutagenesis of PfPlasmoredoxin 
The reduced form of PfPlasmoredoxin (PfPlrx) and target proteins form mixed 
disulfide intermediates during the reduction pathway. Then PfPlrx itself forms an internal 
disulfide bridge thus releasing the reduced target protein. This intermediate step should be 
stabilised when PfPlrx lacks the second cysteine residue and the intermediate should only 
dissociate in the presence of DTT. Site directed mutagenesis PCR was performed as outlined 
in 3.2.2. in order to mutate cysteine 63 to serine and generate the mutated PfPlrxC63S using Pfu 
polymerase (Promega) and mutation primers (Sense: 5'-GGTGTAAATACAGTGTAACCTTT 
ATAG-3'; Antisense: 5'-CTATAAAGGTTACACTGTATTTACACC-3'). The DpnI 
restriction of methylated nonmutated template was performed as outlined in 3.2.2 and the 
mutations verified by sequencing. Competent E. coli XL1-Blue cells were then transformed 
using pQE/ PfPlrxC63S plasmid as outlined in 3.1.3. 
 
3.5.2 Heterologous Overexpression and Purification of PfPlasmoredoxin  
The expression of PfPlasmoredoxin (mutant and wild type) was performed using the 
E. coli M15 strain transformed with the pQE/ PfPlrx plasmid. Cultures of transformed cells 
were grown in 0.5 litre LB media [containing carbenicillin (100 µg/ml) and kanamycin (50 
µg/ml)] until an OD600 0.5 to 0.6. The culture was then induced with 1 mM isopropyl-β-D-1-
thiogalactopyranoside and grown for further 4 hours. Cells were collected as a pellet by 
centrifugation at 8,000 g for 15 minutes at 4 °C and resuspended in 50 mM sodium phosphate 
buffer, 300 mM NaCl, pH 8.0. After addition of protease inhibitor cocktail consisting of 
pepstantin, cystantin and PMSF, the pellet could be stored at -20 oC for future use or purified 
immediately. A small amount of DNase as well as lysozyme (4 mg/g pellet) was added to the 
pellet and stirred over ice for 30 minutes. The cells were sonicated 3 times for 30 seconds 
each at maximum power and centrifuged at 16,000g for 30 minutes. The clear supernatant 
was then applied to a 1 ml Ni-NTA column, washed with 5 ml of 50 mM sodium phosphate 
buffer, 300 mM NaCl, pH 8.0 and eluted using a stepwise imidazole concentration gradient. 
The pure fractions as observed on the SDS gel were pooled together, concentrated and the 
concentration determined using the Bradford protein assay [Bradford, 1976] and a standard 
curve of bovine serum albumin, ranging in concentrations from 0 to 1 mg/ml. In order to 
couple PfPlrx to the activated CNBr-Sepharose 4B resin for the pull down assays, the protein 
was dialysed using 100 mM NaHCO3, 500 mM NaCl, pH 8.3. 
 
3.5.3 Preparation of PfPlasmoredoxin-Immobilised Resin 
PfPlasmoredoxin mutant (PfPlrxC63S) (2-5 mg) in 100 mM sodium carbonate pH 8.3 
containing 500 mM NaCl (coupling buffer) was incubated for 1 h at room temperature under 
gentle agitation with (2 ml) CNBr-activated Sepharose 4B resin, which had been swelled in 1 
mM HCl according to the manufacturer’s instructions. The coupling reaction was terminated 
by centrifugation and after washing the resin with the coupling buffer, the unreacted side 
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chains of the resin were blocked by incubation with 100 mM Tris buffer, pH 8.0 for 2 hours at 
room temperature.  
  
3.5.4 Collection of Target Proteins by Immobilised PfPlrxC63S Mutant 
Plasmodium falciparum cell lysate (prepared as outlined in 3.6.4) containing 7-10 mg 
protein was incubated with 2 ml of PfPlrxC63S immobilized resin at room temperature for at 
least 2 h under gentle stirring. Non specifically bound proteins were then removed by washing 
the resin severally with 100 mM Tris buffer, pH 8.0, 500 mM NaCl until the absorbance of 
the wash solution at 280nm was zero. The resin was then suspended in 100 mM Tris buffer, 
pH 8.0, 500 mM NaCl, and 10 mM DTT and incubated for 30 minutes at room temperature 
under gentle agitation. The eluted proteins were separated from the resin and collected by 
centrifugation. SDS-PAGE was performed with 15 % acrylamide gels and the separated 
protein bands visualized by Coomassie Brilliant Blue.  
 
3.5.5 Protein Bands Excision, Digestion and Identification 
Coomassie stained protein bands were excised manually and destained by washing 
them three times while vortexing for 10 min each using 25 mM NH4HCO3 in 50 % 
acetonitrile solution. The gel pieces were then dried using a vacuum centrifuge and rehydrated 
using 25 mM NH4HCO3 and procine trypsin (Promega). The trypsin digestion was performed 
overnight at 37 °C. The digest solution was then removed followed by the addition of 30 µl 
(enough to cover the gel pieces) of 5 % trifluoroacetic acid in 50 % acetonitrile and incubated 
for 20 min to extract the peptides. The peptide extraction was repeated 3 times. The peptide 
extraction solution was then removed, combined with the trypsin digestion solution and 
concentrated. The concentrated solutions were then loaded onto the MALDI target plate by 
mixing 0.3 µl of each solution with the same volume of matrix solution (10 mg/ml α-
cyanohydroxycinnaminic acid in acetonitrile/H2O (1:1, v/v) and allowed to dry. 
Measurements were performed using a Voyager 4182 matrix assisted laser desorption 
ionization time of flight (MALDI-TOF) instrument (Applied Biosystems, Darmstadt, 
Germany), operating in the positive ion reflector mode with an accelerating voltage of 25 kV. 
The laser wavelength was 337 nm and the laser repetition rate was 20 Hz. The final mass 
spectra were produced by using an average of 60 laser shots. Each spectrum was internally 
calibrated with the masses of two trypsin autolysis products. Peptide mass fingerprinting 
identification was performed by comparing the tryptic peptide mass maps against Swiss-Prot 
(http://www.expasy.uniprot.org) and PlasmoDB (http://www.plasmodb.org) databases using 
the search engine Protein Prospector MS-Fit. Standard search parameters were set to allow a 
mass accuracy of 15 ppm and two missed tryptic cleavages. 
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3.5.6 Biomolecular Interaction Analysis using Biacore ® X System 
Biacore X from Biacore AB is a system for real time biomolecular interaction analysis 
(BIA) using surface plasmon resonance technology. Real time BIA monitors the formation 
and dissociation of molecular complexes on a sensor surface as the interaction occurs by 
attaching one molecule (referred to as the ligand) to the surface, the interaction of another 
molecule in free solution (analyte) with the ligand is followed. Measurements are made under 
conditions of continous flow, where the sensor surface forms one wall of the flow cell. For 
majority of applications, the biospecific surfaces can be regenerated and reused for an 
extended series of analyses.   
The detection principle in BIA is based on surface plasmon resonance (SPR). This is a 
non invasive optical measuring technique which measures the mass concentration of 
biomolecules on the sensor surface. The technique does not require any labelling of the 
interacting components. The response is essentially independent of the nature of the 
biomolecule, so that all steps in an interacxtion analysis are followed with the same criterion. 
 
3.5.6.1 Biacore ® X System 
Protein-protein interaction was studied using a Biacore ® X Biosensor System 
(Biacore AB; Uppsala). Immobilisation of S-adenosyl-L-homocysteine hydrolase (SAHH) to 
the sensor chip CM5 via primary amine groups was performed in the instrument as follows: 
The carboxymethylated surface of the sensor chip CM5 was activated with a 1:1 mixture of 
0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) (provided in the amine coupling kit; Biacore AB). 35 µl 
(60 µg/ml) of SAHH in 10 mM sodium acetate, pH 4.5 were injected to flow cell 2 (FC2) to 
be immobilized on the sensor surface via primary amine groups. Residual unreacted active 
ester groups were blocked with 1 M ethanolamine-HCl, pH 8.5 (amine coupling kit). Studies 
were performed using HBS buffer (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005% 
Nonidet P-40, pH 7.4) at a flow rate of 10 µl/min. Protein-protein interaction studies between 
SAHH and PfPlrxC63S were performed as follows: SAHH which was bound on the sensor chip 
surface was oxidized using 30 µl of 0.5 mM 5,5'-dithiobis (2-nitrobenzoate) (DTNB) before 
30 µl of PfPlrxC63S (10 µM in HBS buffer or the running buffer) were injected, followed by 
buffer flow over the chip and an elution step with 2 mM DTT in a volume of 30 µl. 
Difference in resonance spectra (FC2–FC1) were recorded and evaluated using the software 
BIAevaluation 3.0 (Biacore AB). The sensor chip CM5 surface was equilibrated using HBS 
buffer and was ready for the next cycle.  
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3.6 P. falciparum Cell Culture Methods 
3.6.1 Maintainance of P. falciparum Parasites in Cell Culture 
Intraerythrocytic stages of P. falciparum strains were cultured according to Trager and 
Jensen [1976] with slight modifications. The parasites were propagated in leukocyte free 
erythrocytes (A+) at 33 % haematocrit at 37 oC under reduced oxygen (3 % O2, 3 % CO2, and 
95 % N2) in tissue culture (RPMI 1640-Gibco) medium containing 4 % human serum (A+) 
and 0.2 % Albumax (lipid rich bovine serum albumin). Albumax is needed to reduce the rate 
at which erythrocytes deteriorate in vitro and regulates the pH drift when cultures are exposed 
to ambient air. The media was further supplemented with 9 mM (0.16 %) glucose, 0.2 mM 
hypoxanthine, 2.1 mM L-glutamine and 22 µg/ml gentamycin. Chloroquine sensitive strains 
(3D7 and HB3) and resistant strains (K1 and Dd2) of P. falciparum [Su et al., 1997] were 
grown in continuous culture in the laboratory. Day to day monitoring of parasite growth was 
done by observing the parasitemia on Giemsa stained thin blood films. Depending on the 
strain, parasites typically propagate 3-8 fold every 48 hours, care was taken therefore to avoid 
parasite cultures attaining very high parasitemia beyond that adequate (3-10 %) for growth. 
Normally the percentage parasitemia used varied according to the need or experiment. 
 
Strain Clone Drug resistance Multiplication rate CQ IC50 in nM 
3D7 Yes from NF54 None 4-5     8.6 ± 0.4 
HB3 Yes PYR 6   16.8 ± 0.5  
Dd2 Yes from WR82 CQ,QN,PYR,SDX 5-6   90.2 ± 10.6 
K1 No CQ,PYR 4-5 155.0 ± 11.4 
Table 1: Characteristics of P. falciparum strains used (Fidock et al., 2004; Su et al., 1997) CQ: chloroquine, 
QN: quinine, PYR: pyrimethamine, SDX: sulfadoxine. 
 
3.6.2 Synchronisation 
Synchronisation of the parasites in culture to ring stages was carried out by treatment 
with 5 % (w/v) sorbitol [Lambros and Vanderberg, 1979] which leads to about 10 % 
parasitemia of predominantly ring stage phase of the culture. Five millilitres of 5 % sterile 
sorbitol preheated to 37 oC was added to 0.5 ml parasitised erythrocyte pellet from culture and 
left for 5 minutes at 37 oC. The sorbitol mixture was centrifuged at 1900 rpm for 3 minutes at 
room temperature to spin down the erythrocytes. The sorbitol was then off aspirated and the 
pellet quickly resuspended in complete medium for a quick wash after which the pellet was 
resuspended and returned to culture. In case the culture was not sufficiently synchronised, the 
procedure was repeated after 48 hours when the culture was at the ring stage again.   
 
3.6.3 Drug Sensitivity Assays 
Isotopic drug sensitivity assays using the semi-automated microdilution technique first 
described by Desjardins et al. [1979], was employed to investigate the susceptibility of the 
malaria parasite P. falciparum to inhibitors which had shown enzyme activity inhibition (at 
nanomolar range) towards IDO. The method involves the incorporation of radioactive H3-
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hypoxanthine which is taken up by the parasite as a precursor of purine deoxynucleotides for 
DNA synthesis. 
The assay was performed according to Fivelman et al. [2004]. In brief a two fold serial 
dilution of the starting concentration of each drug to be tested (B1-B12) (Figure 12) was 
performed in 96 well microtitre plates (NuncR) so that each well contained 100 µl of half the 
concentration of the drug in the preceding well above. The starting concentration of each drug 
was chosen such that the IC50 value (concentration that produces 50 % reduction in the uptake 
of H3-hypoxanthine) falls in the middle of the microtitre plate. Using parasites present in 
hypoxanthine free medium, 100 µl of a 2 times stock of previously diluted parasites 
(parasitemia of 0.5 % and a haemocrit of 2.5 %) were added into each well so that the 
parasites were at a final parasitemia of 0.5 %, 1.25 % haematocrit and with over 70 % of the 
parasites being in the ring stage. Parasitised red blood cells were used as the positive control 
whereas non-parasitised red blood cells served as the negative control. The plates were then 
incubated as normal culture for 48 hours after which 50 µl (final concentration 0.5 µCi /well) 
of H3-hypoxanthine was added per well. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Positive control Negative control 
B 
C 
D 
E 
F 
G 
H 
 
 
Drug 1 
 
 
Drug 2 
 
 
Drug 3 
 
 
Drug 4 
 
 
 
Drug 5 
 
 
Drug 6 
 
Figure 12: Semi-automated microdilution method of drug sensitivity assays: Arrangement of drugs on a 96 well 
microtitre plate. A1-A8: Positive control, red blood cells and parasites, A9-A12: Negative control, red blood 
cells only (without parasites), B1-H12: Serial drug dilutions for 6 different compounds in duplicates. 
 
The plates were further incubated for 24 hours after which they were frozen at -80 oC for at 
least 1 hour to freeze the cells. The plates were then thawed and using a glass filter (Perkin-
Elmer, Rodgau-Jügesheim, Germany) harvested and dried. Radioactivity in counts per minute 
(cpm) from each well was measured in a β-counter and considered to be proportional to the 
respective growth of P. falciparum in the well. The IC50 values were determined by linear 
regression analysis on the linear segments of the curve.  Percent reductions in growth were 
used to plot percent inhibition of growth as a function of drug concentration. Assays were 
typically repeated twice or three times on different occasions.     
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3.6.4 Preparation of P. falciparum Proteins from Cell Culture 
The P. falciparum proteins were prepared from 10 large Petri-dishes of P. falciparum 
cell culture with 15 % parasitemia and 3.3 % haematocrit. The parasites were isolated by 
suspending the erythrocytes in a 20 fold volume of saponin buffer containing 7 mM K2HPO4, 
1 mM NaH2PO4, 11 mM NaHCO3, 58 mM KCl, 56 mM NaCl, 1 mM MgCl2, 14 mM glucose 
and 0.02 % saponin pH 7.5 for 10 minutes at 37 oC. After centrifugation (2,700 rpm, 3 
minutes, 25 oC) the pellet was washed 3 times with 20 fold volume of buffer centrifuged to 
form a pellet which was stored at -80 oC after addition of protease inhibitor. 
The pellet which had been stored at -80 oC prepared from 10 Petri-dishes of P. 
falciparum cell culture was thawed. The Eppendorf tube cover was then sealed completely 
using parafilm. The pellet was then frozen and thawed 3 times using liquid nitrogen. In 
between each freezing and thawing procedure, the pellet was vigourously mixed (shaken) 
using a table shaker and briefly centrifuged before being immersed again into the liquid 
nitrogen tank. In case the pellet was too thick or viscous, 200-400 µl of buffer was added. The 
pellet was then sonicated 5 x 20 seconds and the pellet centrifuged at 50,000 rpm for 30 min. 
The concentration of the P. falciparum proteins present in the supernatant was then 
determined using the Bradford [1976] method and a standard curve of bovine serum albumin, 
ranging in concentration from 0 to 1 mg/ml. 
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4 Results  
4.1 PfGluPho 
4.1.1 Heterologous Overexpression and Purification of Recombinant PfGluPho 
Studies using PfGluPho have so far been restricted to the enzyme purified from 
parasite extract which is not only limiting in terms of the quantity of the enzyme required for 
inhibitor testing, crystal screening and biochemical characterisation of the enzyme, but also 
contains a high excess of the RBC G6PD. The desire and difficulties in cloning PfGluPho 
have also been reported [O’Brien et al., 1994; Clark et al., 2001] making it impossible to 
heterologously overexpress PfGluPho so far. 
Our cloning strategy, heterologous overexpression and purification method was 
successful and enabled us to clone, heterogously overexpress and purify PfGluPho to 
homogeneity. The heterologous overexpression and purification of recombinant PfGluPho 
was optimised as summarised in Tables 2, 3 and 4.  
  
Buffer Comments 
US buffer Was found not to be the best buffer for 
resuspension as well as purification  
100 mM Tris, 150 mM NaCl pH 7.4 Was not the optimum buffer for resuspension and 
purification 
100 mM Tris, 150 mM NaCl pH 7.8 Was found to be a good buffer but probably by 
increasing the salt concentration it would be 
better 
100 mM Tris, 500 mM NaCl pH 7.8 Was found to be the best buffer and therefore 
used for further resuspension of the pellet as well 
for the purification process 
Table 2: Optimisation of the buffers used for purification  of PfGluPho  
 
A)     B)    C) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: SDS gel 10 % after Ni-NTA and gel filtration of PfGluPho. A) 10 % SDS gel of elution fractions 
after Ni-NTA column purification where L1 corresponds to: 60 mM imidazole, L2 and L3: 80 mM imidazole L4 
and L5: 250 mM imidazole, L6 and L7: 500 mM imidazole. B)  10 % SDS gel of PfGluPho containing fractions 
after gel filtration. C) Gel filtration chromatogram after Ni-NTA, an elution time of 57.81 corresponds to 636 
kDa. 
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Western blot analysis using anti-histidine antibodies yielded a positive signal for the 
recombinant PfGluPho. When the Western blot was repeated using PfGluPho peptide specific 
antibodies a positive signal was also present for the recombinant protein as well as for P. 
falciparum proteins obtained from cell culture. 
 
 
Figure 14: Western blot analysis using PfGluPho peptide specific antibody. On the blot photo L1 represents 
recombinant PfGluPho whereas L2 (105 µg), L3 (70 µg), L4 (45 µg) represent P. falciparum proteins obtained 
from cell culture lysate. 
 
4.1.2 PfGluPho Oligomerisation Studies 
The oligomeric structure of PfGluPho is obscure and comparable data from other 
protozoan G6PDs is not yet available. Whether GluPho exists as a dimer as it is in most 
G6PD enzymes or as a tetramer as it is reported in doves [Cooper and Irwin, 1968] or if it 
exists in transition between dimer and tetramer as in humans [Birke et al., 1989] is not 
known. PfGluPho was found to be a hexamer with a subunit molecular weight of 106 ± 3.3 
kDa. Oligomerisation studies performed in the presence of G6P (1 mM) and NADP+ (200 
µM) using a native gel filtration chromatography revealed that PfGluPho maintains its 
hexameric structure both in the presence and absence of its substrate and coenzyme (Figure 
15). Addition of DTT (5 mM) to the running buffer (50 mM sodium acetate buffer, 150 mM 
NaCl, 50 mM EDTA pH 7.0)  in the presence or absence of the substrate or coenzyme did not 
lead to any observable change in the hexameric structure of PfGluPho implying that the 
hexameric structure is not due to or influenced by intermolecular disulphide bridges. This 
clearly distinguishes PfGluPho from other G6PDs, e.g. from the human and yeast enzymes 
which have been shown to change their conformation upon binding of substrates [Birke et al., 
1989, Kuby et al., 1974]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: PfGluPho hexameric structure in the presence of G6P and NADP+. In this gel filtration 
chromatogram the elution time of 58.39 corresponds to a molecular weight of 636 kDa. 
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E. coli cell line Medium Temperature oC Time Inductor and 
Concentration 
Western 
blot 
Inference 
Rosetta LB, TB 23, 27, 37 3hrs, 
overnight 
IPTG (0.025, 
0.05, 0.075, 0.1, 
0.5, 1.0 mM) 
Tested 
Positive  
Medium: no significant difference  
Temperature: between 23-27 oC was the best 
IPTG: 0.1 mM was the best, 
Final yield very low   
C41 pRIG LB, TB, 
2xYT 
23, 27, 37 3hrs, 
overnight 
IPTG (0.025, 
0.05, 0.075, 0.1, 
0.5, 1.0 mM) 
Tested 
Positive 
Medium: very low expression with 2xYT  
Temperature: between 23-27 oC was the best 
IPTG: 0.1 mM was the best, 
Final yield very low   
C41 pRARE LB, TB, 
2xYT 
25, 37 3hrs, 
overnight 
IPTG (0.1, 0.5, 
1.0, 2.0 mM) 
Tested 
Positive 
Medium: very low expression with 2xYT 
25 oC was the best 
Overnight expression was the best 
IPTG: 0.1 mM was the best, 
Final yield very low 
PD2000 LB, TB 25, 37 3hrs, 
overnight 
IPTG (0.1, 0.5, 
1.0, 2.0 mM) 
Tested 
Positive 
Medium: no significant difference  
25 oC was the best 
Overnight expression was the best 
Final yield very low 
PD2000 pRAREII LB, TB 25, 37 3hrs, 
overnight 
IPTG 1.0 and 2.0 
mM 
Tested 
Positive 
Medium: no significant difference  
25 oC was the best 
Overnight expression was the best 
Final yield very low although expression better in 
the presence of pRAREII 
KRX LB, TB 37 oC to O.D600 of 0.4 
then room temperature 
until O.D600 of 1.2 
induce 
3hrs, 
overnight 
Rhamnose: 0.05 
and 0.1 % 
Tested 
Positive 
Medium: TB was the best  
Overnight expression was the best 
Rhamnose: 0.1 % was the best 
Final yield improved 
KRX pRAREII LB, TB 37 oC to O.D600 of 0.4 
then room temperature 
until O.D600 of 1.2 
induce 
3hrs, 
overnight 
Rhamnose 0.05 
and 0.1 % 
Tested 
Positive 
Medium: TB was the best 
Overnight expression was the best 
Rhamnose: 0.1 % was the best 
Expression better in the presence of pRAREII 
Final yield the best therefore adopted as the 
standard method for expression of PfGluPho. 
Table 3: Optimisation of the heterologous overexpression of PfGluPho. Western blot was performed using anti-histidine antibody and all samples tested positive for  
 PfGluPho. 
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Material Condition used Inference 
Ni-NTA (one column system) Equilibrated the column material with buffer containing 
10 mM imidazole then loaded the lysate containing 
protein and eluted with an imidazole concentration 
gradient. 
When the column material is pre-equilibrated with 10 mM 
imidazole the protein binds very weakly. 
2’ 5’ ADP Sepharose 4B (one 
column system) 
Loaded the lysate containing protein and eluted with an 
NADP+ concentration gradient. 
When examining the SDS gels of the eluted fractions very 
weak bands are observed. 
Ni-NTA (one column system) Equilibrated the column material with buffer without 10 
mM imidazole then loaded the lysate containing protein 
and eluted with an imidazole concentration gradient. 
Protein binds well. 
20 % pure protein obtained as observed on SDS gels.  
Ni-NTA then 2’ 5’ ADP Sepharose 
4B (two column system) 
Equilibrated the column material with buffer, loaded the 
lysate containing protein on Ni-NTA material and eluted 
with an imidazole concentration gradient then loaded the 
pure fraction as seen on SDS gel on a 2’ 5’ ADP 
Sepharose 4B column. 
20 % pure protein obtained after Ni-NTA column but the 
protein seems to be binding weakly to the 2’ 5’ ADP 
Sepharose 4B column material upon comparison of SDS gels 
of the pure fractions after the 2 columns. 
 
2’ 5’ ADP Sepharose 4B then Ni-
NTA (two column system) 
Loaded the lysate containing protein on a 2’ 5’ ADP 
Sepharose 4B, eluted with an NADP+ concentration 
gradient then loaded the pure fractions as observed on 
SDS on Ni-NTA column. 
Reversing the conditions by using 2’ 5’ ADP Sepharose 4B 
column then Ni-NTA column leads to very weak bands on 
SDS gel. The band of a 20% pure protein obtained when Ni-
NTA is the first column is not present in this case. 
2’ 5’ ADP Sepharose 4B (two 
column system) 
Eluted the protein from the first column, dialysed them to 
remove NADP+ then loaded the pure fraction as seen on 
SDS gel on a second column. 
We can conclude from this experiment that generally the 
protein binds very weakly to the 2’ 5’ ADP Sepharose 4B 
column material. 
 
Ni-NTA (two column system) Ran the first column then dialysed to remove imidazole 
then loaded the pure fraction as seen on SDS gel on a 
second Ni-NTA column material. 
The protein binds very well. 
The protein binds even better on the second column even 
though it had been equilibrated with 10 mM imidazole. 
The two column system using Ni-NTA does not improve 
purity. 
Ni-NTA then gel filtration using 
16/60 superdex 200 prep grade 
column 
Equilibrated the column material with buffer, loaded the 
lysate-containing protein on Ni-NTA material and eluted 
with an imidazole concentration gradient then loaded the 
pure fraction as seen on SDS gel on a FPLC machine for 
gel filtration.  
Protein binds well to Ni-NTA column. 
20 % pure protein obtained as observed on SDS gels after Ni-
NTA column. 
Homogenous pure protein is obtained after gel filtration. 
Best method and adopted for further purifications. 
Table 4: Optimisation of the purification of heterologously overexpressed PfGluPho. 
Mailu B M Results  
 54
4.1.3 PfGluPho’s G6PD Kinetic Studies 
It is appropriate to determine the approximate Km values for each substrate prior to an 
initial velocity experiment. This allowed experiments to be conducted by varying the substrate 
concentration over a specific range relative to each Km value. PfGluPho was found to be 
exhibiting very high affinities and therefore low Km values for both G6P and NADP+ (Table 
5) but exhibited low affinity and therefore high Km values for the G6P analogue 2-
deoxyglucose-6-phosphate. Measuring the G6PD activity in full blood samples showed that 
the human G6PD has a comparatively lower affinity and therefore a higher Km for G6P and 
NADP+ (Table 5). Control G6PD assay experiments were performed using commercial yeast 
G6PD.  
PfGluPho’s G6PD initial rate studies using different combinations of G6P and NADP+ 
yielded linear converging double reciprocal plots (Figure 16). An intersecting pattern was also 
obtained when the results were replotted with G6P as the independent variable (Figure 16). 
The secondary plots of the slopes and intercepts against the reciprocal of the substrate or 
coenzyme also yielded straight linear plots (Figure 17 and 18). In theory for scattered data, a 
simple linear fit may introduce a false weighting. Here however, an internal check was 
applied by using both possible plotting sequences to extract kinetic parameters, i.e. using both 
1/[NADP+] and 1/[G6P] as alternative variables for the primary plots. 
The initial rate equation for the two substrate reaction catalysed by G6PD in the nomenclature 
of Dalziel [1957] is of the form  
 
e/v = Φ0 + ΦX/[X] + ΦY/[Y] + ΦXY/[X][Y] 
 
where X and Y are sugar phosphate and coenzyme respectively. 
 
The Φ (Φ = 1/kcat)  parameters are obtained from initial rate measurements at varying 
concentrations of X for a series of fixed concentrations of Y. Rearrangement of the equation 
shows that the intercepts of primary double reciprocal plots with 1/[X] as the variable are 
given by Φ0 + ΦY/ [Y] and the slopes by ΦX + ΦXY/ [Y]. The secondary plots of these slopes 
and intercepts against 1/[Y] provide estimates for the individual initial rate parameters. 
[Dalziel, 1957]. The Dalziel parameters for the initial rate measurements for PfGluPho are as 
shown in Table 6. The initial rate behaviour gives no indication of any complexities in 
NADP+ binding. 
  
4.1.4 PfGluPho’s G6PD Alternative Substrate Studies 
An alternative substrate, when available can be a useful tool for differentiating kinetic 
models as first reported by Wong and Hanes [1962]. The alternative substrate used here is 2-
deoxyG6P. The corresponding kinetic parameters are given in Table 5 and Table 6. A 
comparison of the kinetic parameters shows that the enzyme has a higher affinity for its 
natural substrate G6P than for the substrate analogue 2-deoxyG6P (Km G6P 18.1 µM vs Km 2-
deoxyG6P 2.5 mM).   
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Figure 16: PfGluPho’s G6PD double reciprocal plots of NADP+ and G6P 
 
 
Figure 17: Secondary plots of slopes of PfGluPho’s G6PD primary plots against 1/ [substrate] 
       
 
Figure 18: Secondary plots of intercepts of PfGluPho’s G6PD primary plots against 1/ [substrate] 
 
4.1.5 PfGluPho’s G6PD Glucoseamine 6-Phosphate Inhibition  
Glucoseamine-6-phosphate which is an analogue of G6P was chosen as a dead end 
inhibitor for our study and was found to be a mixed inhibitor with respect to both G6P and 
NADP+ (Figure 19).  
 
4.1.6 PfGluPho’s G6PD ATP-Ribose Inhibition 
The NADP+ fragment ATP-ribose which is an analogue of NADP+ was found to be a 
mixed inhibitor with respect to both substrates G6P and NADP+ (Figure 20). 
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A) 
 G6PD Enzymes    
Substrate PfGluPho’s G6PD (Recombinant)  Literature Values 
 Km (µM) Vmax (U/mg) kcat s-1 kcat/Km  (M-1 s-1) Km (µM)  
G6P 18.1 ± 0.5 116 ± 5 206 ± 9     11.4 x 107 11a, 27b  
NADP+  5.1 ± 0.4 114 ± 9 203 ± 12 3.98 x 107 0.8a, 4.5b  
2-DG6P 2600 ± 141 105 ± 7 186 ± 12 7.1 x 104 10000a  
       
 Human G6PD (Recombinant)  Literature Values 
 Km (µM) Vmax (U/mg) kcat s-1 kcat/Km (M-1 s-1) Km (µM) kcat/Km (M-1 s-1) 
G6P ND - - - 54.8c, 43.4d c2.9 x 106 
NADP+ ND - - - 6.76c, 11d c2.3 x 107 
2-DG6P ND - - - 1674c c1.9 x 104 
       
 Human G6PD (Full Blood)  Literature Values 
 Km (µM)    Km (µM)  
G6P 24 ± 1.3    27a  
NADP+ 8.1 ± 2.4    9a  
       
 Yeast G6PD (Sigma)    
 Km (µM) Vmax (U/mg)   Km (µM)  
G6P 53 ± 1 323 ± 7   51e  
NADP+    24 ± 0.9   415 ± 14   19e  
       
 
 
B) 
 6-PGL Enzymes    
 PfGluPho’s 6-PGL (Recombinant)  Literature Values 
Substrate Km (µM) Vmax (U/mg) kcat s-1 kcat/Km (M-1 s-1) Km (µM)  
6-PG-δ-L 26.2 ± 4.9 74.9 ± 1.8 133 ± 3 5.08 x 106 -  
       
       
 Human 6-PGL (Recombinant)    
Substrate Km (µM) Vmax (U/mg) kcat s-1 kcat/Km (M-1 s-1) Km (µM)  
6-PG-δ-L 32.5 ± 4.9 712 ± 11 344 ± 3 1.0 x 107 -  
       
 
 
C) 
 6-PGD Enzyme    
 Yeast 6-PGD (Sigma)  Literature Values 
Substrate Km (µM) Vmax (U/mg)   Km (µM)  
6-PGn 48.9 ± 2.4 330 ± 43   55f  
NADP+  9.9 ± 1.5 325 ± 5     
       
 
Table 5: Kinetic parameters of G6PD and 6-PGL enzymes. A) Kinetic parameters of G6PD enzymes determined 
in the study as well as the existing literature values. B) 6-PGL kinetic parameters of the recombinant PfGluPho’s 
6-PGL enzyme in comparison to the recombinant human homologue. C) Yeast 6-PGD kinetic paparameters. 2-
DG6P means 2-deoxyG6P, ND means not determined, 6-PG-δ-L means 6-phosphoglucono- δ-lactone, 6-PGn 
means 6-phosphogluconate. a: Yoshida and Roth, 1987, b: Kurdi-Haidar and Luzzatto, 1990, c: Wang et al., 
2002, d: Birke et al., 1989, e: Gould and Goheer, 1976, f: Weiwei et al., 2007. 
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A) G6P and NADP 
Row 
no. 
Φ0 (s) ΦG6P (µM.s) ΦNADP (µM.s) Φ NADP G6P 
(µM2.s) 
ΦNADP ΦG6P 
(µM2.s2) 
Φ NADP G6P / ΦG6P 
(µM) 
Φ NADP G6P / 
ΦNADP (µM) 
Φ NADP G6P / 
ΦG6PΦNADP (s-1) 
kcat 
(s-1) 
          
1 0.005 0.088 ± 0.003 0.025 0.449 ± 0.4 0.002 5.1 18.13 ± 0.54 206 206 
          
2 0.005 0.089 ± 0.01 0.025 0.455 ± 0.4 0.002 5.1 ± 0.35 18.13 203 203 
          
3 0.005 0.089 ± 0.001 0.025 ± 0.0003 0.45 ± 0.005 0.002 ± 0.001 5.1 18.13 204.5 ± 2.1 205 
          
 
B) 2-DeoxyG6P and NADP 
Row 
no. 
Φ0 (S) Φ2-DG6P 
(µM.s) 
ΦNADP (µM.s) ΦNADP 2-DG6P 
(µM2.s) 
ΦNADPΦ2-DG6P 
(µM2.s2) 
ΦNADP 2-DG6P/ 
Φ2-DG6P  (µM) 
ΦNADP 2-DG6P/ 
ΦNADP (µM) 
ΦNADP 2-DG6P / 
Φ2-DG6P ΦNADP (s-1) 
kcat 
(s-1) 
          
1 0.005 13.98 0.027 71.4 0.383 5.1 2600 186 186 
          
2 0.005 13.4 0.026 68.4 0.352 5.1 2600 194 194 
          
3 0.005  13.69 ± 0.41 0.027 ± 0.0008 69.8 ± 2.1 0.368 ± 0.022 5.1 2600 190 ± 5.5 190 
          
 
C) Human G6PD Literature Values [Wang et al., 2002]. 
Row Φ0 (S) ΦG6P (µM.s) ΦNADP (µM.s) Φ NADP G6P 
(µM2.s) 
ΦNADP ΦG6P 
(µM2.s2) 
Φ NADP G6P /ΦG6P 
(µM) 
Φ NADP G6P / 
ΦNADP (µM) 
Φ NADP G6P / 
ΦG6PΦNADP (s-1) 
kcat (s-
1) 
          
A 0.0062 0.34 0.042 2.3 0.014 6.76 54.8 161 161 
 
 Φ0 (S) Φ2-DG6P 
(µM.s) 
ΦNADP (µM.s) ΦNADP 2-DG6P 
(µM2.s) 
ΦNADPΦ2-DG6P 
(µM2.s2) 
ΦNADP 2-DG6P/ 
Φ2-DG6P (µM)  
ΦNADP 2-DG6P/ 
ΦNADP (µM) 
ΦNADP 2-DG6P / 
Φ2-DG6P ΦNADP (s-1) 
Kcat 
(s-1) 
          
B 0.031 68 0.28 451 19.04 6.64 1643 25 32.3 
          
Table 6: PfGluPho Dalziel parameters calculated using the initial velocity data. A) Kinetic data determined using primary plots against both reciprocal of G6P (row 1) and 
reciprocal of NADP+ (row 2). The mean value for G6P and NADP+ is presented (row 3). B) Kinetic data determined using primary plots against both reciprocal of 2-
DeoxyG6P (row 1) and reciprocal of NADP+ (row 2). The mean value for NADP+ and 2-DeoxyG6P is presented (row 3). C) Human G6PD literature values [Wang et al., 
2002]; Row a: The mean value for G6P and NADP+, Row b: mean value for NADP+ and 2-DeoxyG6P. 
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Figure 19: Glucoseamine 6-phosphate inhibition on PfGluPho’s G6PD. A) Glucoseamine 6-phosphate inhibition 
on NADP+.  B) Glucoseamine 6-phosphate inhibition on G6P.  
  
 
 
Figure 20: ATP-Ribose inhibition of PfGluPho’s G6PD. A) ATP-Ribose inhibition on NADP+. B) ATP-Ribose 
inhibition on G6P. 
               
 
Figure 21: NADPH inhibition of PfGluPho’s G6PD. A) NADPH inhibition on G6P. B) NADPH inhibition on 
NADP+. 
 
4.1.7 PfGluPho’s G6PD NADPH Inhibition  
Product inhibition patterns offer useful information regarding enzyme reaction 
mechanisms. In this case 6-phosphogluconolactone is too labile for kinetic measurements. 
However it is possible to determine the effects of NADPH on this reaction. NADPH was 
found to be a mixed inhibitor with respect to G6P and a non competitive inhibitor with respect 
to NADP+ (Figure 21). The results imply that G6P binds to the enzyme-NADP+ complex and 
not the free enzyme and therefore NADP+ could be the leading substrate. This inhibition 
pattern points toward an ordered sequential mechanism with NADP+ binding first to the 
enzyme. 
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4.1.8 PfGluPho’s G6PD Assay with GSSG, GSH and PfGR 
Formation of mixed disulfides between glutathione (GSSG) and the cysteines of some 
proteins (glutathionylation) has been suggested as a mechanism through which protein 
functions can be regulated by the redox status of glutathione. Experiments of the PfGluPho’s 
G6PD assay performed in the presence of any of the following: 2 mM GSH, 1 mM GSSG, 
PfGR 10 mU/ml or in the presence of both PfGR (10 mU/ml) and GSH (2 mM), showed that 
PfGluPho is not allosterically regulated by PfGR or any kind of interaction with GSSG or 
GSH and thus the redox status of glutathione.  
 
4.1.9 PfGluPho’s G6PD Buffers, pH and Salt 
Although the best buffer for PfGluPho was found to be 100 mM Tris, 10 mM MgCl2 
and the optimum pH was found to be 7.4, our studies were able to demonstrate that the 
standard G6PD buffer (100 mM Tris, 0.5 mM EDTA, 10 mM MgCl2, pH 8.0) could be used 
for further characterisation of PfGluPho. This would enable us to make direct comparisons 
with previously published G6PD enzymes data. 
 
4.1.10 PfGluPho’s 6-PGL Kinetic Analysis  
PfGluPho is a bifunctional enzyme composed of G6PD and 6-PGL. In reactions 
catalysed by G6PD glucose-6-phosphate is quickly converted to 6-phosphogluconolactone 
and concomitantly NADP+ converted to NADPH + H+. At the same time 6-
phosphogluconolactone is quickly hydrolysed to 6-phosphogluconate by virtue of the 
bifunctionality of PfGluPho. The 6-phosphogluconate available is converted to ribulose-5-
phosphate with concomitant production of CO2 and NADPH + H+ in a reaction catalysed by 
6-phosphogluconate dehydrogenase. 
The concentration of 6-phosphogluconolactone made available to 6-PGL in a given 
period of time by the reaction catalysed by PfGluPho’s G6PD was determined as follows: 
Each absorbance value obtained before addition of 6-PGD at a given time t (delta At) 
corresponds to the amount of NADPH produced at time t. Since the extinction coefficient of 
NADPH is 6.22 l mmol-1 cm-1 at 340 nm it follows that 100 µM NADPH is approximately 
equal to an absorbance of 0.622. A graphical plot of 6-phosphogluconolactone available 
against time gives a linear plot showing the amount of 6-phosphogluconolactone available at a 
given time (Figure 23). 
The next step is to estimate the amount of 6-phosphogluconate that is produced by the 
reaction catalysed by PfGluPho’s 6-PGL and available to 6-PGD catalysed reaction. The 
difference in absorbance between the final absorbance readings after addition of 6-PGD (delta 
Af) and the absorbance reading before addition of 6-PGD (delta A) give the corrected delta A 
value (delta Ac) (delta Af – delta A = delta Ac). The calculated delta Ac was then fitted into the 
equation of the line of a standard curve obtained from a Lineweaver-Burk plot of the reaction 
performed using yeast 6-PGD in the absence of PfGluPho to obtain the concentration of 6-
phosphogluconate available. Thus the concentration of 6-phosphogluconate available at given 
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time could be calculated. A plot of 6-phosphogluconate available at given time against time 
gave a linear plot (Figure 23). To test for the influence of PfGluPho in the reactions catalysed 
by yeast 6-phosphogluconate dehydrogenase, control assays of 6-phosphogluconate 
dehydrogenase were performed in the presence and absence of PfGluPho. The results were 
negative which implied that PfGluPho was only actively involved in the enzymatic generation 
of the substrate 6-phosphogluconate. 
 
 
Figure 22: Lineweaver-Burk graph of PfGluPho’s 6-PGL and Human 6-PGL assays. A) Lineweaver-Burk graph 
of PfGluPho 6-PGL assays. B) Lineweaver-Burk graph of Human 6-PGL assays. 
 
A)            B) 
 
Figure 23: PfGluPho’s 6-PGL assay graphs. A) Graph showing the concentration of the products 6-
phosphogluconolactone (6-PG-δ-L) available and the concentration of 6-phosphogluconate (6-PGn) produced by 
PfGluPho’s 6-phosphogluconolactonase. B) Graph showing the ncentration of the products 6-
phosphogluconolactone (6-PG-δ-L) available and the concentration of 6-phosphogluconate (6-PGn) produced by 
human 6-PGL. 
  
The Km value for PfGluPho’s 6-PGL for its substrate 6-phosphogluconlactone was 
found to be 26.2 µM. A comparative study using the human 6-PGL showed that the human 
enzyme had a higher Km value (32.5 µM) than that exhibited by PfGluPho’s 6-PGL. These 
results imply that the parasite enzyme has a higher affinity for the substrate 6-
phosphogluconolactone. Comparison of the Vmax values between the parasite enzyme and its 
human homologue revealed that the human enzyme Vmax value was 5 times higher that 
exhibited by the parasite enzyme (712 against 71.2 U/ mg).  
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4.1.11  PfGluPho’s 6-PGL Assay in the Presence of GSSG and GSH 
Formation of mixed disulfides between glutathione and cysteines in proteins 
(glutathionylation) has long been known to occur after oxidative stress [Brigelius et al., 
1983]. Recently, protein glutathionylation has gained attention as a possible means of redox 
regulation of protein functions. We therefore tested for the possibilities of PfGluPho’s 6-PGL 
being regulated by glutathionylation. Our results demonstrate that no decrease in activity was 
evident in a system containing GSSG, GSH or a GSSG free reaction set up.  
 
4.1.12 PfGluPho Crystal Screening 
Crystal screening trials using PfGluPho have yielded crystals (Figure 24) of 
approximately 50 x 50 µm which can be further optimised to improve the crystal quality and 
thus solve the x-ray structure of PfGluPho. 
  
    
Figure 24: First PfGluPho crystals  
 
4.1.13   PfGluPho Structure Prediction 
4.1.13.1 Structure Prediction: Model of PfGluPho’s G6PD 
Plasmodium falciparum GluPho (PfGluPho) contains some unique structural and 
functional characteristics. A comparison of the C-terminal part amino acid sequence (residues 
311-911) to that of human G6PD revealed only 39 % homology. The NADP+ binding site as 
proposed by Hirono et al., [1989] based on 
clustering of mutations in G6PD genes of 
individuals having low affinity for NADP+ is not 
present in PfGluPho, however the region proposed 
by Persson et al., [1991] based on recognisable 
characteristics of the coenzyme binding site 
GXXGXXG/A and the β-α-β fold are present in 
GluPho (Figure 26). In PfGluPho and in other 
Plasmodium GluPhos the final Gly of the coenzyme 
binding site is replaced by Phe [Clark et al., 2001]. 
The conserved Arg in this area in all other 
organisms is Cys (aa 363) in PfGluPho although 
Arg 378 is conserved. The substrate (G6P) binding 
site IYRIDHYLGKA is highly conserved in 
PfGluPho.   
                                                                                                                 Figure 25: Model of PfGluPho G6PD 
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A unique feature of PfGluPho is the 62 
amino acid insert (within the G6PD part) 
found between the structurally predicted 
NADP+ and G6P binding site that has no 
similarity found to date (Figure 26). 
Similar inserts which differ in size and 
sequence are present in other 
Plasmodium GluPho and have 
nevertheless been demonstrated to be 
essential for GluPho activity [Clark et al., 
2003]. The presence of the insert could 
imply that the distance between the 
substrate and coenzyme binding site of 
PfGluPho may be different from that of 
the human G6PD and therefore there may 
be a difference in the efficiency of 
electron transfer. 
Figure 26: Overlay of the model of Pf GluPho’s G6PD     
(cyan) and human G6PD (orange) differences in the Pf  
protein are marked in red. 
 
 
A)              B) 
      
Figure 27: PfGluPho’s G6PD and human G6PD NADP+ binding site. A) PfGluPho’s G6PD NADP+ binding site 
model in complex with NADP+ (light blue). B)  Human G6PD NADP+ binding site model in complex with 
NADP+ (orange). Dark Blue colour patches show nitrogen, red colour patches show oxygen and yellow patches 
sulphur.   
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Figure 28: Comparison of the G6PD NADP+ binding pocket amino acids of PfGluPho’s G6PD and Human 
G6PD. The NADP+ binding pockets seem to be highly conserved except for a few differences which are marked 
in red in  the model of the PfGluPho (cyan) when compared with the human G6PDH (orange) and NADP+ is 
shown in blue.   
 
4.1.13.2 Structure Prediction: Model of PfGluPho’s 6-PGL 
The structure prediction of PfGluPho’s 6-PGL was performed by comparing with the 
structure of Thermotoga  maritima. The overall structure is very similar although PfGluPho 
has more amino acids than T. maritima (Figure 29) which appear as a beta sheet (amino acid 
168-190). The second observable difference is the additional alpha helix present in PfGluPho 
but absent in T. maritima (Figure 29) (amino acid 263-286). Amino acids 198-208 form an 
alpha helix which is absent in T. maritima (Figure 29) where as amino acids 145-153 of T. 
maritima are present in the form of a short loop when compared to the additional PfGluPho 
alpha helix (Figure 29) (aa 198-208). 
   
            
 
Figure 29: Overlay of the model of PfGluPho’s 6-PGL and 6-PGL from T. maritima.  PfGluPho’s 6-PGL 
(green) vs. 6-PGL from T. maritima (1VL1; salmon), differences in the P. falciparum protein are marked in red. 
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4.1.14 Screening for PfGluPho’s G6PD Inhibitors 
Interestingly early studies showed that many antimalarial drugs effectively inhibit 
commercial supplies of purified yeast G6PD [Cotton and Sutorius, 1971]. Similar studies 
have not been extended to PfGluPho’s G6PD and no known inhibitors exist to date. 
Identification of such inhibitors would lift the lid on probable new compounds with a different 
mode of action for the treatment of malaria. Screening for PfGluPho’s G6PD inhibitors 
(concentration of 5 µg/ml) from a library of 2000 compounds provided by the Hans-Knöll 
institute, Jena yielded 11 compounds which demonstrated an inhibition of above 60 % (Table 
8). Three of these compounds (6983, 8007 and 8012) were obtained in quantities large enough 
for verifying the IC50 values as well as determining the type of inhibition. All the 3 inhibitors 
were found to be non-competitive with respect to G6P (Ki of 1.18, 1.65, 1.26 µM for 6983, 
8007 and 8012 respectively) (Table 7) (Figure 30). In addition compound 8007 was found to 
be non-competitive with respect to NADP+ (Ki 2.58 µM).  
    
A)       B) 
 
Figure 30: Non-competitive inhibition exhibited by compound 8007 on PfGluPho’s G6PD. A) Non-competitive 
inhibition pattern of compound 8007 with respect to G6P. B) Non-competitive inhibition pattern of compound 
8007 with respect to NADP+. 
 
Inhibitor Ki G6P (µM) Type of Inhibition Ki NADP+ (µM) Type of Inhibition 
6983 1.18 Non-competitive ND ND 
8012 1.65 Non-competitive ND ND 
8007 1.26 Non-competitive 2.58 Non-competitive 
Table 7: Ki values for PfGluPho’ G6PD inhibitors tested. ND stands for not determined 
 
These results demonstrate that the inhibitors bind to another binding site other than the 
substrates G6P and NADP+. 
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Inhibitor Inhibitor Strucutre % Inhibition at 
5 µg/ml (IC50) 
 Inhibitor Inhibitor Strucutre % Inhibition at 
5 µg/ml (IC50) 
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Table 8: PfGluPho’s G6PD inhibitors. * are the compounds which were retrieved in larger quantities and IC50 were determined in enzyme assay. 
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4.2 Mouse IDO-1 and Mouse IDO-2 
4.2.1 Heterologous Overexpression of Mouse IDO-2 
The heterologous overexpression of IDO-2 protein was optimised using KRX cells. 
The best expression conditions were obtained using TB medium and induction with a final 
concentration of 0.1 % rhamnose. The expression system was supplemented with ALA, a 
natural precursor of heme in order to increase the heme content as reported for recombinant 
indoleamine 2,3-dioxygenase overexpression [Austin et al., 2004] and other heme proteins 
[Delcart et al., 2003]. Purification of the protein over a Ni-NTA column yielded 15 mg/ml 
protein from a litre of E. coli culture. The enzyme was prone to precipitation and unstable in 
activity. Therefore, glycerol (20-50 %) was added immediately after elution and found to 
enhance stability. Adding bovine serum albumin (0.05 mg/ml) or CHAPS (0.5 mM) did not 
enhance stability. 
                
Figure 31: SDS gel showing the purification of mouse IDO-2 after the Ni-NTA column. On the left hand the 
molecular weight of the marker is given in kDa. L1 flowthrough fraction after binding of the protein. L2 - L7 
imidazole elution concentration gradient (L2 : 50 mM, L3 : 60 mM, L4 : 75 mM, L5 & L6 : 200 mM, L7: 500 
mM) in Tris buffer pH 7.4, 150 mM NaCl. 
 
4.2.2 Optimisation of Heterologous Overexpression of Mouse IDO-1 
The optimisation of heterologous overexpression of mouse IDO-1 was performed by 
varying various conditions as summarised in Table 9. The best expression conditions were 
obtained using LB medium and induction with a final concentration 0.025 mM IPTG. The 
expression system was supplemented with ALA just like in IDO-2 expression. Purification of 
the protein over a Ni-NTA column yielded 40 mg/ml protein from a litre of E. coli culture. 
Unlike IDO-2, IDO-1 was more stable and not prone to precipitation or unstable in activity. 
 
Parameter Condition used Finding 
IPTG Concentration  0.025 – 1.0 mM 0.025 mM was the best 
Medium LB, Terrific Broth, 2x YT LB medium was the best 
Duration of 
expression 
3, 6 hours and overnight expression Overnight expression was the 
best 
E. coli cells type BL 21, Rosetta Rosetta cells were the best 
Temperature oC 37, 30, 25, 20, room temperature Room temperature 
Supplements Heme, δ-aminolevulininc acid (ALA) 0.1-
1.0 mM 
1 mM ALA 
Table 9: Optimisation of the heterologous overexpression of mouse IDO-1. 
 
 
L1     L2        L3        L4        L5          L6      L7 
kDa 
116 
66 
45 
35 
25 
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4.2.3 Kinetic Assays for Mouse IDO-1 and Mouse IDO-2 
The IDO-2 kinetic assays were performed using higher (0-60 mM) L-tryptophan as 
compared to 0-200 µM for IDO-1 and 400 µM as described by Takikawa et al. [1988]. At 
these higher concentrations L-tryptophan exhibited high absorption values by itself therefore a 
corresponding L-tryptophan concentration blank was always set up. The corrected assay 
absorption values were obtained by subtracting the value of the blank. Apart from the 
absorbance which could be subtracted, L-tryptophan did not influence the kynurenine 
calibration curve as observed in three different curves set up with 0.4, 12, and 30 mM L-
tryptophan.  
The values for Km and Vmax are characteristic properties of the enzyme and substrate 
system. Mouse IDO-1 exhibited a low Km value (in the µM range) and therefore a high 
substrate affinity towards the substrate L-tryptophan as compared to IDO-2 which exhibited a 
high Km (in the mM range) value and therefore a low affinity (Table 10). 
 
 L-Tryptophan 
 Km µM Vmax min-1 
   
mIDO-1a 28 203 ± 9 
   
mIDO-2a 12000 ± 3000 0.013 ± 0.001 
   
mIDO-2* 530 ± 100 7.7 ± 0.3 
Table 10: Kinetic parameters of mouse IDO-1 and mouse IDO-2. a: done using methylene blue/ ascorbic acid 
method * : done using cytochrome b5/ cytochrome P450 method. 
 
The IDO-2 Km for the substrate L-tryptophan was found to decrease 20 fold from 12,000 to 
530 µM (therefore increase in affinity for the substrate) when the assay was performed using 
the cytochrome b5/ cytochrome 450 reduction method. A 590 fold improvement in the Vmax 
was observed showing an improvement in L-tryptophan turnover capacity (Table 10). IDO-2 
just like IDO-1 obeys Michaelis-Menten kinetics although it exhibits substrate inhibition at L-
tryptophan concentration above 30 mM (Figure 32). It was also noted that for the freshly 
prepared IDO-2 the Km value increased over time.  
 
A)              B) 
 
Figure 32: Michaelis-Menten and Lineweaver-Burk graph of mouse IDO-2. A) Michaelis-Menten curve of 
mouse IDO-2 showing substrate inhibition. B) Lineweaver-Burk graph of mouse IDO-2. 
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4.2.4 Test for Buffers, pH and Salt for Mouse IDO-1 and Mouse IDO-2 
Several buffers were tested in order to determine the optimal mouse IDO buffer. The 
buffers tested were Hepes, Tricine, MES, MOPS, TEA and potassium phosphate buffer all set 
at a concentration of 100 mM and the pH set at the pKa value. IDO-2 recorded the best 
activity with 100 mM Tricine buffer pH 7.0 and IDO-1 recorded the best activity with 100 
mM MOPS buffer pH 6.5 (Table 11).  
                                                                                                                                                              
Buffer % activity IDO-2 % activity IDO-1 
100 mM Hepes pH 7.2 85.3 90.1 
100 mM Tricine pH 7.5 87.8 73.2 
100 mM Tricine pH 7.0             100.0 97.8 
100 mM MES  pH 7.0 71.6 88.5 
100 mM MOPS pH 7.5   98.3 88.1 
100 mM MOPS pH 6.5  67.8             100.0 
100 mM TEA pH 7.5 86.2 92.0 
100 mM TEA pH 8.0 96.1 57.5 
100 mM Potassium phosphate pH 7.4 46.7 52.62 
Table 11: Mouse IDO-1 and IDO-2 test with different buffers without salt  
 
When tests were performed using these buffers containing in addition 100 mM KCl, 100 mM 
TEA buffer pH 8.0 was the best buffer for IDO-2 whereas 100 mM Tricine pH 7.0 was the 
best buffer for IDO-1 (Table 12).  
 
Buffer  % Activity IDO-2 % activity IDO-1 
100 mM Hepes pH 7.2 78.5 83.7 
100 mM Tricine pH 7.5 86.3 80.1 
100 mM Tricine pH 7.0 92.0             100.0 
100 mM MES pH 7 92.1 81.6 
100 mM MOPS pH 7.5 91.4 74.6 
100 mM MOPS pH 6.5 72.5 87.2 
100 mM TEA pH 7.5 90.6 84.0 
100 mM TEA pH 8.0             100.0 58.2 
100 mM Potassium phosphate pH 7.4 66.0 50.2 
Table 12: Mouse IDO-1 and IDO-2 test with different buffers all containing 100 mM KCl  
 
Tests were also performed using potassium phosphate buffer pH 7.4 (a component of the 
standard IDO assay buffer) with varying amounts of KCl (0-300 mM). The best activities 
were in the presence of 100 mM KCl for IDO-2 and 50 mM KCl for IDO-1 (Table 13). 
  
KCl conc % Activity IDO-2 % activity IDO-1 
0 93.2 99.4 
50 93.4           100.0 
100           100.0 89.3 
150 93.4 83.0 
200 89 87.4 
300 77.5 91.8 
Table 13: Test for different KCl concentrations in 100 mM potassium phosphate (pH 7.4) buffer  
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Comparing pH profiles of IDO-2 and IDO-1 revealed that whereas IDO-1 had an optimum 
activity at pH 6.4 - 6.5, IDO-2 had an optimum activity at pH 7.4 - 7.5 (Figure 33). Tests with 
various buffers showed that the 100 mM potassium phosphate buffer, pH 7.4, 100 mM KCl 
was the best buffer for IDO-2 and was therefore used for further analysis. 
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         Figure 33: Mouse IDO-1 and IDO-2 pH profile 
 
4.2.5 Spectral Characteristics of Mouse IDO-1 and Mouse IDO-2 
IDO-2 protein just like IDO-1 was found to be a ferric (Fe+3) type hemoprotein. Both 
proteins exhibit a characteristic spectrum with an absorption peak in the Soret region (406 
nm) (Figure 34). Treatment of both proteins with sodium dithionite under anaerobic 
conditions leads to a shift in the spectra from 406 nm to 428 nm (Figure 34). This shift in the 
spectra strongly indicates that after purification under aerobic conditions both IDO-1 and 
IDO-2 are present in the Fe+3 oxidised state. A similar phenomenon has earlier been reported 
to occur for the human IDO-1 [Littlejohn et al., 2000]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Mouse IDO-1 and IDO-2 spectrum. The spectrum shows mouse IDO-1 and IDO-2 before and after 
treatment with sodium dithionite. Inset expanded spectral region 530-600 nm  
 
4.2.6 Oligomerisation Studies of Mouse IDO-1 and Mouse IDO-2 
Oligomerisation studies carried out on IDO-2 have revealed that the mouse IDO-2 
exists as both a monomer of 45 kDa (45 %) and a dimer of 90 kDa (55 %) (Figure 35). When 
the dimeric IDO-2 was loaded onto the FPLC column a similar pattern of monomer and dimer 
formation was observed. Addition of DTT to the dimeric IDO-2 form leads to the formation 
of monomeric IDO-2 (76 %). Addition of DTT immediately upon purification leads to the 
formation of about 95 % monomer of IDO-2. In the presence of H2O2, GSSG and GSH, IDO-
2 exists predominantly as a monomer (63 %, 55 % and 78 % respectively). The existence of 
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IDO-2 as a monomer in the highly reductive environment of DTT and GSH could mean that 
dimerisation of IDO-2 involves intermolecular disulfide bonds and the enzyme could be 
regulated by glutathionylation or could have a redox regulated mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Mouse IDO-2 existing in both dimeric and monomeric form. 77.63 correspond to the dimeric form 
whereas 86.99 correspond to the monomeric form.  
 
Measurement of activity of the monomeric IDO-2 against the dimeric form showed no 
difference in activity. IDO-1 on the other hand was found to predominantly exist as a 
monomer.  
 
4.2.7 Crystal Screening of Mouse IDO-1 and Mouse IDO-2 
The crystal screening was performed using the hanging drop method and Hampton 
research crystallisation kits (as described in 3.1.7). The proteins were found to precipitate 
very easily. Addition of DTT to the protein before crystallisation trials reduced precipitation 
of the protein but no crystals were obtained. Crystallisation trials were also performed using 
the conditions described for human IDO-1 by Sugimoto et al. [2006], but no crystals were 
obtained. 
 
4.2.8 Structure Prediction of Mouse IDO-2 
For the evaluation of the structure model of the IDO-2 from mouse an overlay with the 
crystal structure of human IDO1 (PDB ID: 2D0T) was made. 
  
 
 
 
 
 
 
 
 
Figure 36: Mouse IDO-2 structure models. A) A) Overlay of human IDO1 (cyan) with the structure model of 
mouse IDO-2 (green) B) Superposition of the crystal structure of human IDO1 (cyan) with heme (red) and the 
modelled structure of mouse IDO-2 (green). 
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The overall structure was found to be identical to the structure of the human IDO1 (Figure 
36), described by Sugimoto et al. [2006]: it folds into two domains, a large and a smaller one. 
The large domain consists of 13 α-helices and two 310 helices. The small domain is comprised 
of six α-helices, two short β-sheets and three 310 helices. A comparison of the amino acids 
360-380 was not possible, due to disordered electron density in the crystal structure. It is 
assumed that the attachment of a substrate and or a ligand could lead to a conformational 
change in this region (the loop). The heme binding site was analyzed in detail, in order to 
obtain more information about the heme environment of mouse IDO-2 (Figure 37). To a large 
extent the same amino acids were found at identical positions and in identical conformation. 
An important difference in the heme environment is the exchange of the amino acids I217 and 
L384 of the crystal structure by a methionin (M221 and M385) in the structural model. This 
could cause a reinforcement of the heme binding on one hand and or a change of the oxidation 
state of the heme molecule within the structure on the other hand. 
 
A)       B) 
            
  
 
 
 
 
 
 
 
Figure 37: Heme environment of mouse IDO-2 and human IDO-1. A) Heme binding site (green) of the structure 
model of mouse IDO-2. B) Heme binding site (grey) of the crystal structure of human IDO1. All shown amino 
acids are around 4Å of heme. 
 
All amino acid interactions for IDO-1 described by Sugimoto et al. [2006] could also 
be found in the homology model. The salt bridge, between D274 and R343 in the crystal 
structure (3.49 Å and 2.89 Å) is formed by similar amino acids (D278 and R344) in the 
structure model (3.3 Å and 2.9 Å).  The crystal structure of IDO-1 implicates D274 to play a 
key role in the catalytic reaction, a role which could be assigned to D278 in IDO-2. This is 
due to their close confirmation similarities as well their similarities in terms of their position 
in the homology model. The described interaction between R343 of the human IDO-1 and the 
6-propionate of the heme (2.63 Å and 2.9 Å) is also present in the structured model (2.63 Å 
and 2.57 Å), so is the interaction between S267 with 7-propionate of the heme in the 
homology model. Important amino acids F226, F227 and R231, which form the entrance 
tunnel to the heme binding pocket, were mutated to alanine by Sugimoto et al. [2006]. The 
mutations of these 3 amino acids drastically reduced the dioxygenase activity. It is accepted 
that F226 and R231 are directly and F227 is indirectly involved in the substrate recognition 
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N+
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by hydrophobic interactions. In the homology model of mouse IDO-2 F230, Y231 and R235 
occupy the same positions as the aforementioned amino acids of the crystal structure (F226, 
R231, F227). The exchange of F227 to Y231 probably leads to a change in substrate 
specificity of IDO-2 in comparison to IDO-1. Analysing the entire tunnel toward the heme 
binding pocket reveals a bigger substrate binding pocket in IDO-1 as compared to that of 
IDO-2. These findings might point towards changed substrate affinity/ specificity. 
 
4.2.9 Mouse IDO-1 and Mouse IDO-2 Inhibition Using Substrate Analogues  
1-methyl-D-tryptophan and 1-methyl-L-tryptophan, which have a substitution at the 
indole nitrogen atom, are the best known potent substrate analog competitive inhibitors with 
respect to the substrates D-Trp and L-Trp for IDO. Tests performed using these inhibitors 
(Table 14) showed that 1-methyl-L- tryptophan was a better inhibitor for mouse IDO-1 (Ki 
105 µM) as compared to1-methyl-D-tryptophan (Ki 11700 µM). 1-methyl-D-tryptophan on 
the other hand was found to be the best inhibitor with respect to mouse IDO-2 (Ki 2500 µM) 
as compared to 1-methyl-L-tryptophan (Ki 13500 µM).   
 
 1-Methyl-L-
Tryptophan 
1-Methyl-D-
Tryptophan 
Norharman 
 Ki µM Ki µM Ki µM 
mIDO-1 105 11700 1080 
mIDO-2 13500 2500 750 
Table 14: Inhibition of mouse IDO-1 and IDO-2 using substrate analogues. 
 
Norharman is a known non competitive inhibitor of IDO but a competitive inhibitor for TDO 
[Sono and Cady, 1989]. Tests using this inhibitor revealed that it was a better inhibitor for 
IDO-2 as compared to IDO-1 (Table 14). 
 
4.2.10  Screening for Mouse IDO-1 Inhibitors 
Although some IDO inhibitors are available, their inhibitory activities are relatively 
low at micromolar Ki values (Table 14). There is therefore need for more potent IDO 
inhibitors. Screening for more potent IDO specific inhibitors using a library of compounds 
provided by Hans-Knöll institute Jena, yielded compound 55D11 (Figure 38) which is 
capable of inhibiting IDO-1. This inhibitor was found to inhibit IDO-1 and not IDO-2 with an 
IC50 value of 0.02 mg/ml. We always utilised fresh preparations of enzymes for our inhibitor 
test and we found that the specific activity of IDO-1 varied from one preparation to another as 
shown in Table 15. This could be as a result of IDO-1 
being very unstable. Nevertheless the Km values 
remained the same or constant showing that although 
the enzyme might be inactivated there are some active 
sites which were still active.  
Figure 38: Structure of compound 55D11:  
8-aminoacridiziniumbromide 
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In the presence of our inhibitor 55D11 the Km and Vmax values were found to decrease quite 
strongly (Table 15). The decrease in the Km and Vmax values shows that the dose dependent 
effect was quite strong and the data is in accordance with uncompetitive inhibition (Figure 39) 
with the calculated Ki value being 0.05 µM. 
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Figure 39: Inhibition of mouse IDO-1 by inhibitor 55D11. A)  IC50 graph for mouse IDO-1 using inhibitor 
55D11. B) Uncompetitive inhibition pattern exhibited by inhibitor 55D11  
 
This inhibition pattern shows that the inhibitor can not bind to the free enzyme but binds to 
the enzyme-substrate complex thereby inducing a conformational change to the complex 
which leads to changes in Vmax values observed.  
 
 No inhibitor  With Inhibitor conc  
    0.9 µM  0.18 µM  0.018 µM 
Date Km  Vmax   Km  Vmax   Km  Vmax   Km  Vmax  
07.08.07 123 2.21  3.7 0.17  13.2 0.17  51.3 1.2 
            
    0.29 µM  0.22 µM  0.11 µM 
    Km  Vmax   Km  Vmax   Km  Vmax  
11.03.08   49.1 0.21  19.56 0.12  21.38 0.13  31.23 0.16 
02.04.08 155.6 0.05  98 0.14  140.2 0.17  181.6 0.08 
03.04.08 124.5 0.07  174.7 0.14  182.5 0.14  176.3 0.11 
            
Average 113 ± 45 1.05 ± 0.82          
Table 15: Mouse IDO-1 inhibition by 55D11 values. Km in µM and Vmax in U/mg 
 
4.2.11 Structure Activity Study of 55D11 Derivatives as Mouse IDO-1 Inhibitors 
A structure activity study was undertaken to determine which elements or side chains 
of the inhibitor 55D11 could be modified to enhance potency. The derivatives provided by 
Prof Ihmels (University of Siegen) were classified into five major groups; (i) compound 
containg a side chain whose parent chain contains an indole ring or whose parent chains are 
similar to tryptophan (compounds KS 1, 4 and 16), (ii) derivative compounds having an 
amine side chain, and with or without a halide (compounds KS 2, 21, 22, 23 and 24), (iii) 
derivative compounds having a carboxylic side chain (compounds KS 5, 6 and 18), (iv) 
derivative compounds having an amine attached to a benzene ring (compounds KS 9, 10, 12, 
13, 14, 15 and 17), (v) derivative compounds having an acetamide group (compounds KS 19 
and 20) (Table 16).   
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Compound Structure % Inhibition IC50 P.f  Compound Structure % inhibition IC50 P.f 
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Compound Structure % Inhibition IC50 P.f  Compound Structure % Inhibition IC50 P.f 
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NH Cl
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49.6 63 
Table 16: Derivatives of inhibitor 55D11. Percent inhibiton on IDO determined using an inhibitor concentration of 5µg/ml. IC50 also determined in P. falciparum cell culture. P.f 
means P. falciparum 3D7 IC50 in ng/ml. 
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4.3 Thioredoxin Networks 
Members of the thioredoxin superfamily mediate thiol disulphide exchange reactions, 
and can transfer reducing equivalents to other proteins. First, Trx induces the conformational 
change of the targe t protein and facilitates the reduction of the disulphide bridge in the 
molecule [Brandes et al., 1993; Stumpp et al., 1999]. Then Trx and its target protein form a 
mixed disulphide intermediate at the first reactive cysteine in the reactive site CxxC [Brandes 
et al., 1993]. This intermolecular disulphide bond is attacked by the second cysteine of Trx, 
hereby the target protein is reduced and the reduced form of Trx is oxidized. The substitution 
of the second cysteine to serine can interrupt this reduction process at the stage of the 
formation of the mixed disulphide intermediate. This basic concept of Trx affinity 
chromatography was first applied by Verdoucq et al., [1999] to capture the interacting partner 
protein of Trx in yeast. The strategy that was applied was conceptually similar to this work. 
However, in this study the PfPlrx mutant was immobilized on the gel surface and the gel was 
used for the affinity chromatography [Motohashi et al., 2001]. When the protein pool of P. 
falciparum proteins was incubated with this gel, potential PfPlrx target proteins having an 
accessible disulphide bond should form a 
mixed disulphide intermediate with the 
immobilized PfPlrx mutant on the resin. 
This intermediate complex should be 
stable under the experimental conditions, 
i.e. in the absence of any reductants. In 
order to remove non-specifically bound 
proteins the gel was washed with high 
concentrations of NaCl (500 mM). After 
repeated washing, the captured proteins 
were then eluted from the gel using 10 
mM dithiothreitol (DTT), a concentration 
sufficient to reduce the mixed disulphide 
bond formed (Figure 40). By this 
procedure several potential PfPlrx target 
proteins were captured and it was 
possible to identify some of these 
proteins by N-terminal sequencing as 
summarised in Table 17 [Motohashi et 
al., 2001]. 
 
Figure 40: PfPlrx affinity chromatography [Motohashi et al., 2001]. The second cysteine of Plrx was mutated to 
serine. The mutant protein was immobilised on CNBr activated sepharose according to manufacturer’s 
instructions. The prepared resin was incubated with protein mixture for 2 hours at room temperature. After 
repeated washings captured proteins were eluted from the resin using 10 mM DTT.    
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 Accession number     
Protein Name Swiss-Prot/ GenBank PlasmoDB 
Protein MW 
[kDa] 
Protein 
Isoelectric 
point 
Protein 
Coverage [%]
Masses 
Matched 
40S ribosomal protein S12 O97249 PFC0295C 15.4 4.91 23 3 
Acyl carrier protein, putative Q7KWJ1 PFB0385w 15.8 8.87 19 3 
14-3-3 protein homologue, putative Q8IB17 MAL8P1.69 29.5 4.96 20 4 
Co-chaperone GrpE, putative Q8IIB6 PF11_0258 34.5 8.8 20 4 
14-3-3 Protein, putative Q8ID86 MAL13P1.309 35.1 7.08 17 3 
Glyceraldehyde-3-phosphate dehydrogenase Q8IKK7 PF14_0598 36.6 7.59 30 7 
Hypothetical protein Q8IJX6 PF10_0065 37.8 8.67 16 4 
Ribonucleotide reductase small subunit Q8IM38 PF14_0053 40.6 5.37 14 4 
S-adenosylmethionine synthetase Q7K6A4 PFI1090w 44.8 6.28 20 5 
Conserved GTP-binding protein, putative Q8IBM9 MAL7P1.122 45.2 6.88 35 9 
Ornithine aminotransferase Q6LFH8 PFF0435w 46.1 6.47 22 8 
Endonuclease iii homologue, putative Q6LFC2 PFF0715c 49.2 9.37 11 4 
HAP protein/Plasmepsin III Q8IM15 PF14_0078 51.7 8.04 18 8 
Hypothetical protein Q8ILQ4 PF14_0190 54.7 5.53 9 3 
Hexokinase Q6LF74 PFF1155w 55.3 6.72 11 4 
Disulfide isomerase, putative Q8I6S6 MAL8P1.17 55.5 5.56 9 3 
Pyruvate kinase, putative Q6LF06 PFF1300w 55.7 7.5 28 9 
Heat shock protein Q8I2X4 PFI0875w 72.4 5.18 9 6 
Heat shock 70 kDa protein Q8IB24 PF08_0054 73.9 5.5 28 12 
Heat shock protein 86 Q8IC05 PF07_0029 86.2 4.94 13 8 
Elongation factor 2 Q8IKW5 PF14_0486 93.5 6.35 10 5 
Table 17: Potential plasmoredoxin target proteins identified in Plasmodium falciparum 
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Analysis using the Biacore system with immobilised S-adenosyl-L-homocysteine 
hydrolase (SAHH) sensor chip CM5 and PfPlrx showed an association between SAHH and 
PfPlrx. Although the interaction between the SAHH and the wild type PfPlrx was stronger 
than that between SAHH and PfPlrxC63S (Figure 41) the binding was not affected by the flow 
of the buffer over the chip which indicates the presence of a covalent interaction. The 
dissociation of the interaction of SAHH and the analytes (PfPlrx and PfPlrxC63S) in the 
presence of 10 mM DTT confirms that the interaction takes place through formation of 
disulfide bonds. 
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Figure 41: Sensogram of interaction between SAHH and PfPlrx or PfPlrxC63S. 
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5 Discussion  
5.1 PfGluPho’s G6PD 
Using our optimised method of expression and purification we have been able to 
heterologously overexpress and purify PfGluPho to homogenity. It was impossible to purify 
the enzyme using 2’ 5’ ADP Sepharose 4B material a phenomenon which had been earlier 
reported by Kurdi-Haidar and Luzzatto [1990]. Since we overexpressed our protein with a 
His-tag it was possible to use the Ni-NTA column for the first purification step followed by a 
size exclusion chromatography using gel filtration which yielded a homogenous pure protein. 
Typically 1 mg of purified enzyme could be obtained from 1 litre of E. coli culture. This 
unique bifunctional enzyme from P. falciparum has for the first time been successfully 
cloned, heterologously overexpressed and purified. 
Antibodies specific for different parts of PfGluPho were produced in rabbits. Using 
these antibodies recombinant PfGluPho as well as the native protein in P. falciparum whole 
cell extracts could be identified by Western blot. The results confirm that PfGluPho is present 
as a bifunctional enzyme in P. falciparum parasites and that the recombinant protein is 
PfGluPho. 
Earlier studies on the oligomeric structure of PfGluPho were rather contradictory. 
Kurdi-Haidar and Luzzatto [1990] estimated the molecular weight of PfGluPho to be 450 kDa 
and predicted that it was an octamer of an “ordinary size” consisting of 8 subunits of 50-60 
kDa each. O’Brian et al. [1994] on the other hand disputed this finding and predicted that 
PfGluPho was a tetramer of “oversized” subunits. Molecular studies of G6PD have indicated 
that the dimer is the minimal catalytically active structure and often aggregates to form 
tetramers [Levy, 1979] but since PfGluPho exhibits high substrate affinities, this implies that 
the enzyme does not exist as a tetramer. Our data clearly indicates that PfGluPho has a 
molecular weight of 636 kDa with a subunit molecular weight of 106 kDa which does not 
differ from the predicted molecular weight of 107 kDa. PfGluPho therefore exists as a 
hexamer and not an octamer or an oversized tetramer.  
When comparing PfGluPho Km values with those documented for the human G6PD 
(Table 5) [Birke et al., 1989; Wang et al., 2002], PfGluPho was found to be more active and 
exhibits substrate affinities that favour turnover by the parasite enzyme (Km values for G6P 
differ by a factor of 3) in comparison to the human G6PDH. This implies that in infected RBC 
where G6P and particularly NADP+ concentrations are lower than Km values of human G6PD, 
PfGluPho utilises most of the G6P and NADP+ present for the generation of NADPH through 
the PPP. This high substrate affinity of PfGluPho makes the Plasmodium enzyme unique 
amongst G6PD enzymes characterised so far and also from other protozoa (Table 16). The 
discrepancy between the PfGluPho Km values from our study and those from earlier studies 
could be due to reliance on PfGluPho obtained from parasitised cells which contains a large 
excess of RBC G6PD (homogeneity of the enzyme used). 
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Assays with the substrate analogue 2-deoxyglucose-6-phosphate revealed that 
PfGluPho had a low affinity for the analogue (Km 2.5 mM), when compared to the affinity of 
G6P (Km 18.1 µM) this affinity differs by a factor of 138. When compared to the human 
G6PD (Km 1.67 mM) [Wang et al., 2002], which has a better affinity to the analogue 
compared to PfGluPho, the affinity for the substrate analogue differs by a factor of 1.5 in 
favour of the human G6PD.  
 
 Km (µM)  
Organism G6P NADP+ Reference 
Giardia 3 isolates 360 
691 
565 
2.4 
2.1 
2.3 
Bertram et al., 1983 
Leishmania 150 12 Walter, 1979 
Trypanosoma cruzi 300 87 Funayama et al., 1977 
P. falciparum 11 0.8 Yoshida and Roth, 1987 
P. falciparum 27 4.5 Kurdi-Haidar and Luzzatto, 1990 
P. falciparum 18 5.1 Present study 
Table 18: Summary of biochemical properties of G6PD from protozoa 
 
The initial rate studies yielded double reciprocal plots suggesting a sequential (ternary 
complex) mechanism in which both substrates must first bind to the enzyme before product 
formation can occur. Product inhibition studies are among the most useful methods of 
elucidating the order of binding of substrates and the release of products which serve as an 
independent test that helps to differentiate between an ordered and random sequential 
mechanism. NADPH was found to be a mixed inhibitor with respect to G6P and a non-
competitive inhibitor with respect to NADP+. This inhibition pattern points toward an ordered 
sequential mechanism with NADP+ binding first to the enzyme.  
The dead end inhibitor glucoseamine 6-phosphate was found to be a mixed inhibitor 
with respect to both substrates G6P and NADP+. This indicates that the inhibitor binds to the 
enzyme-NADP+ binary complex and not to the free enzyme. Since glucoseamine 6-phosphate 
is an analogue of G6P, it seems likely that this inhibition pattern confirms that G6P binds only 
to the enzyme-NADP+ complex and that PfGluPho follows an ordered sequential mechanism. 
Tests using the NADP fragment ATP-ribose further confirmed the existence of an ordered 
sequential mechanism. 
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Figure 42: Schematic representation of an ordered sequential mechanism where E is the enzyme, A and B are 
the leading and following substrates.  
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An independent test of the mechanism may be applied using the Dalziel parameters 
(Table 6). For a compulsory order mechanism with substrate X binding first to the enzyme, 
ΦXY/ ΦY gives Kd the dissociation constant for substrate X leaving the binary enzyme 
complex EX. This value should not change if an alternative substrate is used. Similarly the 
values of ΦX and ΦXY/ΦXΦY should remain unchanged regardless of the nature of substrate Y 
even though there may be changes in the individual values of Φ0, ΦY, ΦXY [Dalziel, 1957; 
Fromm, 1979]. There is a corresponding relationship if Y is the leading substrate. The 
relationship was tested for G6P by the alternative substrate 2-DeoxyG6P. If NADP+ is the 
leading substrate the Φ NADP G6P / ΦG6P should be equal to Φ NADP 2-DeoxyG6P / Φ2-DeoxyG6P. The 
mean values obtained were 5.1 for both cases (Table 6). The Φ NADP with G6P as the substrate 
is 0.025 µMs and Φ NADP with 2-DeoxyG6P as the substrate is 0.027 µMs which are quite 
similar. The mean values for ΦXY/ΦXΦY (Φ NADP 2-DeoxyG6P / Φ2-DeoxyG6P Φ NADP and Φ NADP G6P / 
ΦG6P Φ NADP) were found to be 190 against 204 s-1 (Table 6) which are almost similar. The 
results confirm that PfGluPho exhibits a compulsory order mechanism with NADP+ as the 
leading substrate. 
Using a similar relationship Wang et al. [2002] were able to test for the possibility of 
the human G6PD exhibiting an ordered sequential mechanism with NADP+ being the leading 
substrate. The Φ NADP G6P / ΦG6P and Φ NADP 2-DeoxyG6P / Φ2-DeoxyG6P were found to be very 
similar, 6.8 against 6.6 µM [Table 6]. The Φ NADP with G6P as the substrate was 0.042 µM.s 
which was 6.6 fold lower than Φ NADP with 2-DeoxyG6P as the substrate (0.28 µM.s). 
Consequently ΦXY/ΦXΦY (Φ NADP 2-DeoxyG6P / Φ2-DeoxyG6P Φ NADP and Φ NADP G6P / ΦG6P Φ NADP) 
also revealed very different values for the two sugar phosphate substrates (161 s-1 vs. 25 s-1). 
A compulsory order mechanism with NADP+ as the leading substrate was therefore ruled out 
for the human G6PD. Wang et al. [2002] went ahead to demonstrate that the human G6PD 
exhibits a rapid equilibrium random order mechanism.  
The reaction of PfGluPho’s G6PD follows an ordered sequential mechanism as 
compared to the random order sequential mechanism found in the human G6PD. Comparing 
the catalytic efficiency (kcat/Km) between PfGluPho’s G6PD and the human G6PD (Table 5) 
demonstrates that PfGluPho’s G6PD is a more efficient in conversion of its substrates G6P 
(1.14 x 107 M-1S-1) and NADP+ (3.98 x 107 M-1S-1) to products than its human homologue 
(G6P 2.9 x 106 M-1S-1 and NADP+ 2.3 x 107 M-1S-1). These findings imply that PfGluPho’s 
G6PD is more efficient in the production of NADPH as compared to its human counterpart.  
Atamna et al. [1994] demonstrated an increase in the PPP activity with parasite 
maturation from ring to trophozoite stage and suggested that this upregulation could be a 
consequence of increased parasite biomass and upregulation of the PPP enzymes (the increase 
in PPP is even larger than the increase in parasite biomass). In the light of our findings we 
would like to suggest that the upregulation of the PPP is due partly to the high efficiency in 
the production of NADPH by PfGluPho which catalyses the first step of the PPP and not 
necessarily due to an up regulated synthesis of PPP enzymes. 
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5.1.2 PfGluPho’s 6-PGL  
Time dependent assays for 6-PGL have been described earlier by Rakitzis and 
Papandreou, [1995], Bauer et al., [1983] and Schofield and Sols, [1976].  We modified the 
method in order to measure the 6-phosphogluconolactone available and the amount of 6-
phosphogluconolactone consumed by the reaction catalysed by PfGluPho’s 6-PGL. Our 
modified method differs mainly from other methods in the way the experimental data was 
generated and analysed. The generation of 6-phosphogluconolactone by the action of an 
excess of G6PD, and subsequent determination of the amount of 6-phosphogluconolactone 
hydrolysed by the addition of an excess of 6-PGD has been employed by Schofield and Sols 
[1976] and also by Bauer et al. [1983]. However to this end Schofield and Sols [1976] have 
determined initial rate constants rather than the utilisation of reaction time course thereby 
introducing a methodological error [Rakitzis and Papandreou, 1995]. Bauer et al. [1983] have 
used log residual 6-phosphogluconolactone against reaction time plots to determine the rate 
constants of the uncatalysed hydrolysis of 6-phosphogluconolactone without using the end 
point of the reaction. In 6-PGL activity determinations, Bauer et al. [1983] have used two 
identical 6-phosphogluconolactone / 6-PGD solutions in one of which the 6-PGL preparation 
was added. Enzyme activity was then determined by subtracting concurrent absorbance values 
of the enzyme containing solution and the control solution.  Rakitzis and Papandreou [1995] 
have on the other hand performed a time course study on the hydrolysis of 6-
phosphogluconolactone with the change in absorbance being recorded and analysed. In this 
study involving PfGluPho’s 6-PGL, a time course study of 6-PGL activity was performed by 
monitoring the concentration of 6-phosphogluconolactone formed after the reaction catalysed 
by G6PD and 6-phosphogluconate formed after 6-PGL assay.  
The principles of the method employed rest on two assumptions:  
(1) That all the 6-phosphogluconolactone produced by action of PfGluPho’s G6P is 
immediately available to PfGluPho’s 6-PGL. 
(2) The activity of 6-PGD is not influenced by the assay parameters and therefore not 
rate limiting in any way. 
The plots of 6-phosphogluconolactone available against time and plots of 6-
phosphogluconate against time gave linear plots. The Km value for PfGluPho’s 6-PGL for its 
substrate 6-phosphogluconolactone was found to be 26.2 µM which is 1.45 times higher that 
exhibited by PfGluPho’s G6PD for its substrate G6P (18.1 µM). The Vmax on the other hand 
was found to be 74.9 U/mg for PfGluPho’s 6-PGL compared to 116 U/mg exhibited by 
PfGluPho’s G6PD for G6P. The Vmax differed by a factor of 1.5 in favour of G6PD. The 
catalytic efficiency (kcat/Km) was found to be 206 s-1 and 133 s-1 for PfGluPho’s G6PD and 6-
PGL respectively, which implies that PfGluPho’s G6PD is catalytically more efficient than 
the lactonase. 
Comparing the activity of PfGluPho’s 6-PGL to its human homologue revealed that 
although PfGluPho’s 6-PGL had a higher affinity for its substrate (Km 26.2) when compared 
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to the human enzyme (Km 32.5). The human enzyme on the other hand had a higher rate of 
substrate turnover (344 s-1) as well as catalytic efficiency (1.0 x 107 M-1s-1) when compared to 
PfGluPho’s 6-PGL (133 s-1 and 5.08 x 106 M-1s-1). 
Under conditions of oxidative stress, formation of mixed disulfides between 
glutathione and cysteines in proteins (glutathionylation) has not only been known to occur but 
implicated as a mechanism through which protein functions can be regulated by the redox 
status [Brigelius et al., 1983]. Glutathionylation takes place by thiol-disulfide exchange 
between protein sulfhydryls and oxidized glutathione (GSSG), a reversible process that can be 
catalyzed by glutaredoxin. The GSH/GSSG ratio is an indicator of the redox status of the cell, 
and the extent of protein glutathionylation will vary accordingly: a higher ratio will promote 
glutathionylation; a lower ratio will result in deglutathionylation/release of glutathione. Tests 
for PfGluPho’s 6-PGL assay in the presence of either GSSG or GSH in the presence or 
absence or glutaredoxin showed that PfGluPho’s 6-PGL activity was neither inhibited nor 
influenced any way. These findings imply that PfGluPho’s 6-PGL is not allosterically 
influenced or regulated by glutathionylation a finding that conforms to that found for other 6-
phopshogluconolactonases [Hofer and Bauer, 1987]; although the activity of 6-PGL prepared 
from red blood cell lysates has been shown to be inactivated by GSSG [Fratelli et al., 2002].  
One of the major aims of this study was to identify PfGluPho’s G6PD inhibitors as a 
strategy for rational drug development against malaria. We have been able to characterise 
fully the inhibition of compound 8807 against G6P and NADP+. Compound 8807 was found 
to be non-competitive with respect to both the substrates. This implies that the inhibitor is 
able to bind to the enzyme-substrate complex. However the enzyme-substrate-inhibitor 
complex does not proceed to form product. The non-competitive phenomenom exhibited by 
compound 8807 has the advantage of not being overcome by increase in the concentration of 
the substrate.   
The notion that different performance requirements may mediate natural selection for 
the high activity of different enzymes in a pathway and the realisation of the importance of 
the intrinsic chemical properties of metabolic intermediates helps to elucidate a puzzling but 
recurrent finding in P. falciparum evolutionary history and its adaptation towards overcoming 
oxidative stress. Namely adaptation of P. falciparum PPP to conditions that require very high 
rates of NADPH production is accompanied by a large increase in the substrate affinities 
namely G6P and NADP+ by PfGluPho’s G6PD at the same time not being inhibited by its 
product NADPH but being rather more efficient in its production. 
In the battle to eradicate malaria, effective drug targets are needed. An essential 
feature for a molecule to be considered as a potential drug target is that it must be 
distinguishable from its counterpart in the human host. The enzyme PfGluPho might prove 
valuable in this respect, as mammals do not express this bifunctional enzyme, do not express 
insertion sequences within their two homologues and the enzymes differ in their mechanism 
of action. Besides PfGluPho occupies position 75 of the TDR targets database against 
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neglected tropical diseases [http://tdrtargets.org]. In summary this study offers the first clear 
documentation of the cloning, heterologous expression and biochemical as well as kinetic 
characterisation of the bifunctional enzyme PfGluPho.  
 
5.2 Mouse IDO-1 and Mouse IDO-2 
At least 3 forms of IDO have been thought to exist from the experiments of Shizu et 
al. [1978] but until recently only one form of IDO (IDO-1) has been heavily investigated. The 
identification of IDO-2 in man and mouse and the demonstration of its capacity using 
heterologously overexpressed protein to metabolise tryptophan along the kynurenine pathway 
adds a new dimension to the understanding of how this pathway is regulated under normal 
and abnormal physiological conditions. IDO-1 and TDO are two phylogenetically unrelated 
genes that have evolved to have a similar function (i.e. catalysing the first step in tryptophan 
catabolism). Although there are differences in enzyme activity with regard to substrates other 
than L-tryptophan, the major difference between IDO-1, IDO-2 and TDO that may play a role 
during the generation of functional diversity is the different expression patterns of the 
proteins. TDO is the enzyme responsible for tryptophan metabolism in the liver, but it is also 
expressed in the brain and epididymis [Haber et al., 1993; Britan et al., 2006]. IDO-1 is 
expressed in the intestines, kidney and reproductive system, including the epididymis, and is 
also induced in many tissues in response to stimuli such as inflammatory mediators. The 
overlapping expression of IDO-2 with the other two enzymes in the kidney, epididymis and 
liver might be taken to indicate some redundancy, but the different cellular localisation of the 
enzymes also suggests a distinct role for each of the enzymes [Ball et al., 2007]. 
 
 Mouse IDO-1 Mouse IDO-2 
Molecular mass 45,335 Da 45,255 Da 
pI 5.94 6.21 
Amino acids 424 405 
ε280 nm (assuming all Cys are reduced) 48220 M-1 cm-1 40680 M-1 cm-1 
ε280 nm (assuming all Cys are oxidized) 48820 M-1 cm-1 41280 M-1 cm-1 
Table 19: Comparison of other properties of mouse IDO-1 and IDO-2 
 
Using the methylene blue/ ascorbic acid method IDO-2 exhibited Km values which 
were approximately 300 fold higher than those exhibited by mouse IDO-1. Using a similar 
method (methylene blue/ ascorbic acid) the human IDO-2 protein as well as IDO-2 like 
proteins from lower vertebrates, such as Xenopus, have been reported to also exhibit L-
tryptophan Km values which are approximately 500–1000-fold higher than those of  their 
corresponding IDO-1 enzymes [Yuasa et al., 2007]. When compared to the cytochrome b5/ 
cytochrome P450 method a 20 fold decrease in the Km value which was accompanied by 590 
fold improvement in the Vmax value was observed which implied that the enzyme had an 
improved substrate affinity as well as turnover capacity under the cytochrome b5/ cytochrome 
P450 method. Substrate inhibition observed for IDO-2 at relatively high concentrations of L-
tryptophan could be due to the formation of a low spin ferric enzyme complex with L-
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tryptophan. A similar phenomenon had earlier been reported for IDO-1 by Sono [1989]. The 
substrate analogue inhibitor 1-methyl-D-tryptophan was found to inhibit IDO-2 whereas 1-
methyl-L- tryptophan inhibited IDO-1. Similar IDO inhibition by substrate analogues has 
been reported by Metz et al. [2007]. 
Oligomerisation studies carried out on IDO-2 have revealed that the mouse IDO-2 
exists as both a monomer of 45 kDa (45 %) and a dimer of 90 kDa (55 %). In the presence of 
DTT and GSH IDO-2 was found to exist predominantly as a monomer. The existence of IDO-
2 as a monomer in the highly reductive environment of DTT and GSH could mean that 
dimerisation of IDO-2 involves intermolecular disulfide bonds and the enzyme could be 
regulated by glutathionylation or could have a redox regulated mechanism. These results 
could also imply that in the dimeric structure of IDO-2, the relative configuration of each 
monomer in the dimerized form might be changed by the association or dissociation of O2 
thus triggering a conformational change or signal transduction. This interpretation was based 
on the R-T transition of haemoglobin. Although we do not know what kind of cellular 
response is affected by IDO-2, it is very interesting to note that the redox state of the 
environment could determine the oligomeric structure of the enzyme. It is most likely that the 
redox sensing by IDO-2 leads to a conformational change which could be associated with the 
O2 dissociation from the heme iron. The conformational change could initiate a signal 
transduction. The activities of IDO-1 as well as IDO-2 have been reported to be responsible 
for triggering signalling pathways such as phosphorylation of the translation initiation factor 
eIF-2α and translation of liver enriched inhibitory protein (LIP), an inhibitory isoform of 
CEPBβ transcription factor (Metz et al., 2007). 
The induction of IDO has been implicated in cerebral malaria and many other 
diseases. Suppression of IDO activity by use of IDO inhibitors alone or in combination with 
other chemotherapeutics might provide another tool in the cerebral malaria armamentarium. 
Strikingly almost all IDO inhibitors known so far, whether competitive or non-competitive, 
retain the indole ring of the natural substrate tryptophan [Muller et al., 2005; Malachowski et 
al., 2005]. The compound 55D11 and its derivatives do not contain the indole ring of the 
natural substrate tryptophan and therefore it is not necessary for its inhibition activity. 
Currently the most potent IDO inhibitor reported is 3-butyl-β-carboline, a non-competitive 
inhibitor with a Ki of 3.3 µM [Peterson et al., 1993]. However the most commonly used 
inhibitor is 1-methyl-Trp, a commercially available compound with a Ki of 34 µM. Our 
inhibitor has a lower Ki of 0.05 µM compared to the 2 mostly known IDO inhibitors.  
Cerebral malaria is the most severe complication of P. falciparum infection therefore 
an inhibitor with the capabilities to inhibit IDO and at the same time have some anti-malaria 
activity would be a big boost in the fight against cerebral malaria. Tests of compound 55D11 
did not show significant antimalarial activity in the mouse model, parasitemia or survival of 
the mouse model [Austin and Hunt, personal communication]. This could be due to the 
compound being rapidly renally eliminated in the mouse model.  
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Further structure activity relationships using derivatives of 55D11 were done with the 
aim of discovering more potent IDO inhibitors. Compound KS 2 which is structurally similar 
to 55D11 was the most potent derivative with a percent inhibition value of 73.02 (at 5 µg/ml 
inhibitor concentration) for IDO. A clear structure function relationship was also observed in 
the inhibition of P. falciparum cell culture. However reproducibility of the inhibition assays 
was limited due to the instability of the enzyme and the compounds which were light 
sensitive. Nevertheless the inhibitory activity demonstrated by 55D11 and derivative KS 2 
create new opportunities for further inhibitor development that avoids the pharmacological 
liabilities of the indole ring and leverage the wealth of chemical methods for benzene 
substitution. 
 
5.3  Thioredoxin Networks 
The redox-active protein plasmoredoxin which is unique and highly conserved among 
Plasmodium species was first described by Becker et al, [2003]. The physiological function of 
PfPlrx is still unknown and the protein seems not to be essential for the survival of the 
parasite under conditions of oxidative stress as shown very recently by Buchholz et al, [2008]. 
One of the factors limiting the understanding of PfPlrx function is the lack of information on 
target proteins and enzymes that interact with it. The present findings suggest that PfPlrx 
participates in the regulation of at least 8 known metabolic functions and 2 other unknown 
functions (Table 20) in P. falciparum parasites. Although PfPlrx has been reported to reduce 
ribonucleotide reductase [Becker et al., 2003], PfPlrx could also be involved in other 
physiological capacities some of which are highlighted in Table 20.  
 
Transcription/Translation  Polyamine metabolism 
Elongation factor 2  Ornithine aminotransferase 
40S ribosomal protein S12  S-adenosylmethionine synthetase 
   
Protein folding  Lipid metabolism 
Heat shock protein  Acyl carrier protein, putative 
Heat shock 70 kDa protein   
Heat shock protein 86  Hemoglobin catabolism 
Co-chaperone GrpE, putative  HAP protein/Plasmepsin III 
Disulfide isomerase, putative   
  DNA synthesis and repair 
Carbohydrate metabolism  Endonuclease iii homologue, putative 
Hexokinase  Ribonucleotide reductase small subunit 
Pyruvate kinase, putative   
Glyceraldehyde-3-phosphate dehydrogenase  Others 
  Hypothetical protein 
Signal transduction    Hypothetical protein 
14-3-3 protein homologue, putative   
  14-3-3 Protein, putative   
  Conserved GTP-binding protein, putative   
Table 20: Functional clusters of PfPlrx target proteins captured in the present study. 
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S-adenosyl-L-homocysteine hydrolase (SAHH) catalyzes the hydrolysis of S-
adenosyl-L-homocysteine, produced from S-adenosyl-L-methionine dependent methylation 
reactions, into L-homocysteine and adenosine. Surface plasmon resonance analyses were 
carried out (Figure 41) in order to identify the cysteine(s) of the three redox-active proteins 
which are responsible for the interaction with SAHH. The study using PfPlrx demonstrates 
that the C-terminal active site cysteine (Cys 63) is obviously involved in complex formation 
since its mutation into a serine significantly impairs binding to SAHH (Figure 41). This might 
be the reason why SAHH was not captured by the PfPlrx affinity column. 
From the study its evident that PfPlrx could be playing a role in a wide variety of 
pathways. Further studies are required to elucidate the modes and functional consequences of 
these interactions. 
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